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Abstract
The bestrophin family of ion channels consists of four human homologues, known as be-
strophin 1–4 (BEST1–4), as well as closely related homologues found in animals and more 
distantly related homologues found in plants, fungi and prokaryotes. BEST1 and other an-
imal homologues have been shown to form chloride channels that are activated by calcium 
binding. The currents produced by these bestrophin homologues are, however, distinct from 
the calcium activated chloride currents previously known to electrophysiologists, suggesting 
other physiological roles for bestrophins. 
At the start of this project, animal bestrophins were assumed to form multimeric ion channels 
with several membrane spanning helices, but the molecular structure of bestrophins was not 
understood. It was also not known what makes bestrophins selective for certain ions, how the 
flow of ions is gated or how the binding of calcium causes channel opening. For prokaryotic 
bestrophins, even less was known, since the function of those homologues had not been stud-
ied before. It was thus not known if prokaryotic bestrophins also form anion selective chan-
nels and if they are activated by calcium, some other ligand or even by another mechanism. 
By studying which functional features are conserved between the animal bestrophins and the 
distantly related prokaryotic homologues, I was hoping to learn more about the general prin-
ciples for ion selectivity and activation in bestrophins. Since no structural information was 
available, I decided to attempt to solve a structure of a prokaryotic bestrophin homologue 
at atomic resolution and use that structure as the first step towards an understanding of the 
function of prokaryotic bestrophins, thereby broadening the available knowledge of the entire 
bestrophin protein family. 
As a first step, I attempted to identify prokaryotic bestrophin homologues that could be over-
expressed and purified. More than a hundred homologues were cloned from prokaryotic 
organisms. Homologues that could be overexpressed in Escherichia coli and extracted with 
detergent were further characterised, to assess their stability in a detergent solution. Eight 
homologues were found to be well expressed and sufficiently stable to allow for crystallisation 
screening. For seven of the homologues, crystals could be grown and their diffraction prop-
erties could be evaluated. After extensive optimisation, crystals of a bestrophin homologue 
cloned from Sphingobacterium spiritivorum were found to diffract to a resolution of 3.9 Å. 
To further improve the diffraction of this homologue, nanobodies were generated. Sixteen na-
nobodies could be identified that formed stable complexes with the S. spiritivorum bestrophin 
homologue. Nine of these complexes were used for crystallisation trials, which yielded crystals 
xii
of seven different complexes. Eventually, one nanobody was found to significantly improve 
the diffraction of the S. spiritivorum bestrophin homologue and a complete dataset could be 
collected to a resolution of 3.1 Å. The structure could be solved using molecular replacement, 
since another bestrophin structure had in the meantime been published. 
In agreement with other recently published bestrophin structures, the bestrophin homologue 
from S. spiritivorum was found to form an alpha-helical pentameric ion channel, with the in-
dividual monomers arranged symmetrically around a long, central pore axis thought to form 
the ion conduction pathway. Like in animal bestrophins, the gate in the S. spiritivorum be-
strophin homologue is made up of three hydrophobic amino acid residues, indicating that the 
gating mechanism is at least partially conserved across evolutionary distantly related homo-
logues. Furthermore, the structure of the ligand binding site of the S. spiritivorum homologue 
is similar to that of animal bestrophins, although the activating ligand has not yet been identi-
fied. With recent studies suggesting that prokaryotic bestrophins might form cation selective 
channels, structural features in the S. spiritivorum homologue could be identified that might 
contribute to the selectivity. The presented structure will thus serve as a valuable tool to direct 
future functional experiments. 
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Zusammenfassung
Die Ionenkanalfamilie der Bestrophine umfasst vier menschliche Homologe, welche als Be-
strophin 1–4 (BEST1−4) bezeichnet werden. Neben den menschlichen Bestrophinen finden 
sich nahe Homologe auch in Tieren sowie auch entfernt verwandte Proteine in Pflanzen, Pil-
zen und Prokaryoten. Für BEST1 und andere tierische Homologe konnten eine Chloridkana-
laktivität nachgewiesen werden, welche durch die Bindung von Kalzium aktiviert wird. Der 
in Funktionsstudien gemessene Strom unterscheidet sich aber von klassischen Kalzium-ak-
tivierten Chloridströme, was eine neue physiologische Rolle der Bestrophine vermuten lässt.
Zu Beginn dieses Projektes wurde angenommen, dass tierische Bestrophine aus gleichen Un-
tereinheiten mit mehreren Transmembranhelices bestehen. Die molekulare Struktur von Ver-
tretern dieser Proteinfamilie war aber zu dieser Zeit noch nicht bekannt. Auch war unklar wie 
der Kanal bestimmte Ionen selektiert, der Ionenfluss gesteuert wird und wie die Bindung von 
Kalzium den Kanal öffnet. Über prokaryotische Bestrophine war noch weniger bekannt, da 
für diese keine Funktionsstudien vorlagen. Ebenfalls war es unklar, ob prokaryotische Bestro-
phine anionenselektive Kanäle formen und ob der Kanal, wie in tierischen Homologen, durch 
Kalzium oder mittles anderer Liganden aktiviert wird, oder ob ein völlig anderer Mechanis-
mus der Aktivierung vorliegt.
Durch die Untersuchung, welche funktionellen Eigenschaften zwischen den tierischen und 
entfernt verwandten prokaryotischen Homologen konserviert sind, erhoffte ich Einblick in 
die generellen Prinzipien der Ionenselektivität, der Steuerung des Ionenflusses und der Akti-
vierung von Bestrophinen zu erlangen. Da zu Beginn dieser Arbeiten noch keine strukturellen 
Informationen vorhanden waren, versuchte ich die Struktur eines prokaryotischen Bestro-
phins aufzuklären, um damit dessen Funktion und damit die generellen Mechanismen dieser 
Proteinfamilie besser zu verstehen. 
Der erste Schritt in dieser Arbeit war es prokaryotische Homologe der Bestrophine zu identifi-
zieren, die überexpremiert und aufgereinigt werden konnten. Dafür habe ich über einhundert 
Homologe aus verschiedenen prokaryotischen Organismen kloniert und in Escherichia coli 
exprimiert. Exprimierte Homologe, die mit Hilfe von Detergentien extrahiert werden konn-
ten, wurden weiter auf ihre Stabilität untersucht. Dabei konnten acht Proteine identifiziert 
werden, die sich als stabil erwiesen und die in Folge für die Proteinkristallisation verwendet 
wurden. Bei sieben dieser Homologe konnte ich Proteinkristalle herstellen und deren Diffrak-
tionseigenschaften charakterisieren. Nach intensiven Optimierungen konnte Diffraktion von 
Proteinkristallen des Bestrophins aus Sphingobacterium spiritivorum bis zu einer Auflösung 
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von 3.9 Å gemessen werden.
Um die Diffraktion dieses Homologs zu verbessern, habe ich in Folge Nanobodies generiert. 
Sechzehn Nanobodies konnten identifiziert werden, die mit dem Bestrophinhomolog von S. 
spiritivorum einen stabilen Komplex bildeten. Mit neun verschiedenen Komplexen wurden 
Kristallisationsexperimente durchgeführt, wobei für sieben Komplexe Proteinkristalle erhal-
ten wurden. Unter diesen verschiedenen Kristallen konnte ich einen Nanobody identifizieren, 
der die Diffraktion des S. spiritivorum-Homologs bedeutend verbesserte. Mit Kristallen dieses 
Komplexes konnte ich einen kompletten Datensatz mit einer Auflösung von 3.1 Å erhalten. 
Die Kristallstruktur des Komplexes konnte ich mittels ‘Molecular Replacements’ mit einer 
Struktur eines anderen Bestrophins, das in der Zwischenzeit von einer anderen Gruppe pub-
liziert wurde, bestimmen. 
In Übereinstimmung mit der in letzter Zeit veröffentlichten Strukturen konnte gezeigt wer-
den, dass das Bestrophinhomolog von S. spiritivorum einen alpha-helikalen pentameren Io-
nenkanal bildet, wobei die einzelnen Monomere symmetrisch um eine Achse angeordnet 
sind. Die Pore für den Ionenfluss befindet sich entlang der Symmetrieachse. Wie in den tie-
rischen Bestrophinen wird der Ionenfluss im S. spiritivorum-Homolog durch drei hydropho-
be Aminosäurereste an der Engstelle des Kanals in der Mitte der Membran beeinflusst. Dies 
deutet darauf hin, dass der Ionenfluss bei den evolutionär entfernt verwandten Homologen 
ähnlich reguliert wird. Ausser der Pore ist auch die Struktur der Ligandenbindungsstelle im S. 
spiritivorum-Homolog ähnlich zu den tierischen Proteinen, wobei für prokaryotische Bestro-
phine noch kein Ligand identifiziert werden konnte. Kürzlich veröffentlichte Studien legen 
nahe, dass prokaryotische Bestrophine kationenselektive Kanäle formen. In der vorliegenden 
Struktur des S. spiritivorum-Homologs konnten strukturelle Merkmale identifiziert werden, 
die einen Einfluss auf die Selektivität haben könnten. Die in dieser Doktorarbeit präsentierte 
Struktur bildet deswegen eine wertvolle Grundlage für zukünftige funktionelle Experimente. 
11. Introduction
1.1. Ion flow across membranes
All living cells are surrounded by a cell membrane, which separates the outside from the inside 
of the cell. In eukaryotic cells, membranes also enclose intracellular compartments, separating 
the inside of those compartments from the cytosol, but in the following only the cell mem-
brane is discussed. 
The cell membrane mainly consists of lipids and proteins. The lipid molecules are the main 
constituents of the cell membrane. They spontaneously form lipid bilayers, which act as barri-
ers. The core of the lipid bilayer is very hydrophobic, making it difficult for many water-soluble 
compounds to diffuse across the membrane. Larger, polar molecules permeate only slowly 
across a lipid bilayer, while ions are essentially impermeant. 
The cell membrane is, unlike a pure lipid bilayer, not impermeant to ions and many larger po-
lar molecules. It is in fact semi-permeable, thanks to the presence of many kinds of membrane 
embedded proteins that allow solutes to move across the membrane. Many other kinds of 
proteins are also present in the membrane, but in this thesis the focus will be put on proteins 
that are directly involved in the movement of ions across the membrane. 
1.1.1. Ion channels
By the action of membrane proteins, a living cell maintains different concentrations of vari-
ous ions on the inside compared to the outside, which essentially creates a chemical gradient 
across the membrane. Due to the selective permeability properties of biological membranes, 
the downhill flow of certain ions generates an electrical potential difference across the mem-
brane, also known as the membrane potential. The combined effects of the membrane poten-
tial and the chemical gradient can be described as an electrochemical potential. The flow of 
any ion across the membrane is affected by this electrochemical potential. For ions flowing 
downhill, all that is needed is an open path that permits the ions to pass the hydrophobic 
barrier of the membrane. However, for ions to move in the opposite direction, an open path 
is not enough and the input of energy is required. Not surprisingly, proteins that allow ions 
to move across the membrane can be divided into two main groups. Ion channels allow the 
passive flow of ions down the gradient, whereas ion transporters move ions against this gra-
dient. Ion transporters will not be discussed further, since the topic of this thesis concerns an 
ion channel.  
2If the cell membrane would only contain permanently open ion channels of different selectiv-
ities, it would be difficult for a cell to maintain an electrochemical gradient. For this reason, 
channels typically contain a gate that can be opened or closed to regulate the flow through the 
channel. The use of the word gate is conceptual, since the actual mechanism of gating varies 
between different families of ion channels. Generally gating can be understood as a transition 
that occurs as the channel changes from a closed to an open state or the other way round 
(Figure 1a).
Another characteristic of ion channels concerns their selectivity, which means that only cer-
tain ions are permitted to flow through a typical channel (Figure 1b). The region that is re-
sponsible for the selectivity is often referred to as the selectivity filter. Many ion channels 
are charge selective, i.e. they are selective for either anions or cations. Additionally, some ion 
channels are also size-selective, meaning that they only allow ions of a certain size to pass 
through the pore. As an example, potassium channels show a strong selectivity for potassium 
ions over sodium ions [1].
1.1.2. Activation of ion channels
A typical ion channel containing a gate needs to be activated in some way before the gate 
opens. Ion channels can be grouped into different categories, based on the mechanism of 
activation. Some commonly observed activation mechanisms are summarised in figure 2 and 
described briefly below.  
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Figure 1 – Gating and selectivity of ion channels. Channels are show in green, cell membranes in grey. (A) A gated 
channel shown in closed (upper panel) and open (lower panel) conformations. Only the open state allows ions to 
flow through the channel. (B) Examples of selectivity in ion channels. The upper panel shows a cation selective 
channel with a selectivity filter (light purple) that only permits the flow of cations. The lower panel shows a channel 
that is selective for larger cations. Smaller cations cannot flow through the selectivity filter (light green).  
3In some channels, known as voltage-gated ion channels, the gating is regulated by the mem-
brane potential. These include for example voltage-gated sodium channels that are involved in 
the propagation of action potentials in neurons [2]. 
Another regulatory mechanism is seen in the mechanosensitive channels, which are regulated 
by mechanical pressure that induces stretch or curvature in the membrane. The best studied 
mechanosensitive channels are prokaryotic homologues [3], but eukaryotic mechanosensitive 
channels also exist [4]. 
Other channels, the so-called volume regulated channels, respond to changes in cell volume. 
Some volume regulated channels might respond to changes in membrane stretch or curvature 
or respond to forces exerted by intracellular or extracellular proteins [5]. However, for the vol-
ume regulated anion channel, VRAC, the underlying mechanism appears to be the sensing of 
a change in the ionic strength, which occurs as an effect of hypotonic stress. [6,7]. 
Finally, many channels are found to be activated by a ligand. Examples include various re-
ceptors of the Cys-loop family that are activated by different neurotransmitters [8], calcium 
activated potassium channels [9], or calcium activated chloride channels, as discussed later.
Importantly, one type of channel might also be regulated by several different mechanisms at 
the same time. For instance, the large conductance calcium activated potassium channels are 
not only regulated by calcium, but also by voltage [10]. Additionally, other activation mech-
− − − −
+ + − ++ + + −
+ + + + + + + +
+ − − −− + − −
− − − −
Voltage-gated Mechanosensitive Volume-regulated Ligand-gatedA B C D
Figure 2 – Examples of channel activation mechanisms. Cell membranes are shown in grey. The upper panels show 
the closed states, whereas the lower panels show the open states. (A) A voltage-gated channel (green) becomes 
activated as the membrane depolarises. (B) A mechanosensitive channel (red) opens as a response to mechanical 
stretch of the membrane. (C) A simplified mechanism illustrating how a volume-regulated channel (blue) responds 
to a drop in osmolarity on the outside of the cell. Black dots indicate solutes. (D) A ligand-gated channel (orange) 
is activated by the binding of a ligand (yellow). 
4anisms exist, such as activation by other proteins, e.g. by G proteins [11], or activation by a 
change in pH [12]. 
1.2. Calcium activated chloride channels
The study of membrane permeability by electrophysiology dates back many decades to a time 
where the molecular identities of ion channels were not yet known [1]. This was also the case 
for calcium activated chloride currents that were discovered long before the molecular identi-
ty of calcium activated chloride channels (CaCC) could be determined. Already in 1982, anion 
currents that required influx of calcium and could be blocked by intracellular EGTA were ob-
served in retinal rod cells from the tiger salamander (Ambystoma tigrinum) [13]. The influx of 
calcium was achieved by depolarisation of the membrane, which opened voltage-dependant 
calcium channels. The observed anion currents were described as outward currents, which by 
electrophysiological convention is equal to either an influx of negatively charged ions or efflux 
of positively charged ions. Since caesium had been added to the inside of the cell to block the 
efflux of potassium, the observed currents were believed to be due to the influx of anions, 
presumably chloride. 
Currents with similar properties were shortly after also observed in Xenopus laevis oocytes 
[14]. Here the currents were found to be increased when the extracellular concentration of 
calcium was increased and abolished when calcium current blockers such as magnesium were 
added to the extracellular solution. All of this was consistent with the idea that the influx of 
calcium activated the observed currents. While it was found to be necessary to depolarise 
the membrane to above −20 mV, consistent with the activation of inward calcium currents, 
it was also found that making the membrane potential too positive essentially abolished the 
observed anion current, consistent with calcium not flowing into the cell, when the inside 
was too positive. Furthermore, the observed anion current was found to be transient, since 
it decreased over time. Similar currents were also observed in a study of cells isolated from 
rat tear glands [15] and in a study with Xenopus laevis oocytes [16], which confirmed that the 
observed currents were indeed chloride currents. A later study conducted on cells isolated 
from rat tear glands, verified the calcium dependence in a more direct manner, by varying the 
intracellular calcium concentration. [17]. 
Since those early studies, currents from calcium activated chloride channels have been ob-
served in many different cell types and they appear to be involved in many physiological pro-
cesses, including, but not limited to, taste and olfactory transduction, phototransduction, reg-
ulation of neuronal and cardiac excitability, smooth muscle contraction and fluid secretion in 
epithelia and glands [18]. 
5Certain characteristics of the current arising from these channels have over the years been es-
tablished without knowing the molecular identity of the channels. At low intracellular calcium 
concentrations, the observed current is voltage dependent and the activation is time depen-
dant. However, those dependencies disappear at concentrations above approximately 1 µM 
of Ca2+ [19]. The time dependence at low calcium concentrations can be observed as a slow 
activation, while the voltage dependence can be observed as an outward rectification (higher 
currents at positive voltages). 
Due to the high concentrations of chloride ions present in living organisms, the name calci-
um activated chloride channel seems reasonable. CaCCs are, however, rather non-selective, 
allowing anions of different sizes to permeate through the channel. Larger anions have been 
found to have a higher permeability following the sequence I− > NO3− > Br− > Cl− > F− [1]. 
1.2.1. TMEM16 and bestrophins
As previously mentioned, many early studies of CaCCs were done without knowing the mo-
lecular identities of the channels. Although different candidate proteins were suggested over 
the years, it was only in the 2000s that anoctamins and bestrophins were proposed to form 
CaCCs. 
The first member of the bestrophin protein family was identified as the gene responsible for an 
eye disease called Best Vitelliform Macular Dystrophy [20]. The encoded protein, now known 
as BEST1 (hBEST1 when referring to the human homologue), was suggested to be a trans-
membrane protein with at least four transmembrane segments, based on hydropathy plots. 
Later, three additional bestrophin homologues were identified in the human genome. [21]. 
These are now referred to as BEST2–4 (or hBEST2–4 for the human homologues). hBEST1 
and hBEST2 were shown to form chloride channels and hBEST1 was furthermore shown to 
be activated by sub-micromolar concentrations of calcium [22]. However, unlike the classi-
cal CaCCs described in the previous sections, hBEST1 and hBEST2 did not show any time 
dependency of activation and despite using sub-micromolar concentrations of calcium, no 
strong voltage dependence was observed [22]. In a later study, the homologues hBEST3 and 
hBEST4 also did not show the characteristics expected for classical CaCCs [23]. hBEST3 did 
show strong rectification and time dependence of activation, but unlike classical CaCCs, the 
rectification was in the inward direction and the currents continuously increased over the 
course of several seconds.
While the members of the bestrophin protein family do appear to form chloride channels that 
are activated by intracellular calcium, their currents do not appear to match the currents that 
have typically been described as CaCC currents. Instead, those classical CaCCs now appear to 
have been identified as members of the TMEM16 (or anoctamin) protein family [24–26]. Two 
6members of this family, TMEM16A and TMEM16B appear to form calcium activated chloride 
channels with properties that are in agreement with the classical CaCCs [27]. 
1.3. Closer look at the bestrophin protein family
Members of the bestrophin family are thus not responsible for the classical calcium activated 
chloride currents, but they still appear to form chloride channels that are activated by calcium 
and they still appear to be involved in physiologically relevant processes as it will be described 
later. 
As previously mentioned, four bestrophin homologues are found in the human genome 
(hBEST1–4), but only three (mBEST1–3) exist in mouse. Typically, 3–4 homologues are found 
in all vertebrates. All vertebrate bestrophins can phylogenetically be divided into four groups, 
each containing one of the four human homologues [28]. For non-vertebrate animals, the 
number varies significantly. Based on a recent search of the UniProt database, four homo-
logues are found in Drosophila melanogaster, while twenty-six are found in Caenorhabditis 
elegans. Additionally, distantly related homologues are also found in plants, algae, fungi [28] 
and in prokaryotes [29]. 
The four human bestrophins, and other animal bestrophins, vary greatly in length. hBEST1–4 
consist of 585, 509, 668 and 473 amino acid residues, respectively. Several splice variants have 
been reported for hBEST1 [20] and hBEST3 [21], but it is unknown if these are of any physio-
logical importance. Chicken BEST1 (cBEST1), which is discussed later, consists of 762 amino 
acid residues in the isoform which is most comparable to canonical hBEST1 sequence. As 
shown in figure 3, there is a high degree of sequence conservation between different bestro-
phins until approximately residue number 370 (numbering based on hBEST1). The following 
C-terminal region appears poorly conserved and is also aligning poorly when comparing dif-
ferent homologues. Furthermore, large parts of the non-conserved C-terminal regions are 
predicted to be intrinsically disordered, based on meta analyses of the human bestrophin ho-
mologues with the metaPrDOS disorder prediction web server [30]. Such intrinsically disor-
dered regions are often observed in the cytoplasmic domains of eukaryotic plasma membrane 
proteins [31]. 
After the discovery of the bestrophin protein family, two studies tried to predict the transmem-
brane topology of these proteins. In a study by Tsunenari et al. [23], insertion of TEV cleavage 
sites and N-linked glycosylation sites was used along with MTSET modifications, to propose 
a model of hBEST1 with four membrane spanning helices and a re-entrant loop, where the 
N- and C-termini were located on the inside of the cell. This was in partial agreement with 
a hydropathy analysis showing two pairs of strongly hydrophobic peaks, interspersed with 
two weakly hydrophobic peaks. However, when comparing to bacterial sequences, only the 
7four strongly hydrophobic peaks seem to be conserved [29], suggesting a potential flaw of 
the Tsunenari model. Another study by Milenkovic et al. [32] analysed the ability of putative 
membrane spanning helices to insert into the endoplasmic reticulum membrane. Based on 
this, a model with four membrane spanning helices was proposed. Between the first and the 
second helices as well as between the third and fourth, short extracellular loops were pre-
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Figure 3 – Multiple sequence alignment of cBEST1 and hBEST1–4. Only parts of the disordered and non-con-
served C-termini are shown. The constricting residues in the neck and aperture and the conserved Ca2+ binding 
site are labelled. 
8dicted, while a large intracellular segment of more than hundred amino acid residues was 
predicted between the second and third transmembrane helices. The N- and C-termini were 
predicted to be on the cytosolic side. Crystal structures (described in a following section) have 
since then confirmed the model proposed by Milenkovic et al., suggesting that this probably 
represents the general topology of bestrophin homologues. 
Regarding the oligomeric assembly of bestrophins there has been some confusion. One study 
suggested that hBEST1 forms a tetramer or pentamer [22], while another study suggested a 
dimer [33]. With the availability of pentameric crystal structures (described later), a pentam-
eric assembly now seems to be a general feature of the family that is necessary for the function 
of the protein. It has been shown by co-transfection that hBEST1 can associate with hBEST2 
[22], suggesting that heteropentamers might form. The physiological relevance is, however, 
unknown, since only the function of homopentamers has been studied.  
Like many other chloride channels, bestrophins appear to be permeable to several different 
anions. For hBEST1 the larger ions appear to permeate more easily through the channel, ac-
cording to the following typically reported permeability sequence SCN− > NO3− > I− > Br− > 
Cl− > F− [28]. Bestrophins have additionally been shown to be permeable to HCO3−, with a 
permeability that is slightly lower than for Cl− [34]. Furthermore, mBEST1 has been reported 
to be permeable to gluconate [35] and glutamate [36], although that could not be verified for 
cBEST1, neither using a liposome assay [37] nor in bilayer experiments [38].
1.3.1. Activation by calcium
As previously mentioned, hBEST1 has been shown to be activated by calcium [23]. Calcium 
activation has also been shown for mBEST2 [39] and hBEST4 [40]. EC50 values of 141 nM 
Ca2+ for hBEST1 [41], 230 nM for mBEST2 [39] and 230 nM for hBEST4 [40] have been re-
ported. While hBEST2 has been reported to mediate currents in the presence of calcium [22], 
the calcium dependence has not been investigated. It would, however, not be surprising if it is, 
similar to mBEST2, inactive in the absence of calcium. 
Initially, it was not clear if bestrophins were activated directly by binding of calcium or by 
interacting with other calcium binding proteins. Sequence analysis did suggest a possible cal-
cium binding site with the conserved sequence Glu-Asp-Asp-Asp-Asp, located immediately 
after the last transmembrane helix (Figure 3), since a similar stretch of acidic residues has 
been found to form the calcium binding bowl in large conductance calcium activated potassi-
um channels [42]. Mutations of these residues in hBEST1 resulted in non-functional protein, 
without affecting the plasma membrane localisation, but mutations in residues following this 
acidic stretch also affected the activation by calcium [41]. Later structural studies on cBEST1 
have, however, confirmed that calcium can be directly bound by the acidic residues in this re-
9gion [37]. Furthermore, since purified and reconstituted cBEST1 can be activated by calcium, 
it can be concluded that the activation is due to direct binding of calcium and not due to other 
endogenous factors [37,38]. 
1.3.2. Possible regulation by phosphorylation
While it seems clear that calcium can activate some vertebrate bestrophins, it is still possible 
that other factors might be involved in the activation as well. Marmorstein et al. [43] noticed 
that porcine BEST1 coimmunoprecipitated with protein phosphatase 2A, when it was ex-
tracted from porcine retinal pigment epithelium cells. Furthermore, hBEST1 was shown to 
be phosphorylated when expressed in cultured retinal pigment epithelium cells. The level of 
phosphorylation was, however, not quantified and the functional state of the phosphorylated 
bestrophin was not confirmed. Thus, the study gives little more than an indication that phos-
phorylation of porcine BEST1 and hBEST1 might be taking place. In another study Xiao et al. 
[44] identified a phosphorylation site in hBEST1 for protein kinase C (Ser358), which appeared 
to affect the function of hBEST1. The same group had previously demonstrated a rundown of 
the hBEST1 current, which became faster in the presence of higher concentrations of calcium 
[41]. When phosphorylated or when a glutamate residue was introduced at this position, the 
rundown was decreased, meaning that the channel remained active for longer.  
Interestingly, in a study on fruit fly BEST1, which activates slowly after the addition of calci-
um, ATP was found to increase the rate of activation, while a non-hydrolysable ATP analogue 
decreased the activation rate [45]. The same study found that inhibitors of calcium/calmod-
ulin-dependent protein kinase II decreased the current amplitude. Together these findings 
suggested another mechanism for calcium activation of a bestrophin besides the direct calci-
um binding to the described site, namely through a calcium dependent kinase. As the calcium 
binding site is conserved in fruit fly BEST1 (dBEST1), it is possible that these distinct mecha-
nisms could operate in parallel. Although the role of phosphorylation appears to be different 
for dBEST1 compared to hBEST1, it does seem to affect the activity in both cases, suggesting 
that phosphorylation might generally play a role in the modulation of bestrophin activity, 
although the exact effect might vary between different homologues and possibly between dif-
ferent cell types.   
1.3.3. Regulation by a C-terminal motif
hBEST3 and mBEST3 have been reported to be very slowly activated, mediating inward rec-
tifying currents only after several seconds [23,46]. This is unlike the other human and murine 
bestrophins that are activated in a largely time-independent manner, without any rectification. 
This has led to the notion that hBEST3 and mBEST3 may not be activated by calcium, even 
though they might bind calcium and require it for their function. 
10
As previously mentioned, most animal bestrophins have a rather long C-terminus that is pre-
dicted to be largely unstructured. In mBEST3 it was discovered that deletion of most of the 
C-terminus, starting from residue 353, led to larger currents with time-independent activa-
tion and no rectification [46]. Since deletions after residue 405 showed effectively the same 
behaviour as the wild-type mBEST3, the responsible region could eventually be pinpointed to 
a small motif consisting of residues 356–362 and it could furthermore be shown that the dele-
tion of this motif in hBEST3, had the same effect as the deletion in mBEST3. The motif had the 
sequence Ile-Pro-Ser-Phe-Leu-Gly-Ser and mutation of any residue, except proline, to alanine 
activated the channel [47]. A similar sequence was found in mBEST2 (Gln-Pro-Ser-Phe-Gln-
Gly-Ser), but when the sequence of this motif in mBEST2 was mutated to that of mBEST3, 
the currents of mBEST2 were increased, suggesting that this region also had an inhibitory 
role in mBEST2 [47]. This has led to the discovery that some feature of mBEST2 in the region 
405–454 might suppress the effect of the inhibitory sequence. Consequently, introducing the 
405–454 region from mBEST2 into mBEST3, increased the current of mBEST3, whereas in-
troducing the same region from mBEST3 into mBEST2, decreased the currents of mBEST2. 
The authors thus hypothesised that the effect of the inhibitory sequence was outcompeted by 
the effect of the facilitatory region (405–454) in mBEST2 [47]. Unfortunately, it was not inves-
tigated further which exact residues might be responsible for this facilitatory effect. 
1.3.4. Bestrophins and volume regulation
Another regulatory mechanism that has been proposed for certain bestrophin homologues, 
is volume sensitivity. Chien and Hartzell [48] found that osmotically activated anion currents 
in Drosophila S2 cells, could be abolished with RNA interference directed against the en-
dogenous dBEST1 and rescued by transfecting the cells with a plasmid encoding dBEST1. 
Calcium was not found to be required for this osmotically activated current, but it did in-
crease the measured peak current. Calcium could also activate the current alone, suggesting 
a dual mechanism of activation, in addition to the previously discussed possible effects of 
phosphorylation. A later genome wide RNA interference study by Stotz and Clapham [49], in-
dependently found that dBEST1 was responsible for anion currents activated by extracellular 
hypo-osmotic solutions in Drosophila S2 cells. In the same study, an mBEST2 chimera, where 
the first 64 residues from the dBEST1 N-terminus replaced the native N-terminus of mBEST2, 
was found to be activated by hypo-osmotic solutions, unlike the wild-type mBEST2.   
However, a later study by Chien and Hartzell did not find any differences in volume-regulat-
ed anion currents observed in peritoneal macrophages isolated from wild-type or BEST1−/−/
BEST2−/− mice [50], suggesting that bestrophins probably are not responsible for the classical 
VRAC currents observed in mammalian cells. Considering the recent discovery that VRACs 
are formed by LRRC8 proteins [7,51], this does not seem surprising. Nonetheless, the pos-
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sibility remains that bestrophins in certain cell types could be either directly responsible for 
VRAC currents, in some way be involved in the generation of those currents or be regulated 
by changes in osmolarity. 
The notion that bestrophins might be involved in volume regulation in some cell types has re-
cently gained more credibility following a study by Milenkovic et al. [52]. The study has char-
acterised VRAC currents in retinal pigment epithelium cells derived from human induced 
pluripotent stem cells. These currents were not affected by knockdown of LRRC8A, but were 
instead greatly reduced in the cells from patients with pathological BEST1 mutations. Fur-
thermore, a greatly reduced fertility was observed in male BEST1−/− mice, consistent with a 
high BEST1 expression level in the testes of wild-type mice. Sperm cells from the BEST1−/− 
mice showed lower motility and abnormal morphology. These sperm cells were found to cope 
less well with changes in osmolarity, which indirectly suggested a role for BEST1 in volume 
regulation. Furthermore, both hBEST1 and mBEST1 were tested in a Xenopus laevis oocyte 
swelling assay. Oocytes injected with only aquaporin-1 mRNA were quickly rupturing when 
exposed to a hypotonic solution, but this effect could be significantly delayed by co-expressing 
hBEST1 or mBEST1. Swelling induced currents were more than twice as high when oocytes 
were co-expressing hBEST1 or mBEST1 along with aquaporin-1, compared to aquaporin-1 
alone.  
The findings by Milenkovic et al. are, however, somehow contradicted by an earlier study by 
Fischmeister and Hartzell [53] that investigated hBEST1 and mBEST2. Overexpression of ei-
ther of those proteins in HEK293 cells did not appear to have any significant effect on the 
currents induced by hypotonic solutions. Milenkovic et al. argued that HEK293 cells are not 
ideal for studying BEST1 in this case, since a large fraction of overexpressed BEST1 appears 
to be retained inside the cells. Also, the use of mBEST2 by Fischmeister and Hartzell might 
not have been ideal, since the properties of mBEST1 in this regard appear to be more directly 
comparable to hBEST1. Based on the study by Milenkovic et al., it does seem likely that BEST1 
is involved in the generation of VRAC currents in certain cell types, but more studies are 
needed to fully understand this function of BEST1.
1.3.5. Potential interactions with other proteins
Various reports have suggested that Best1 might act as a regulator of voltage-dependant calci-
um channels (CaV1.3). Rosenthal et al. [54] observed a faster activation of currents which were 
believed to be mediated by L-type calcium channels in rat retinal pigment epithelium cells, 
when these were transfected with a hBEST1 plasmid. The observed effects, however, appear 
relatively small and one might also question the relevance of examining hBEST1 in cultured 
cells from rats. 
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Two later studies [55,56] from the same group have found similar effects in Chinese hamster 
ovary cells that were microinjected with the subunits of a voltage-dependant calcium channel 
from rats and human BEST1. These studies argued that there was an interaction between the 
so-called β-subunit of the rat calcium channel and proline-rich motifs in the C-terminus of 
human BEST1. The evidence for this interaction was membrane colocalisation and coimmu-
noprecipitation. The latter, however, requires detergent extraction of the proteins and as many 
membrane proteins are not stable in detergents, such results should be interpreted with cau-
tion. Additionally, misfolded protein retained in the ER could potentially also be extracted by 
the used detergents, which would further complicate the interpretation of the results. 
Another group has reported that the current from a rat L-type voltage-dependent calcium 
channel (CaV1.3) expressed in HEK293 cells was inhibited when human BEST1 was coex-
pressed [57]. No apparent effect was observed when mBEST1, mBEST2 or mBEST3 were 
used instead of hBEST1. The inhibitory effect could also be observed by coexpression of a 
C-terminal hBEST1 fragment that did not have any channel activity. By coexpressing vari-
ous truncated fragments of hBEST1 the observed effect was located to the region 330–370. 
The biochemical stability of the truncated proteins was unfortunately not reported. A direct 
interaction between a C-terminal fragment of hBEST1 and a β-subunit (β2a) was shown by 
coimmunoprecipitation, but here the results should probably be interpreted with the same 
caution as described above. The interaction was furthermore analysed by a pull-down assay 
of a C-terminal hBEST1 fragment and a rat β-subunit (β2a). Both were, however, expressed 
in Escherichia coli and their biochemical stability was not evaluated, thus also these results 
should be interpreted with caution. 
Based on the described studies, it is a possibility that an interaction can take place between 
human BEST1 and voltage-dependant calcium channels from rats. It is, however, still unclear 
if the same interaction would be seen with voltage-dependant calcium channels from humans. 
Also, due to the discussed weaknesses, the conclusions presented in the described studies 
should be interpreted with caution. 
1.3.6. Bestrophin-1 in the brain
Several studies from one group have recently suggested that BEST1 might have a physiolog-
ical role in the brain. Park et al. [36] measured calcium activated anion currents in cultured 
mouse astrocytes and found that those currents could be reduced by a knock-down of mB-
EST1, which appeared to be expressed at high levels [36,58].  In another study mBEST1 was 
suggested to be responsible for GABA release from glial cells in the cerebellum [59]. It has also 
been suggested that two different modes for release of glutamate in astrocytes, fast and slow 
release, are mediated by TREK-1 and BEST1, respectively [60]. The proposed involvement of 
TREK-1 is surprising, since TREK-1 is a potassium channel. Potassium channels are generally 
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very selective for potassium and the permeation of large, negatively charged ions through 
TREK-1 is thus a controversial proposal. As previously mentioned, glutamate could also not 
be found to permeate through cBEST1 [37,38], making the proposal of a potential permeation 
through mBEST1 controversial as well. 
The role of BEST1 in the brain is an intriguing topic. BEST1 does seem to be expressed in 
certain brain cells [36,58,61], but the question whether its function is the release of GABA and 
glutamate requires further investigations.  
1.3.7. Other physiological roles of bestrophins
Since the BEST1 gene was discovered as the gene responsible for Best vitelliform macular 
dystrophy, a large focus has been put on the investigation of possible roles of BEST1 in ocular 
epithelia. The exact role of BEST1 in the eye is not entirely clear, but mutations in the BEST1 
gene are known to cause several different eye diseases [62]. 
mBEST2 has been studied in various contexts. It has been proposed to secrete HCO3− in gob-
let cells of the colon [63] and to be involved in sweat secretion [64]. It has also been proposed 
to form CaCCs in olfactory sensory neurons [65], but a later study found the same currents in 
BEST2−/− mice, so probably BEST2 has some different role in that type of tissue. Unfortunate-
ly, several studies on bestrophins were conducted before members of the TMEM16 family of 
proteins were shown to form the classical CaCCs. It is thus possible that some of the physi-
ological functions that were initially assigned to bestrophins, might instead be mediated by 
members of the TMEM16 family. 
1.3.8. Bestrophins in non-animal organisms
Although bestrophin homologues can be found in other eukaryotes apart from animals as well 
as prokaryotes, few studies have investigated the properties of those distantly related homo-
logues. One study found that a homologue from the filamentous fungus Aspergillus nidulans 
formed an anion channel, that was apparently permeable to citrate [66]. Interestingly, the fun-
gal bestrophin homologue required calcium for activation, even though only two out of five 
residues were conserved in the previously described acidic stretch, corresponding to Asp301 
and Asp304 in hBEST1. The EC50 was reported to be 1.6 µM Ca2+, which is considerably high-
er than the values reported for animal bestrophins. As previously mentioned, an EC50 value 
of 141 nM Ca2+ has been reported for hBEST1 [41]. 
1.4. Bestrophin structures
During the course of the project described in this thesis, two bestrophin structures were solved 
independently by two different groups. Yang et al. [67] solved the structure of the prokaryotic 
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homologue kpBEST at a resolution of 2.3 Å. Later Kane Dickson et al. [37] solved the structure 
of cBEST1 at 2.85 Å resolution. As described below, these two homologues were shown to 
form pentameric channels of a similar architecture. 
1.4.1. Structure of kpBEST
The prokaryotic bestrophin homologue kpBEST was cloned from Klebsiella pneumoniae and 
expressed in E. coli. Structures were solved of two C-terminal truncations. A construct where 
the last 7 amino acid residues had been removed, yielded crystals diffracting to 2.9 Å. Remov-
ing the last 11 amino acid residues, resulted in crystals diffracting to 2.3 Å. In the crystal struc-
ture, 22–24 residues on the N-terminus (varying between the monomers) and a few residues 
on the C-terminus could not be resolved. 
Figure 4 – Ribbon models of kpBEST and cBEST1. The figure shows the pentameric structures of (A) kpBEST 
and (B) cBEST1. Within each pentamer, the five monomers are coloured in different colours. The upper part of 
the figure shows the proteins viewed from the side, with the extracellular sides on top and the intracellular sides on 
the bottom. Sheets of red and blue balls indicate the predicted boundaries of the hydrocarbon cores of the bilayers. 
The extracellular sides are labelled "out" and the intracellular sides "in". The lower part of the figure shows the views 
from the extracellular side (top view), with the pores visible as holes in the middle of the proteins.  
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The structure is a homopentamer (Figure 4a), consisting mainly of α-helices. Four of these 
helices are membrane spanning.  A large cytoplasmic region can be observed and only a small 
part of the protein is predicted to protrude from extracellular side of the membrane. When 
viewing the protein from either the extracellular or intracellular sides, a pore can be seen 
running through the middle of the protein, with the five monomers arranged symmetrically 
around the pore axis. 
1.4.2. Structure of cBEST1
The chicken (Gallus gallus) BEST1 homologue cBEST1 is closely related to hBEST1 (Figure 3). 
The crystallisation construct consisted of the first 405 out of 762 amino acid residues. cBEST1 
was expressed in yeast and co-crystallised with a Fab fragment that binds preferentially to the 
calcium bound form of cBEST1. Crystals were grown in the presence of calcium and diffracted 
to a resolution of 2.85 Å. In the solved structure residues 2–367 could be modelled. The struc-
ture of cBEST1 (Figure 4b) is overall similar to that of kpBEST, since both are homopentamers 
with a very similar fold. In the membrane region, the structure of cBEST1 appears wider as 
some of the helices are tilted at a different angle. In the cytoplasmic region some differences 
are observed as well, since cBEST1 has both a structured N-terminal region before the first 
transmembrane helix and a longer structured C-terminus that wraps around the cytoplasmic 
region. 
1.4.3. Ion pores 
As the architectures of kpBEST and cBEST1 appear very similar, general features of the bestro-
phin ion pore will be described below, based on the observations from both crystal structures. 
In each bestrophin structure, the pore runs in the centre of the protein along the non-crystal-
lographic symmetry axis. The pore is thus perpendicular to the membrane and connects the 
extracellular side to the intracellular side, as it is expected for an ion channel. Constrictions 
are found along the pore axis in two separate locations (Figure 5). Three residues on the sec-
ond transmembrane helix in the so-called “neck” form a long constriction, which is located 
towards the cytoplasmic side of the membrane. Another, shorter constriction is seen on the 
exit from the cytoplasmic region of the protein. This constriction is referred to as the “aper-
ture”. The residues forming these constrictions are all hydrophobic, but vary between the two 
structures, except for the innermost residue in the neck-region, which is a phenylalanine in 
both structures. Between the two constrictions a large inner cavity is found. 
Based on mutational studies of cBEST1 [38], it seems that the residues in the neck-region 
might be involved in gating of the channel. Mutating the three residues in the neck to alanines, 
resulted in a structure that overall appeared very similar to the wild-type structure, except for 
the three mutated residues. This triple-mutant was active in the absence of calcium, indicating 
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that the neck region might form a gate than can open upon calcium binding. The triple-muta-
tion did not alter the selectivity of the channel, which indicated that the residues in the neck 
did not form a selectivity filter. Mutating the valine in the aperture to alanine did not change 
the selectivity for anions over cations, but it did change the size-selectivity. Whereas the rel-
ative permeability for different anions in the wild-type channel follows the sequence SCN− > 
I− > Br− > Cl−, the V205A mutant showed indistinguishable permeabilities for those anions, 
suggesting that the aperture might form a size-selective filter. It is still not clear what causes 
cBEST1 to be anion selective, while kpBEST has been reported to be cation selective [67], 
but one possible explanation could be the presence of anion binding sites that were observed 
along the pore in the crystal structure of cBEST1 [38]. 
1.4.4. Ligand binding
kpBEST is reported to have basal activity in the absence of a ligand [67], but it is unknown if 
the protein can be activated further by some unknown ligand. cBEST1, however, is activated 
by calcium and, as mentioned previously, calcium was present during the crystallisation. One 
calcium ion could be observed for each monomer in the structure.  The binding site was found 
to be located after the last transmembrane helix, close to the membrane interface, in a region 
containing the five highly conserved acidic residues that were previously described. Only two 
of the conserved acidic residues (Asp301 and Asp304) were involved directly in the binding, 
while the rest of the binding interactions were contributed by main-chain carbonyls from the 
surrounding region and the N-terminus and by a water molecule (Figure 6). As expected, mu-
tating the two aspartates directly involved in the calcium binding to alanines affected the ac-
Figure 5 – Views along the pores of kpBEST and cBEST1. The structures of (A) kpBEST and (B) cBEST1 are shown 
as white ribbons. From each structure, approximately two whole monomers are hidden, resulting in free views to 
the pores. Approximate membrane boundaries are shown. The residues causing constrictions along the pores are 
shown as purple sticks and labelled. 
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tivation by calcium. Whereas the wild-type channel was activated by Ca2+ with an EC50 value 
of 17 nM, the D301A-D304A mutant could not be activated by 2 µM Ca2+ [38]. 
1.5. Aim of this thesis
At the time when the project described in this thesis was started, no structures of bestrophin 
homologues had been solved. It was also not known if bestrophins were truly channels or 
some sort of channel regulators. It was therefore my goal to identify a bestrophin homologue 
that was stable when overexpressed and purified. Using such a homologue, the next goal was 
to solve a bestrophin structure at atomic resolution and use the structural knowledge to un-
derstand the function of bestrophins. 
This thesis describes the identification of several prokaryotic bestrophin homologues suitable 
for structural studies. Against one of these homologues, nanobodies were selected to aid in 
crystallisation and thus the crystal structure of a prokaryotic bestrophin homologue in com-
plex with a nanobody could be solved. The structure revealed a pentameric ion channel where 
the ion conduction pathway could readily be identified. Based on the structure, features be-
lieved to be important for selectivity and activation could be identified and discussed.   
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Figure 6 – Ca2+ binding site of cBEST1. (A) Location of the Ca2+ binding site in the structure of cBEST1. N-terminal 
region coloured cyan, Ca2+ binding loop coloured yellow. (B) Ca2+ binding site of cBEST1. All five acidic residues 
and the main-chain carbonyls that are involved in Ca2+ binding are shown and labelled. 
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2. Results
2.1. Small scale expression screening
2.1.1. Selection and cloning of prokaryotic homologues
Although bestrophin homologues at first were identified exclusively in eukaryotic organisms, 
one paper has suggested that prokaryotic homologues also exist. Hagen and colleagues were 
able to identify 30 putative prokaryotic bestrophin homologues by using the hBEST1 protein 
sequence as a query for a BLAST search [29]. Based on multiple sequence alignments, these 
prokaryotic homologues were found to share four short sequence motifs with the eukary-
otic homologues. Furthermore, a similar number of transmembrane helices were predicted 
for prokaryotic and eukaryotic homologues. The prokaryotic homologues were also found to 
be shorter than the eukaryotic bestrophin homologues, making the prokaryotic homologues 
interesting targets for structural studies. Eukaryotic membrane proteins are often difficult to 
purify and crystallise and it was therefore hoped that the more compact prokaryotic homo-
logues would prove to be more amenable to overexpression, purification and crystallisation. 
Starting with a collection of prokaryotic genomic DNA, which was acquired for other proj-
ects, bacterial bestrophin homologues were identified by searching the NCBI database [68], 
while limiting the results to organisms that were represented in the available genomic DNA 
collection. Searching for the keyword “bestrophin”, 30 sequences were immediately identified 
(Table 1). These were sequences that had been automatically annotated as belonging to the 
bestrophin protein family. BLAST searches did not reveal more homologues within the avail-
able collection. 
The 30 identified sequences belonged to a total of 18 different organisms. In most organisms, 
only one homologue was identified, but some contained between one and five additional ho-
mologues. To avoid confusion, each homologue was given a unique name, which consisted of 
a sequentially increasing number and a three-letter abbreviation of the species name (Table 1). 
All homologues are referred to exclusively by this name in the following. 26 of the 30 homo-
logues were successfully cloned and sequenced. Screening of these homologues is described 
in a later section. 
Since the initial screening was based exclusively on genomic DNA that had been acquired by 
our lab in order to clone different membrane transporters for other projects, the first round 
might have been biased towards prokaryotic organisms containing those transporters. It there-
fore became a concern that the sequence diversity might have been limited in the first round, 
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as bestrophins could potentially be present in other phylogenetic groups than the transporters 
selected for other, unrelated projects. 
Searching the NCBI database for prokaryotic protein sequences belonging to the bestrophin 
family gave a list of approximately 700 sequences. From those sequences, a phylogenetic tree 
was constructed. Homologues from the first round of screening were included in the tree. Ho-
mologues were then selected throughout the tree, primarily from organisms where genomic 
DNA was commercially available. Like in the first round, when a selected organism contained 
more than one homologue, all of them were chosen for cloning. Additionally, some homo-
logues were chosen based on similarity to the ones that performed well in the first round. Two 
homologues (69MCA and 70MCA) were found in the thermotolerant prokaryote Methylococ-
cus capsulatus (strain Bath), which grows well at temperatures up to 50°C, with the optimum 
at 37°C [69]. Another homologue (94TEL) was found in the thermophilic cyanobacterium 
Thermosynechococcus elongatus BP-1, which grows well at temperatures up to 60°C, with the 
optimum at 57°C [70]. In total, 64 new homologues were selected from 38 different organisms 
(Table 2). Of these, 56 were successfully cloned and sequenced. Screening of these homo-
logues is described in a later section. 
Homologue 
name Species
NCBI protein 
accession no. 
Length 
(aa)
Score
1 2 3 4 5 6
1SPH Sphingomonas sp. SKA58 ZP_01302606.1 294 x
2GAU Gemmatimonas aurantiaca T-27 YP_002762845.1 337 x
3GAU  - YP_002762641.1 285 x
4DFE Dyadobacter fermentans DSM 18053 YP_003089799.1 335 x
5DFE  - YP_003085689.1 333 x
6DFE  - YP_003085569.1 293 x
7DFE  - YP_003085312.1 297 x
8DFE  - YP_003084712.1 302 x
9DFE  - YP_003084476.1 300 x
10PHE Pedobacter heparinus DSM 2366 YP_003092309.1 286 x
11CPI Chitinophaga pinensis DSM 2588 YP_003124670.1 305 x
12CPI  - YP_003121699.1 289 x
13CPI  - YP_003120949.1 305 x
14SLI Spirosoma linguale DSM 74 YP_003389066.1 314 x
15SLI  - YP_003386700.1 308 x
16SLI  - YP_003386305.1 309 x
17BPS Bacillus pseudomycoides DSM 12442 ZP_04152149.1 310 x
18ABO Alcanivorax borkumensis Yakimov et al. 1998 YP_692019.1 315 x
19STY Salmonella typhimurium LT2 NP_460487.1 315 x
20ECO Escherichia coli MC1061 YP_001730508.1 304 x
21MMA Microscilla marina ATCC 23134 ZP_01689721.1 312 x
22MMA  - ZP_01689715.1 326 x
23MMA  - ZP_01687254.1 293 x
24RPA Rhodopseudomonas palustris TIE-1 YP_001992432.1 307 x
25MEX Methylobacterium extorquens PA1 YP_001637861.1 306 x
26ZPR Zunongwangia profunda SM-A87 YP_003586571.1 296 x
27CAL Cellulophaga algicola DSM 14237 YP_004163015.1 332 x
28MTR Marivirga tractuosa DSM 4126 YP_004052572.1 290 x
29MAN Maribacter sp. HTCC2170 (‘antarcticus’) YP_003862288.1 334 x
30RBI Robiginitalea biformata HTCC2501 YP_003193808.1 345 x
Table 1 – Overview of the first round of screening. Prokaryotic bestrophin homologues selected for screening 
and results of the screening are listed. For 20ECO, the listed NCBI accession number corresponds to a different 
strain. Score 1: Cloning failed; score 2: low whole-cell GFP fluorescence; score 3: poorly extracted with DDM; score 
4: degraded / not well folded / no FSEC peak; score 5: FSEC peak, but low expression; score 6: FSEC peak, good 
expression.  
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Homologue 
name Species
NCBI protein 
accession no. 
Length 
(aa)
Score
1 2 3 4 5 6
31SSP Sphingobacterium spiritivorum ATCC 33300 ZP_03967349.1 342 x
32SSP  - ZP_03966718.1 295 x
33SSP  - ZP_03967326.1 294 x
34HHY Haliscomenobacter hydrossis DSM 1100 YP_004450215.1 328 x
35HHY  - YP_004448050.1 292 x
36HHY  - YP_004447651.1 308 x
37RSL Runella slithyformis DSM 19594 YP_004653851.1 311 x
38RSL  - YP_004655318.1 287 x
39FJO Flavobacterium johnsoniae UW101 YP_001195730.1 315 x
40FJO  - YP_001195282.1 287 x
41FJO  - YP_001196255.1 305 x
42BMY Bacillus mycoides DSM 2048 ZP_04169863.1 310 x
43PLI Planctomyces limnophilus DSM 3776 YP_003630025.1 306 x
44PLI  - YP_003630739.1 303 x
45MFU Myxococcus fulvus HW-1 YP_004668339.1 323 x
46MFU  - YP_004665463.1 387 x
47MFU  - YP_004665484.1 306 x
48PMA Planctomyces maris DSM 8797 ZP_01853801.1 305 x
49FTA Fluviicola taffensis DSM 16823 YP_004344559.1 290 x
50MMO Methylotenera mobilis JLW8 YP_003047530.1 287 x
51MTU Methylobacter tundripaludum SV96 ZP_08783233.1 319 x
52PBR Planctomyces brasiliensis DSM 5305 YP_004269127.1 302 x
53BMA Blastopirellula marina DSM 3645 ZP_01089321.1 295 x
54BMA  - ZP_01089414.1 316 x
55PSY Pseudomonas syringae pv. aptata str. DSM 50252 EGH76367.1 295 x
56PSY  - EGH75905.1 314 x
57XGA Xanthomonas gardneri (ex Sutic 1957) Jones et al. 2006 ZP_08183953.1 298 x
58GDI Gluconacetobacter diazotrophicus PAl 5 YP_001602096.1 291 x
59CTE Comamonas testosteroni KF-1 ZP_03544906.1 315 x
60SMA Stenotrophomonas maltophilia K279a YP_001974135.1 305 x
61OIN Oceanibulbus indolifex HEL-45 ZP_02155189.1 301 x
62ABA Acinetobacter baumannii ATCC 19606 ZP_05829321.1 303 x
63BTH Burkholderia thailandensis E264 YP_439619.1 302 x
64BPH Burkholderia phymatum STM815 YP_001858405.1 306 x
65PMI Proteus mirabilis ATCC 29906 ZP_03841694.1 305 x
66CTU Cronobacter turicensis z3032 YP_003210555.1 303 x
67KPN Klebsiella pneumoniae subsp. pneumoniae ATCC 13882 ZP_06017540.1 303 x
68MCH Methylobacterium chloromethanicum CM4 YP_002419264.1 306 x
69MCA Methylococcus capsulatus str. Bath YP_115444.1 277 x
70MCA  - YP_115096.1 315 x
71S21 Sphingobacterium sp. 21 YP_004316568.1 293 x
72S21  - YP_004319178.1 308 x
73S21  - YP_004318133.1 296 x
74CHU Cytophaga hutchinsonii ATCC 33406 YP_677610.1 290 x
75CHU  - YP_678981.1 297 x
76CHU  - YP_678426.1 313 x
77CHU  - YP_677323.1 335 x
78LBY Leadbetterella byssophila DSM 17132 YP_003996785.1 292 x
79LBY  - YP_003997008.1 324 x
80CGL Chryseobacterium gleum ATCC 35910 ZP_07089386.1 305 x
81CGL  - ZP_07089184.1 292 x
82CGL  - ZP_07088791.1 342 x
83CGL  - ZP_07086903.1 334 x
84CGL  - ZP_07086450.1 292 x
85CGL  - ZP_07084811.1 293 x
86CGL  - ZP_07084468.1 292 x
87FPS Flavobacterium psychrophilum JIP02/86 YP_001295539.1 287 x
88PSA Pedobacter saltans DSM 12145 YP_004273412.1 285 x
89CAL Cellulophaga algicola DSM 14237 YP_004163015.1 287 x
90CME Cupriavidus metallidurans CH34 YP_587474.1 303 x
91CNE Cupriavidus necator N-1 YP_004682225.1 338 x
92CNE  - YP_004681119.1 285 x
93RSO Ralstonia solanacearum GMI1000 NP_521533 306 x
94TEL Thermosynechococcus elongatus BP-1 NP_682999 326 x
Table 2 – Overview of the second round of screening. Prokaryotic bestrophin homologues selected for screening 
and results of the screening are listed. For 67KPN, the listed NCBI accession number corresponds to a different 
strain. 89CAL is identical to 27CAL from the first round, except that a later start codon was chosen. 66CTU could 
not be analysed by FSEC due to technical issues. Score 1: Cloning failed; score 2: low whole-cell GFP fluorescence; 
score 3: poorly extracted with DDM; score 4: degraded / not well folded / no FSEC peak; score 5: FSEC peak, but 
low expression; score 6: FSEC peak, good expression.  
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In the third, and last, round of screening it was attempted to find homologues that were sim-
ilar to the ones that behaved well in the second round. Approximately 1500 sequences were 
downloaded from the NCBI database and used to construct a phylogenetic tree. Within this 
tree, a clade was identified which contained several of the homologues that had behaved well 
in the previous rounds (3GAU, 12CPI, 33SSP, 40FJO and 69MCA). In total, 63 homologues 
were present in this clade, of which 25 had been tested in the previous rounds. A few addi-
tional sequences were found by BLAST searches using 33SSP as a query sequence. This way a 
total of 34 new homologues were selected for screening (Table 3). Unlike the previous rounds, 
other homologues from the selected organisms were omitted if they were not belonging to this 
clade. 13 of the selected homologues could be cloned from commercially available genomic 
DNA. For the remaining 21 homologues, the corresponding genes were synthesised. All 34 
Homologue 
name Species
NCBI protein 
accession no. 
Length 
(aa)
Score
1 2 3 4 5 6
95FIN Flavobacterium indicum GPTSA100-9 YP_005357091.1 287 x
96NKO Niastella koreensis GR20-10 YP_005006142.1 293 x
97PAG Pedobacter agri PB92 ZP_11219306.1 286 x
98FAE Fibrella aestuarina BUZ 2 YP_007323946.1 292 x
99FAE  - YP_007320478.1 311 x
100FLI Fibrisoma limi BUZ 3 ZP_10333830.1 304 x
101FLI  - ZP_10333173.1 309 x
102EOL Emticicia oligotrophica DSM 17448 YP_006871835.1 290 x
103OHO Owenweeksia hongkongensis DSM 17368 YP_004990241.1 289 x
104FDU Fluoribacter dumoffii NY23 ZP_10139395.1 284 x
105SGR Saprospira grandis DSM 2844 ZP_18267275.1 309 x
106GOB Gemmata obscuriglobus UQM 2246 ZP_02732374.1 281 x
107CAN Cesiribacter andamanensis AMV16 ZP_23804627.1 300 x
108FBR Flavobacterium branchiophilum FL-15 YP_004844850.1 287 x
109FCO Flavobacterium columnare ATCC 49512 YP_004941078.1 287 x
110FFR Flavobacterium frigoris PS1 ZP_09896637.1 285 x
111LLO Legionella longbeachae NSW150 YP_003455895.1 287 x
112LPN Legionella pneumophila subsp. pneumophila ATCC 43290 YP_005184430.1 286 x
113FBA Flavobacteria bacterium BAL38 ZP_01735098.1 287 x
114MSA Mariniradius saccharolyticus AK6 EMS34534.1 293 x
115FSP Flavobacterium sp. CF136 ZP_10730490.1 287 x
116CSP Chryseobacterium sp. CF314 ZP_10726656.1 293 x
117ASP Algoriphagus sp. PR1 ZP_07722495.1 293 x
118EAN Elizabethkingia anophelis Ag1 ZP_09414660.1 290 x
119FSP Flavobacterium sp. F52 ZP_10480769.1 287 x
120PSP Pedobacter sp. BAL39 ZP_01882510.1 286 x
121LDR Legionella drancourtii LLAP12 ZP_09618728.1 284 x
122FSP Flavobacterium sp. WG21 AMYW01000055 287 x
123PCU Flavobacterium sp. Leaf359 AHJF01008472 288 x
124FSP Flavobacterium sp. B17 BACY01000542 293 x
125LAN Legionella anisa str. Linanisette CANP01000031 282 x
126PSP Pontibacter sp. BAB1700 ZP_10400757.1 286 x
127FIM Fulvivirga imtechensis AK7 ZP_20982534.1 290 x
128FBA uncultured Flavobacteriia bacterium CCF99166 290 x
Table 3 – Overview of the third round of screening. Prokaryotic bestrophin homologues selected for screening and 
results of the screening are listed. For the homologues 122FSP, 123PCU, 124FSP and 125LAN protein sequences 
were not available in the NCBI database, when the list was compiled. For those homologues, the corresponding 
DNA sequences are listed instead. The DNA sequence for the homologue 123PCU is a whole genome shotgun se-
quence from the organism Pseudoperonospora cubensis, but the cloned sequence actually belongs to the organism 
listed in the table.  For 110FFR, 127FIM and 128FBA an earlier start codon was chosen than the one annotated 
in the NCBI database. For 104FDU, the listed NCBI accession number corresponds to a different strain. Score 1: 
Cloning failed; score 2: low whole-cell GFP fluorescence; score 3: poorly extracted with DDM; score 4: degraded 
/ not well folded / no FSEC peak; score 5: FSEC peak, but low expression; score 6: FSEC peak, good expression. 
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homologues were successfully cloned and sequenced. Screening of these homologues is de-
scribed in a later section. 
2.1.2. Screening methodology and workflow
Green fluorescent protein (GFP) fusion proteins have previously been shown to be useful for 
expression and purification screening of integral membrane proteins. With GFP fusions, small 
amounts of protein can be detected in a size-exclusion chromatography (SEC) experiment, 
by using a liquid chromatography system coupled to a fluorescence detector. This technique, 
known as fluorescent-detection size-exclusion chromatography (FSEC), makes it possible to 
evaluate the monodispersity and expression level of small amounts of protein in crude deter-
gent extracts [71]. Monodispersity, defined as a single, symmetrical peak in a size-exclusion 
chromatography experiment, is generally considered to be an important factor for protein 
crystallisation [72].
GFP can additionally also be used as a folding indicator. When fused to the C-terminus of a 
target protein, the correct folding of GFP is typically dependent on the correct folding of the 
target protein [73]. Folded  protein and aggregated protein can then be separated by SDS-
PAGE, where the aggregated protein tend to migrate with a higher apparent molecular weight 
than the correctly folded protein [74]. 
Since all the selected homologues were from prokaryotic organisms, Escherichia coli was cho-
sen as the host for the expression screening. As an expression vector the plasmid pBXC3GH 
was used. This vector encodes C-terminal GFP and 10×His fusion tags as well as a HRV 3C 
cleavage site, allowing removal of those tags by proteolytic cleavage with the HRV 3C pro-
tease. In this vector, expression of the fusion protein is under the control of the L-arabinose 
inducible ParaBAD promoter. Since expression under the control of this promoter is known to 
be tightly controlled and can be modulated over a wide range of inducer concentrations [75], 
it was thought to be ideal for the expression of integral membrane proteins, which are often 
difficult to produce. 
While the first round of screening only included 30 homologues, it was considered likely that 
more homologues would be screened at a later point. For that reason, a high-throughput ex-
pression and screening method was chosen. Different cultures were grown in parallel in small 
volumes (typically 1–4 ml in 96 or 24-well plates) with subsequent cell lysis, detergent ex-
traction and various centrifugation steps also carried out in parallel. 
E. coli cells were generally induced at 25°C as this temperature had been found optimal for 
other projects [76,77]. In the initial round of screening, several different concentrations of 
inducer were used. As the concentration of 0.004% L-arabinose was found to work well, this 
was used for subsequent rounds. After overnight incubation, the cells were harvested by cen-
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trifugation. Whole cell GFP fluorescence was used to identify poorly expressing homologues, 
which were omitted from subsequent steps. 
After lysing the cells, the detergent n-Dodecyl-β-D-maltoside (DDM) was added to extract 
the membrane proteins. Non-solubilised material was removed by ultracentrifugation and the 
extraction efficiency was judged by comparing the GFP fluorescence of the lysate before (total 
protein fraction) and after (soluble protein fraction) the ultracentrifugation. Homologues with 
poor extraction efficiency (below 30–40%) were excluded at this point. 
Samples of the total and soluble protein fractions were subsequently analysed by SDS-PAGE. 
Using in-gel fluorescence, bands of correctly folded fusion protein could be identified. Af-
ter recording the in-gel fluorescence, the same gels were analysed by western blotting, which 
made it possible to visualise the misfolded protein in addition to the bands of correctly folded 
protein. Since all homologues were similar in length (average 303 amino acid residues; SD = 
17 amino acid residues), the expected molecular weight of a GFP fusion was around 60 kDa. 
This knowledge was used to distinguish full-length fusion proteins from degradation products 
when analysing the gel images. Homologues that were predominantly misfolded or degraded 
were thus excluded at this step. 
Finally, samples of the soluble protein fractions were analysed by FSEC. Most of the tested 
homologues gave no clear peak, but certain homologues resulted in a single, monodisperse 
peak that eluted at the expected volume. Homologues that resulted in very small peaks, barely 
distinguishable from the background signal, were generally not investigated further. 
2.1.3. First round of screening
The aim of the first screening round was primarily to test whether bacterial bestrophin ho-
mologues could be expressed in E. coli and purified, since no published study at that time had 
investigated this question. Initial results were positive, since 23 of the 26 tested homologues 
resulted in green fluorescent E. coli cells. Of the remaining 23 homologues, 17 could be ex-
tracted efficiently with DDM. Some produced mainly aggregated protein, which was seen as 
a band of higher molecular weight in the western blot analysis. Others seemed to produce 
well-folded protein, but did not give a single peak in the FSEC analysis. Results for the differ-
ent homologues are summarised with a score in table 1. 
Two homologues behaved very well, each showing a single peak on the FSEC chromatogram. 
The results for these two homologues, 3GAU and 12CPI, are shown in figure 7. The homo-
logue 20ECO (from E. coli) is included as an example of a poorly behaving homologue. As 
both 3GAU and 12CPI were fused to GFP, the calculated molecular weights were 61 kDa and 
63 kDa, respectively. The positive control, LacS, by comparison had a slightly higher calculated 
molecular weight of 83 kDa with GFP fused to the C-terminus and 54 kDa when only fused 
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to a C-terminal His-tag. 3GAU and 12CPI, however, eluted earlier than LacS-GFP, which in-
dicated that these proteins might form higher oligomeric structures. 3GAU did not produce 
a monodisperse peak, since there was a shoulder on the trailing edge of the peak. By compar-
ison, the homologue 20ECO (the homologue from E. coli), did not show a well-defined peak. 
As illustrated by the in-gel fluorescence analysis in figure 7, 3GAU and 12CPI both showed a 
clear fluorescent band at a lower molecular weight than LacS. As it is often seen for integral 
membrane proteins, all proteins migrated faster than their corresponding sizes of marker pro-
teins. 20ECO (64 kDa) also showed a clear fluorescent band. Both 3GAU and 20ECO showed 
several lower molecular weight bands, which might indicate partial degradation. 
3GAU and 20ECO also both showed significant amounts of misfolded protein, resulting in 
characteristic double bands on the western blot. The higher molecular weight bands were 
Figure 7 – Results of the first round of small scale expression screening. (A) FSEC traces for three of the tested 
homologues. 3GAU and 12CPI were selected for further testing, whereas 20ECO was not. LacS-GFP and LacS-
His were included as positive and negative controls, respectively. Numbers next to the peaks indicate the elution 
volumes of the peaks. (B) In-gel fluorescence results for the same three homologues. The Lane "M" indicates a 
prestained molecular weight marker. Lanes labelled "T" show the total protein content in the lysate before ultra-
centrifugation and "S" show the soluble protein left in the supernatant after ultracentrifugation. (C) Western blot 
analysis of the same gel as shown in the previous panel. Detection with anti-His-HRP antibody. The bands of the 
prestained marker are not all visible on the shown images, but they were visible on the membrane and their posi-
tions are shown. 
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thought to contain misfolded GFP and were therefore not seen in the in-gel fluorescence im-
ages. Most of the misfolded protein was removed by ultracentrifugation, since the intensities 
of the higher molecular weight bands were greatly reduced after this purification step. 
For the two homologues 3GAU and 12CPI, the in-gel fluorescence and the western blots were 
in good agreement with the FSEC results. 12CPI produced a much cleaner signal in the in-
gel analysis and showed a monodisperse peak in the FSEC analysis. For 3GAU, the presence 
of lower molecular weight bands observed on the gels could explain the FSEC behaviour and 
also suggested that the protein was sensitive to degradation and therefore might require the 
addition of protease inhibitors during purification. The presence of misfolded protein before 
ultracentrifugation suggested that the inducer concentration might have been too high, since 
this often leads to misfolded protein [74]. 
Based on the in-gel analysis alone, it could not have been anticipated that 20ECO would not 
produce a peak in the FSEC analysis. This underlines the importance of performing the FSEC 
analysis in addition to the gel-based expression screening. 
2.1.4. Second round of screening
In comparison to the first round, the second round of screening included significantly more 
homologues. Of 56 proteins investigated, 50 showed clear fluorescent signals in intact E. coli 
cells. 36 proteins could be extracted with DDM and were investigated further. 17 proteins 
did not yield sufficient amounts of well folded protein in the gel analyses or did not show sin-
gle peaks in the FSEC analysis, and were therefore not studied further. Of the remaining 19 
proteins, 13 only resulted in very small FSEC peaks and were therefore not studied further, 
as higher priority was given to the remaining 6 homologues with higher yields. Table 2 sum-
marises the results for the entire set of tested homologues. 
Results for the best behaving homologues are shown in figure 8. The homologue 12CPI from 
the previous round was included as a control. Since the FSEC analysis in this round of screen-
ing was done on a different SEC column, all peaks eluted earlier compared to the first round. 
67KPN (from Klebsiella pneumoniae) is closely related to the E. coli homologue 20ECO, which 
was tested in the first round of screening. The two proteins share a sequence identity of 56% 
and cluster in proximity in the phylogenetic tree (Figure 9). However, unlike 20ECO, 67KPN 
showed a single monodisperse peak. Additionally, the gel-analysis showed a clear band and no 
significant amounts of misfolded protein or degradation products. 
As mentioned previously, the homologue 69MCA was cloned from a thermotolerant organ-
ism. The FSEC and the gel analyses indicated that this protein behaved well and expressed in 
larger amounts than the control. 
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Figure 8 – Results of the second round of small scale expression screening. (A) FSEC traces for six well behaving 
homologues. 12CPI-GFP and 12CPI-His were included as positive and negative controls, respectively. Numbers 
next to the peaks indicate the elution volumes of the peaks. (B) In-gel fluorescence results for the same six homo-
logues. The Lane "M" indicates a prestained molecular weight marker. Lanes labelled "T" show the total protein 
content in the lysate before ultracentrifugation and "S" show the soluble protein left in the supernatant after ultra-
centrifugation. (C) Western blot analysis of the same gels as shown in previous panel. Detection with anti-His-HRP 
antibody. The bands of the prestained marker are not all visible on the shown images, but they were visible on the 
membranes and their positions are shown. 
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The homologues 33SSP, 40FJO and 55PSY all behaved promising, although 33SSP and 55PSY 
did show some misfolded protein before the ultracentrifugation step. 55PSY also showed an 
additional band at a lower molecular weight, indicating degradation. Both homologues, how-
ever, gave good results in the FSEC analysis. 
49FTA gave a single monodisperse peak in the FSEC analysis, but only a faint band was visible 
on the gels after ultracentrifugation. It was still included in the further analysis, since the FSEC 
peak indicated a high expression level. 
2.1.5. Third round of screening
34 homologues were tested in the third and final round of screening. Results are summarised 
in table 3. Judged by the whole cell fluorescence, 6 homologues did not express well. Of the re-
Figure 9 – Maximum likelihood phylogenetic tree showing the phylogeny of all tested homologues. The tree was 
calculated using PhyML. The scale bar indicates the average number of amino acid substitutions per site. Homo-
logues that performed well in the small scale expression screenings are highlighted with green dots. 
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maining 28 homologues, 2 could not be extracted and 9 did not show any signal during FSEC 
analysis. 
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Figure 10 – Results of the third round of small scale expression screening. (A) FSEC traces for four well behaving 
homologues. 33SSP-GFP and 33SSP-His were included as positive and negative controls, respectively. Numbers 
next to the peaks indicate the elution volumes of the peaks. (B) In-gel fluorescence results for the same four homo-
logues. The Lane "M" indicates a prestained molecular weight marker. Lanes labelled "T" show the total protein 
content in the lysate before ultracentrifugation and "S" show the soluble protein left in the supernatant after ultra-
centrifugation. (C) Western blot analysis of the same gels as shown in previous panel. Detection with anti-His-HRP 
antibody. The bands of the prestained marker are not all visible on the shown images, but they were visible on the 
membranes and their positions are shown. Less marker was loaded than in the first two rounds of screening and as 
a result of that, the 20 kDa band of the marker was not clearly visible. 33SSP did not express well with only a His-tag 
and therefore no band is visible in the lane labelled 33SSP-His.
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From this screening round, in total 17 homologues resulted in FSEC peaks eluting at the ex-
pected volume. This was almost as many as the second round of screening, where peaks were 
observed for 19 homologues. Considering that significantly more homologues were tested in 
the second round, this meant that the success rate was higher in the third round. This is likely 
an effect of choosing homologues closely related to the ones that were performing well in 
previous rounds. 
The homologues that expressed the best and gave the cleanest gel signals, without signs of 
much degradation or misfolding, were selected for further studies. Figure 10 shows the results 
of FSEC and gel analyses for the homologues 95FIN, 103OHO, 113FBA and 119FSP. Based 
on the FSEC elution profiles, all four homologues expressed at least at the same level or even 
higher than the homologue 33SSP, which was included as a control for comparison. Peaks 
were symmetric and monodisperse. 
For each of the four homologues a single band was visible in the in-gel fluorescence analysis. 
Lower molecular weight bands, indicating degradation, were faint. Similarly, the western blot 
analysis showed little misfolded protein, which could be removed by ultracentrifugation.
The sequences of the four homologues selected for further characterisation were aligned to 
the sequences from the previous rounds of screening and are shown in figure 11. The sequenc-
es aligned well, except for a few regions where some homologues were significantly shorter 
than others. 
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Figure 11 – Multiple sequence alignment of the homologues selected during initial screening. The alignment was 
prepared with PROMALS3D. α-helices are shown as blue rectangles for the homologue 67KPN based on the PDB 
entry 4WD8. The membrane spanning helices are labelled as TM1–4. 
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2.2. Characterisation of selected homologues
2.2.1. Choosing detergents and additives
Integral membrane proteins are typically crystallised as detergent-protein complexes. A de-
tergent molecule consists of a hydrophilic head group and a hydrophobic tail. In aqueous 
solutions, detergents can spontaneously assemble into micelles when the concentration is suf-
ficiently high. In these micelles, the hydrophobic tails are in the middle and the hydrophilic 
head groups on the surface. When a membrane protein is solubilised in a detergent, the deter-
gent micelle surrounds the hydrophobic region of the protein like a belt. In most membrane 
protein crystals, the protein stays inside the detergent micelle [78].
The size of a micelle can vary dependent on the type of the detergent head group as well as the 
length of the detergent alkyl chain. Shorter chain detergents generally form smaller micelles 
than longer chain detergents. When crystallising detergent solubilised membrane proteins, 
it is generally thought that larger micelles can hinder the formation of crystal contacts and 
therefore result in crystals that diffract less well [79]. Unfortunately, shorter chain detergents 
are generally harsher than longer chain detergents, so a balance must be found between the 
improved crystallisation properties of shorter chain detergents and the improved protein sta-
bility of the longer chain detergents. 
DDM, which was used in the small-scale screening, is a mild detergent which has been widely 
used for the purification and crystallisation of membrane proteins. The detergent n-Decyl-β-
D-maltoside has the same maltoside head group as DDM, but has an alkyl chain that is two 
carbon atoms shorter. Thus, DM produces smaller micelles than DDM, but it is also harsher. 
Since bacterial membrane proteins are often more stable than comparable eukaryotic homo-
logues [79], I expected that the shorter chain detergent DM could be a good choice for crys-
tallisation of the bacterial bestrophin homologues 3GAU and 12CPI. 
Animal bestrophins are known to form calcium activated ion channels. Nothing was known 
about the activation of prokaryotic bestrophin homologues, but it was considered a possibility 
that they could also be activated by calcium. Therefore, crystallisation screens were, whenever 
possible, performed both with and without the addition of calcium. Typically, one protein 
drop contained no added calcium and another contained 1–5 mM CaCl2.
2.2.2. Purification and crystallisation of homologues from the first round
For their crystallisation, several milligrams of protein are typically required to screen thou-
sands of different conditions at once. Therefore, the expression of 3GAU and 12CPI had to 
be scaled up to larger volumes of E. coli culture. Essentially the expression was carried out 
as during the small-scale screening, except that larger culture vessels were used. Typically, 
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cultures were grown in 2 l shaker flasks or in a fermenter. Typical volumes were 32 × 0.6 l in 
shaker flasks or 9 l in a fermenter. 
To purify the protein, a two-step protocol was developed. In the first step the protein was 
purified using immobilised metal ion affinity chromatography (IMAC), where the C-terminal 
His-tag of the protein was bound to Ni2+-ions that were immobilised on agarose beads. After 
proteolytic removal of the GFP–His-tag, the protein was then purified using size-exclusion 
chromatography (SEC). 
Since initial attempts to purify 3GAU and 12CPI using the detergent DDM looked promising 
(data not shown), I decided to attempt to purify the homologues in DM instead, hoping that 
the shorter micelle size of DM would be beneficial during crystallisation screening. Figure 
12a–b shows the size-exclusion chromatograms from purifications using approximately 1–1.5 
l fermenter culture. For both homologues, a comparably large peak was obtained at the void 
volume, followed by a single, monodisperse peak eluting after 11.08 ml (3GAU) or 11.54 ml 
(12CPI). When comparing to reference protein standards, these elution volumes would cor-
respond to soluble, globular proteins with sizes ranging between 290 kDa (12CPI) and 360 
kDa (3GAU). Since the hydrodynamic radius of a protein-detergent-complex depends both 
on the amount of protein and the size of the detergent micelle, and since the size of a deter-
gent micelle surrounding a membrane protein is not exactly known, the exact oligomeric state 
of the proteins could not be determined based solely on the SEC profiles. Nevertheless, the 
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Figure 12 – Purification of 3GAU, 12CPI and 3GAU-C9 in DM. (A) 3GAU. (B) 12CPI. (C) 3GAU-C9. The shown 
chromatograms are SEC profiles. Numbers on the chromatograms indicate elution volumes of the peaks. Blue lines 
on the bases of the chromatograms indicate the peak fractions, which were loaded on the shown gels. (D) SDS-
PAGE analyses of the peak fractions.
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chromatograms show that the proteins assembled into higher-order oligomers, consisting of 
several identical chains. As shown in figure 12d, both protein samples were pure. 
Several attempts were made to crystallise 3GAU and 12CPI purified in DM, but no crystals 
were obtained. 3GAU was found to have a C-terminus that was 13 amino acid residues longer 
than that of 12CPI. A shorter version of the C-terminus of 3GAU, which was constructed by 
removing the last 9 residues (referred to as 3GAU-C9), was found to be expressed at similar 
levels as the full-length protein and to be stable during purification. Figure 12c shows the 
size-exclusion chromatogram from a purification of 3GAU-C9, which was used for crystallisa-
tion screening. Despite several attempts, 3GAU-C9 did not crystallise in DM either. Also, the 
addition of calcium did not seem to have any effect on crystallisation. 
Interestingly, when purifying larger amounts of protein, I often observed that the void peak 
was comparably large compared to the main protein peak (e.g. the purification in figure 12c). 
This observation led to the question of how stable these homologues were in DM. To inves-
tigate this, a simple stability experiment was performed with purified 3GAU-C9 as shown in 
figure 13. Small amounts of protein from a size-exclusion peak was incubated either at room 
temperature or at 4°C. After 24 hours at room temperature, a large fraction of the protein had 
aggregated, indicating a limited stability of the protein in DM. Since there was also aggrega-
tion of the protein at 4°C the suitability of this homologue for crystallisation studies in DM 
was questionable. 
With the hope of improving its stability, crystallisation screening was subsequently carried out 
with 3GAU-C9 and 12CPI purified in DDM. Both crystallised at 4°C in various conditions, 
predominantly at low concentrations of PEG400. Unfortunately, the crystals diffracted to low 
resolution. The addition of calcium did not have any effect on crystallisation or diffraction. 
Figure 14 shows a diffraction image from the best diffracting crystal of the homologue 
3GAU-C9. Diffraction spots were visible to a resolution of about 8 Å. Most other crystals 
diffracted to lower resolution with less well-defined diffraction patterns. Details of the data 
Figure 13 – Stability test of 3GAU-C9 in DM. (A) SEC profile from purification of 3GAU-C9 in DM. Blue lines on 
the base of the chromatogram indicate the peak fraction. A part of the peak fraction was split into separate tubes 
that were incubated at different temperatures. (B) Samples were reanalysed by SEC after 36 h at 4°C (blue curve) 
or 12 h at 4°C + 24 h at 20°C (red curve). 
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collection are shown in table 4. The data 
was complete up to a resolution of 7.8 Å. 
Based on the size of the unit cell, it can be 
assumed that the crystal contains several 
copies of a large membrane protein–de-
tergent complex. This experiment showed 
that the crystallisation of bacterial bestro-
phins was possible, but the limited diffrac-
tion quality of the crystals meant that focus 
should be shifted towards the homologues 
identified in the second round of screening, 
in the hope to identify better behaved ho-
mologues. 
2.2.3. Initial purification of homologues from the second round
Based on the experience with the homologues 3GAU and 12CPI, all of the selected homo-
logues from the second round of screening were expressed and purified the same way. As a 
detergent DDM was chosen, since it had resulted in the best crystals of 3GAU. The size-exclu-
sion chromatograms from the purifications together with images of the peak fractions loaded 
on SDS-PAGE are shown in figure 15a–b. The homologues 33SSP, 40FJO, 55PSY and 69MCA 
Figure 14 – Best diffracting crystal of 3GAU-C9. (A) Observed diffraction pattern. Blue ring indicates the 8 Å 
resolution ring. (B) Picture of the crystal in the loop, mounted at the beamline.
8 Å
A
B
Crystal
Protein:  3GAU-C9 in DDM
Additive: 5 mM CaCl2
Condition:  500 mM KCl
 50 mM HEPES pH 7.4
 15% PEG400
Data collection
Beamline: X06SA, SLS
Wavelength: 1.000 Å
Space group: P 1 21 1
Cell dimensions:  
a, b, c (Å) 148.23, 253.76,194.28
α, β, γ (°) 90.00, 100.80, 90.00
Resolution (Å): 49.30 – 7.80 (7.93 – 7.80)
Rmerge (%): 9.2 (93.9)
Rmeas (%): 10.1 (101.2)
CC1/2: 0.997 (0.734)
|I|/σ(I): 10.5 (2.0)
Completeness (%): 99.76 (99.87)
Redundancy:  6.7
Table 4 – Details of crystallisation and data collection 
statistics for the best diffracting crystal of 3GAU-C9. 
Numbers in parentheses indicate the highest resolution 
shell and its statistics.
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Figure 15 – Purification of homologues from the second round in DDM and test of stability. (A) SEC results. Blue 
lines on the bases of the chromatograms indicate the peak fractions. (B) SDS-PAGE analysis of the peak fractions. 
The gel containing 49FTA and 55PSY was contaminated with activated charcoal particles. (C) Parts of the peak 
fractions were reanalysed by SEC after being stored at the indicated temperatures for the indicated number of days 
at a concentration of 5 mg/ml. Traces are coloured blue for samples stored at 4°C and red for samples stored at 
20°C.
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all eluted as single monodisperse peaks. All four homologues eluted at volumes consistent 
with those observed for 3GAU and 12CPI. In contrast 69MCA and 55PSY eluted almost 0.7 
ml earlier than 33SSP and 40FJO, similar as observed for the elution behaviour of 3GAU and 
12CPI, where 3GAU eluted earlier than 12CPI. The difference could potentially be explained 
by the observation that 3GAU, 55PSY and 69MCA all had longer C-termini (Figure 11 in an 
earlier section), which were predicted to be disordered (data not shown).   
The homologue 49FTA did not elute as a monodisperse peak and showed a large shoulder on 
the leading edge. The homologue 67KPN (from Klebsiella pneumoniae; identical to kpBEST, 
whose structure was later published by another group) started precipitating during proteolyt-
ic cleavage with HRV 3C protease. The supernatant injected on a size-exclusion column eluted 
in the void volume (Figure 15a). 
For each homologue, a simple stability test was performed to test the long-term stability of the 
proteins (Figure 15c). 33SSP and 69MCA appeared to be stable for several days, both in the 
cold and at room temperature. For 40FJO and 55PSY a more significant amount of aggrega-
tion was observed when samples were stored at room temperature. However, since samples of 
40FJO and 55PSY were stored longer than samples of 33SSP and 69MCA, direct comparisons 
should be taken with caution. Since similar to 67KPN also 49FTA appeared predominantly ag-
gregated, both proteins were not investigated further, while 33SSP, 40FJO, 55PSY and 69MCA 
were all used for crystallisation studies. 
33SSP, 40FJO and 69MCA all crystallised in various conditions. 55PSY, in contrast, neither 
crystallised in initial experiments nor in broader screening efforts carried out by Nathalie 
Cornillie, a master student working with me on the project. Focus was therefore shifted to the 
three homologues 33SSP, 40FJO and 69MCA for which crystals have been obtained in initial 
screening experiments. 
2.2.4. Crystallisation of 33SSP
For 33SSP, besides the crystallisation in DDM, crystallisation was also attempted in short-
er chain detergents n-Undecyl-β-D-maltoside (UDM) and DM. The latter was chosen since 
33SSP was stable in DM, even when stored for two days at room temperature (Figure 16). 
However, with UDM and DM, only a few needle shaped crystals were observed, which were 
too small for diffraction analysis and thus not further investigated.  
In DDM initial crystals of 33SSP were observed in several different conditions. Most crystals 
grew at low concentrations of PEG400 and only a few in drops with low concentrations of 
PEG4000. Crystals appeared over a range of pH values ranging from 5.5 to 9.4 and in different 
salts. One crystal diffracted better than all other crystals. As shown in figure 17, spots could be 
detected up to a resolution of approximately 4.5 Å, based on a visual inspection. A complete 
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dataset was not collected, as the observed diffraction quickly deteriorated, possibly due to 
radiation damage. Therefore, the data was only processed for the first 25° of rotation. The data 
collection statistics are shown in table 5. The data extended to 4.8 Å, but was not complete due 
to the limited number of collected images. 
Interestingly, the crystallisation condition 
(500 mM KCl, pH 7.4, 15% PEG400) was 
the same as for the best diffracting crystal of 
3GAU-C9. Attempts were made to improve 
the diffraction by variation of the pH, salt 
and PEG400 concentration and by increas-
ing the volume of the setups. Even though 
the crystals did get bigger, their diffraction 
was not improved. Calcium added to the 
Figure 17 – Best diffracting crystal of 33SSP without any additives. (A) Observed diffraction pattern. Blue ring 
indicates the 4 Å resolution ring. (B) Picture of the drop in the crystallisation plate.
4 Å
A
B
Figure 16 – Purification of 33SSP in DM and test of stability. (A) SEC result. Blue lines on the base of the chroma-
togram indicate the peak fraction. (B) SDS-PAGE analysis of the peak fraction. (C) Parts of the peak fraction were 
reanalysed by SEC after being stored at the indicated temperatures for the indicated number of days at a concentra-
tion of 5 mg/ml. Traces are coloured blue for samples stored at 4°C and red for samples stored at 20°C.
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Figure 18 – FSEC based thermostability assay of 33SSP 
in UDM. The amount of non-denatured 33SSP was meas-
ured from the FSEC peak heights. Lipids were E. coli po-
lar lipids added at a concentration of 0.5 mg/ml. Fraction 
remaining is the peak height normalised against the peak 
height of a control sample stored at 4°C. 
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drop did also not improve the diffraction. 
It was, however, observed that by slight-
ly varying the PEG concentration and the 
pH value, crystals could be grown in UDM 
with similar diffraction properties. Using a 
simple thermostability assay, where small 
protein samples were incubated at differ-
ent temperatures before being analysed by 
FSEC [80,81], it was observed that the ad-
dition of E. coli polar lipids increased the 
thermostability of 33SSP in UDM (Figure 
18). An even larger effect was observed by 
the addition of calcium, even though calci-
um so far did not seem to make any differ-
ence in crystallisation. 
New crystallisation screens were performed, 
using 33SSP purified in UDM with addition 
of lipids or lipids and calcium. Unlike in previous trials with 33SSP not containing additives, 
crystals were now observed in several drops containing lipids with several crystals growing in 
similar conditions as observed for 33SSP in DDM. In addition, a new condition was identified 
containing 200 mM CaCl2, which grew in a pH range between 5.5 and 9.4. Like previously, 
crystals appeared in low concentrations of PEG400. The best diffracting crystal was found at a 
Crystal
Protein:  33SSP in DDM
Additive: none
Condition:  500 mM KCl
 50 mM HEPES pH 7.4
 15% PEG400
Data collection
Beamline: X06SA, SLS
Wavelength: 0.920 Å
Space group: P 1 21 1
Cell dimensions:  
a, b, c (Å) 113.94, 101.37, 114.68
α, β, γ (°) 90.00, 100.24, 90.00
Resolution (Å): 43.88 – 4.80 (4.88 – 4.80)
Rmerge (%): 6.6 (30.7)
Rmeas (%): 8.3 (39.4)
CC1/2: 0.999 (0.874)
|I|/σ(I): 6.7 (2.4)
Completeness (%): 24.31 (27.51)
Redundancy:  2.1
Table 5 – Details of crystallisation and data collection 
statistics for the best diffracting crystal of 33SSP with-
out any additives. Numbers in parentheses indicate the 
highest resolution shell and its statistics. Data was only 
processed for a rotation of 25°, since the diffraction quali-
ty quickly deteriorated, possibly due to radiation damage. 
B
A
4 Å
Figure 19 – Diffraction of 33SSP in UDM with the addition of lipids. 0.5 mg/ml E. coli polar lipids were added. (A) 
Observed diffraction pattern. Blue ring indicates the 4 Å resolution ring. The dashed line indicates the region which 
is enlarged in following panel. (B) Enlargement of the highlighted part of the diffraction image.
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pH value of 7.4 and diffraction could be de-
tected up to a resolution of approximately 
4.0 Å (Figure 19). This appeared as a signif-
icant improvement over the previously de-
scribed crystal without lipids, where spots 
could only be observed up to a resolution 
of 4.5 Å. The statistics from a partial dataset 
of this crystal are shown in table 6. The data 
extends to 4.7 Å and is thus only marginally 
better than the previously described dataset 
from the crystal grown without lipids. 
Unfortunately, it proved to be difficult to re-
produce crystals that diffracted equally well 
or better. Eventually, after optimising the 
pH, type of PEG, salt concentration and lip-
id type, a better diffracting crystal was iden-
tified. An example of the diffraction pattern 
is shown in figure 20. According to the data collection statistics shown in table 7, the data was 
complete to a resolution of 3.9 Å. Space group and unit cell dimensions were similar to previ-
ous datasets. Interestingly this crystal had been grown in DDM. Thus, despite being stable in 
UDM and DM, 33SSP did not only crystallise better in DDM, but the crystals grown in DDM 
also diffracted to higher resolution. 
Crystal
Protein:  33SSP in UDM
Additive: 0.5 mg/ml E. coli polar lipids
Condition:  200 mM CaCl2
 50 mM HEPES pH 7.4
 15% PEG400
Data collection
Beamline: X06SA, SLS
Wavelength: 1.000 Å
Space group: P 1 21 1
Cell dimensions:  
a, b, c (Å) 106.51, 103.04, 114.80
α, β, γ (°) 90.00, 98.57, 90.00
Resolution (Å): 46.92 – 4.70 (4.78 – 4.70)
Rmerge (%): 6.9 (39.1)
Rmeas (%): 9.1 (51.8)
CC1/2: 0.999 (0.789)
|I|/σ(I): 6.9 (2.5)
Completeness (%): 32.41 (34.41)
Redundancy:  1.9
Table 6 – Details of crystallisation and data collection 
statistics for the best diffracting crystal of 33SSP in UDM 
with lipids added. Numbers in parentheses indicate the 
highest resolution shell and its statistics. Data was only 
processed for a rotation of 30°, since the diffraction quali-
ty quickly deteriorated, possibly due to radiation damage. 
Figure 20 – Observed diffraction of 33SSP in DDM with high concentration of lipids and detergent. 1 mg/ml 
DOPC and 0.1% DDM were added. The crystallisation solution consisted of 200 mM CaCl2, 50 mM HEPES pH 6.9 
and 14% PEG300. Blue ring indicates the 4 Å resolution ring. 
4 Å
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Even despite extensive trials it was not pos-
sible to obtain crystals of 33SSP diffracting 
higher than 3.9 Å, whereas most crystals 
grown in the same condition only diffracted 
to much lower resolution. As screening for 
additives did not bring any improvement, 
the method used for adding lipids to the 
purified protein was modified. Instead of 
adding a liposome solution directly to the 
purified protein, lipid mixtures in chloro-
form were added to small glass tubes. After 
evaporating the chloroform, concentrated 
protein and additional detergent was added 
directly to the glass tube along with a small 
stirrer bar. Typically, different amounts of 
lipid and detergent were tested. After stir-
ring overnight, the non-solubilised lipids were removed by ultracentrifugation. This method, 
also known as HiLiDe [82], improved the reproducibility of the crystals, but still did not result 
in better diffracting crystals. 
2.2.5. Crystallisation of 69MCA
As previously mentioned, the homologue 69MCA was cloned from a thermotolerant organ-
ism. It therefore seemed likely that this protein would be more stable than other investigated 
homologues in different detergents. 69MCA was therefore from the beginning purified in 
both DDM and DM. Figure 21 shows the result of a purification in DM and a simple stability 
test performed with the purified protein. As shown in the figure, unlike some other investigat-
ed proteins, 69MCA is stable in DM, even at 20°C. 
Crystal
Protein:  33SSP in DDM
Additive: 1 mg/ml DOPC
Condition:  200 mM CaCl2
 50 mM HEPES pH 6.9
 14% PEG300
Data collection
Beamline: X06SA, SLS
Wavelength: 1.000 Å
Space group: P 1 21 1
Cell dimensions:  
a, b, c (Å) 113.10, 101.04, 114.91
α, β, γ (°) 90.00, 99.96, 90.00
Resolution (Å): 49.37 – 3.90 (3.97 – 3.90)
Rmerge (%): 7.7 (136.1)
Rmeas (%): 8.3 (145.6)
CC1/2: 0.999 (0.898)
|I|/σ(I): 12.1 (2.2)
Completeness (%): 99.73 (99.40)
Redundancy:  7.7
Table 7 – Details of crystallisation and data collection 
statistics for the best diffracting crystal of 33SSP in DDM 
with lipids added. Numbers in parentheses indicate the 
highest resolution shell and its statistics. 
Figure 21 – Purification of 69MCA in DM and test of stability. (A) SEC result. Blue lines on the base of the chro-
matogram indicate the peak fraction. (B) SDS-PAGE analysis of the peak fraction. (C) Parts of the peak fraction 
were reanalysed by SEC after being stored at the indicated temperatures for the indicated number of days at a 
concentration of 5 mg/ml. Traces are coloured blue for samples stored at 4°C and red for samples stored at 20°C.
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After extensive screening, crystals of 69MCA appeared in both detergents. In DDM the pro-
tein crystallised in different salts and at different pH values, in low concentrations of PEG400 
or PEG4000. With DDM crystallisation was only attempted at 4°C. Unfortunately, none of the 
tested crystals diffracted to more than 8 Å. When purified in DM, no crystals were obtained 
at 4°C and crystals grown at 20°C had poor diffraction properties. 
After discovering that lipids had a positive effect on the crystallisation of 33SSP, I attempted 
to crystallise 69MCA in the presence of lipids. For this purpose, 69MCA was purified in UDM 
and liposomes were added to the purified protein after concentration. Crystals appeared at 
both 4°C and 20°C, but the crystals were generally bigger when grown at 20°C and thus only 
those were tested. Unfortunately, none of these crystals showed promising diffraction be-
haviour. 
Since 69MCA has a longer C-terminus than other homologues (Figure 11 in an earlier sec-
tion), different C-terminal truncations were constructed and tested by small scale expression 
and FSEC (data not shown). Truncation of up to 7 residues, was tolerated and resulted in 
expression levels similar to the full-length protein. Crystallisation was attempted in DM, at 
both 4°C and 20°C. Although small crystals were observed, these were not large enough for 
diffraction studies. 
2.2.6. Crystallisation of 40FJO
The initial crystallisation screens performed with 40FJO showed crystals in many different 
conditions. Crystals grew in a broad range from pH 5.5 to 9.4, but they seemed to grow best 
in the range from 6.5 to 8.4. Although most crystals were observed at low PEG400 concen-
trations, some also grew at low concentrations of PEG4000. Work with this homologue, de-
scribed below, was carried out by master student Nathalie Cornillie, who performed the work 
as her master thesis project. 
Based on the experience of crystallising 33SSP, lipids were included in the crystallisation tri-
als. In this case lipids were added as liposomes after the protein had been concentrated to the 
final concentration used for crystallisation. As an additive, primarily DOPC was used, but 
E. coli polar lipids were also tested. As in the case of 33SSP, calcium was found to improve 
the thermostability of 40FJO (data not shown). 10 mM CaCl2 was therefore included during 
screening. Crystals were observed in several different conditions. Crystals were frozen from 
several different conditions. Most diffracted to less than 8 Å, but two crystals showed better 
diffraction properties than the rest. The best diffracting crystal, grown in 1M NaCl at pH 8.4, 
resulted in visible diffraction spots up to a resolution better than 5 Å (Figure 22). Unfortunate-
ly, the diffraction turned out to be anisotropic and the data was only complete to a resolution 
of 6.2 Å (Table 8). The crystal system was found to be orthorhombic (space group P 21 21 21). 
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For comparison, the best diffracting 33SSP 
crystals were all monoclinic (space group P 
1 21 1). 
Another crystal, grown in 1M ammonium 
formate at pH 7.4, also showed diffraction 
spots extending to around 5 Å. The diffrac-
tion from this crystal was also anisotropic 
and the data was only complete to a reso-
lution of 6.6 Å. The space group was found 
to be the same as for the first crystal (P 21 21 
21), and unit cell dimensions were virtually 
identical (data not shown).
Several attempts were made to improve the 
quality of the crystals by refining the con-
ditions. That did, however, not improve the 
diffraction. Other lipids were also tried without seeing any improvements. 
As with 33SSP, purification and crystallisation was also attempted using the detergent UDM. 
Crystals appeared in UDM and when PEG200 or PEG300 was used as precipitant, the crystals 
got significantly bigger than the crystals grown in PEG400 and DDM. Although the crystals 
6 Å
6 Å
5 Å
5 Å B
A
Figure 22 – Diffraction of 40FJO in DDM with lipids and calcium. 1 mg/ml DOPC and 10 mM CaCl2 were added. 
(A) Observed diffraction pattern. Blue rings indicate the 5 and 6 Å resolution rings. The dashed line indicates the 
region which is enlarged in following panel. (B) Enlargement and contrast enhancement of the highlighted part of 
the diffraction image.
Crystal
Protein:  40FJO in DDM
Additive: 1 mg/ml DOPC, 10 mM CaCl2
Condition:  1M NaCl
 50 mM Tris-HCl pH 8.4
 15% PEG400
Data collection
Beamline: X06SA, SLS
Wavelength: 1.000 Å
Space group: P 21 21 21
Cell dimensions:  
a, b, c (Å) 118.85, 125.36, 180.68
α, β, γ (°) 90.00, 90.00, 90.00
Resolution (Å): 49.65 – 6.20 (6.31 – 6.20)
Rmerge (%): 6.7 (74.3)
Rmeas (%): 7.4 (79.7)
CC1/2: 0.995 (0.911)
|I|/σ(I): 13.2 (2.6)
Completeness (%): 99.74 (100.00)
Redundancy:  7.0
Table 8 – Details of crystallisation and data collection 
statistics for the best diffracting crystal of 40FJO in DDM. 
Numbers in parentheses indicate the highest resolution 
shell and its statistics. 
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got bigger, the diffraction did not improve. Similarly, various additives were also tested, with-
out any improvement. 
In this case crystallisation was also attempted in the shorter detergent DM. Unlike 33SSP, 
40FJO did crystallise in DM, but diffraction was not improved further. 
2.2.7. Estimating the size of 33SSP and 69MCA
All purified bacterial bestrophins eluted from the size-exclusion columns at volumes that 
would suggest big, multimeric assemblies. At the time of these studies, no conclusive experi-
ments had been performed to determine the exact oligomeric state of bestrophins. One study 
concluded that porcine BEST1 most likely forms a homodimer [33], based on ultracentrifu-
gation experiments performed with porcine BEST1 extracted in Triton X-100. Another study 
found that overexpressed hBEST1 most likely forms either tetramers or pentamers [22]. For 
this study cells were co-transfected with two different BEST1 constructs that contained dif-
ferent epitope tags, and the stoichiometry was estimated based on co-immunoprecipitation. 
To get a better understanding of the oligomeric state of bacterial bestrophins, multi-angle 
light scattering (MALS) experiments were performed with 33SSP and 69MCA purified in 
DDM. Using this method, it is possible to determine the mass of protein excluding detergent, 
as well as the mass of the whole-protein detergent complex. The results of this analysis are 
shown in figure 23. The molecular weights of the protein complexes without detergent, were 
determined to be a slightly below 150 kDa. Given the molecular weights of 33SSP and 69MCA 
monomers (34.7 and 32.2 kDa, respectively), the number of monomers per protein complex 
could be calculated. The calculated values were between 4 and 5 and it was thus not possible 
Figure 23 – Multi angle light scattering analysis of 33SSP and 69MCA. Chromatograms show the normalised 
scattering signals. Molecular weights of the protein–detergent complexes are shown in blue and the molecular 
weights of the proteins alone are shown in red. The table shows the measured, average molecular weights of the 
protein–detergent complexes as well as the molecular weights of the proteins complexes alone (without the de-
tergent micelle). For comparison, the molecular weights of the 33SSP and 69MCA monomers (calculated from 
the amino acid sequences) are shown. The calculated stoichiometry is the ratio between the measured molecular 
weight of the protein complex and the calculated molecular weight of a monomer.
Protein 33SSP 69MCA
MW (kDa)
protein–detergent 284.6 292.5
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protein alone 144.7 148.2
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to say if the protein complexes were tetramers or pentamers. Some inaccuracy might be due 
to assumptions that were made for the protein–detergent complexes, regarding the refractive 
index increments of protein and detergent. It was assumed that the micelle consisted purely 
of protein and detergent. Other compounds, such as lipids, were not taken into account. The 
accuracy of the calculations might therefore have been affected by the presence of lipids. 
2.2.8. Initial purification of homologues from the third round
Homologues identified in the third round of screening that performed well in the small-scale 
experiments, were all expressed in larger scale cultures and purified in DDM. Two of the ho-
mologues, 95FIN and 113FBA, performed well in this analysis. These homologues each re-
sulted in a single, monodisperse peak eluting from the size-exclusion column (Figure 24a). 
Figure 24 – Purification of homologues from the third round in DDM and test of stability. (A) SEC results. Blue 
lines on the bases of the chromatograms indicate the peak fractions. 103OHO and 119FSP were not analysed 
further. (B) SDS-PAGE analysis of the peak fractions. (C) Parts of the peak fractions were reanalysed by SEC after 
being stored at the indicated temperatures for the indicated number of days at a concentration of 5 mg/ml. Traces 
are coloured blue for samples stored at 4°C and red for samples stored at 20°C.
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The protein appeared pure, as judged by SDS-PAGE (Figure 24b), and stable for several days 
at both 4°C and 20°C (Figure 24c).
Two other investigated homologues did not perform well, even though they each gave a single, 
monodisperse peak in the small-scale purification. The homologue 103OHO appeared to be 
aggregated, judging from the chromatogram (Figure 24a). The fractions containing the void 
volume were visibly green (data not shown), which indicated that the GFP-tag was not effi-
ciently removed by HRV 3C protease, possibly because the protein was already aggregated at 
that point. This homologue was thus not investigated further. 
The homologue 119FSP seemed to express at similar levels as other homologues, with a simi-
lar amount of protein eluting from the IMAC column (data not shown). However, after incu-
bation with HRV 3C protease almost all protein was captured on the IMAC column, indicat-
ing that the protein was not cleaved. The small amount that did pass through the column was 
nonetheless analysed by SEC, but there was no single, monodisperse peak visible (Figure 24a). 
Therefore, this homologue was also not investigated further. 
2.2.9. Crystallisation of 95FIN
Since the addition of lipids was beneficial for the crystallisation of 33SSP, I decided to crys-
tallise 95FIN with lipids. For the initial crystallisation screens, more than 15 mg protein was 
purified. Two samples were prepared without lipids, either with CaCl2 or EGTA added. Four 
samples were prepared with CaCl2 and different lipid-detergent ratios. Finally, three samples 
contained EGTA in addition to different lipid-detergent ratios. Lipids (DOPC) were added us-
ing the HiLiDe method, which had worked well for 33SSP. Plates were set up exclusively at 4°C.
Within a week, crystals appeared in a variety of different salts, over a pH range from 5.5 to 
9.4. Only a few tiny crystals appeared in PEG4000; all other appeared in low concentrations of 
PEG400 (typically 15%). In plates containing EGTA, crystals were only observed in few condi-
tions and they were all very small. Overall crystals grew much better in conditions containing 
calcium.
20 conditions with promising crystals were selected for fine screening in larger drops with a 
gradient of PEG400. For each of the 20 conditions four different samples were tested. The first 
sample contained lipids and calcium, the second contained lipids without addition of calcium, 
the third contained calcium without addition of lipids and to the fourth neither calcium nor 
lipid was added. 
In those plates crystals appeared both in drops with and without addition of calcium. Crystals 
were frozen from 10 different conditions but none of the tested crystals diffracted to a higher 
resolution than 7–8 Å. Since the homologues 33SSP and 40FJO had shown more promising 
diffraction properties, no further attempts were made to improve the diffraction of 95FIN. 
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2.2.10. Crystallisation of 113FBA
The initial crystallisation screening for 113FBA was done similarly to 95FIN, building on the 
experience obtained from 33SSP. The protein was purified in DDM. Three samples contained 
CaCl2 in addition to lipid (DOPC) and detergent, which were both added using the HiLiDe 
method. These samples were used to set up plates at 4°C. Three additional samples of the pro-
tein were prepared. One contained EGTA and no added lipids, another contained CaCl2 and 
no added lipids and the last contained CaCl2 and lipids added from a liposome solution. These 
samples were used to set up plates at both 4°C and 20°C.
Like for the other homologues, crystals appeared typically within a week in plates that had 
been incubated at 4°C. Crystals could be observed in several different salts over a pH range 
from 5.5 to 9.4. In contrast to most of the other homologues, 113FBA appeared to crystallise 
well in low concentrations of both PEG400 and PEG4000. Ca2+ and the addition of lipids were 
beneficial for crystallisation.
Crystals were frozen from 10 different conditions and their diffraction was investigated. Al-
though most crystals showed poor diffraction properties, one crystal grown in ammonium 
sulphate at pH 6.5 showed a well-defined diffraction pattern with spots up to a resolution of 
4 Å (Figure 25). Processing the data, showed that the data was complete up to a resolution of 
4.2 Å (Table 9). Like 40FJO, 113FBA crystallised in the P 21 21 21 space group, with very simi-
lar unit cell dimensions. Given the molecular weight of a monomer (34.4 kDa) and assuming 
that the protein would be present as a pentamer, these unit cell dimensions would most likely 
correspond to one pentamer per asymmetric unit and a solvent content of 66%. The high 
Figure 25 – Diffraction of 113FBA in DDM with the addition of high concentrations of lipid and detergent and 
10 mM CaCl2. (A) Observed diffraction pattern. The blue ring indicates the 4 Å resolution ring. The dashed line 
indicates the region which is enlarged in following panel. (B) Enlargement of the highlighted part of the diffraction 
image.
4 Å
A
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solvent content seemed reasonable, since 
membrane protein crystals include deter-
gent micelles around the hydrophobic part 
of the protein. 
Several attempts of improving this crystal 
form were made, but their diffraction was 
highly heterogeneous. Since after extensive 
screening all of the described attempts failed 
to yield crystals of a prokaryotic bestrophin 
homologue diffracting to higher resolution, 
all subsequent attempts were put on the im-
provement of crystals of 33SSP.
Crystal
Protein:  113FBA in DDM
Additive: 0.15% DOPC, 0.75% DDM 
 10 mM CaCl2
Condition:  200 mM (NH4)2SO4
 50 mM ADA pH 6.5
 15% PEG400
Data collection
Beamline: X06SA, SLS
Wavelength: 0.920 Å
Space group: P 21 21 21
Cell dimensions:  
a, b, c (Å) 113.75, 124.66, 177.20
α, β, γ (°) 90.00, 90.00, 90.00
Resolution (Å): 49.67 – 4.20 (4.27 – 4.20)
Rmerge (%): 10.0 (103.8)
Rmeas (%): 10.4 (108.0)
CC1/2: 0.999 (0.830)
|I|/σ(I): 14.5 (2.4)
Completeness (%): 99.98 (100.00)
Redundancy:  13.2
Table 9 – Details of crystallisation and data collection 
statistics for the best diffracting crystal of 113FBA in 
DDM. Numbers in parentheses indicate the highest reso-
lution shell and its statistics. 
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2.3. Targeting 33SSP with nanobodies
2.3.1. Nanobodies as crystallisation chaperones 
The growth of well diffracting crystals of membrane proteins can be difficult. One cause for 
the poor quality of crystals is the poor stability of the target protein in the chosen detergent. 
This limitation can be addressed by using a different detergent, stabilising the protein with 
mutations or by co-crystallising the protein in complex with a stabilising ligand. In the case of 
33SSP, different detergents and additives were tested. The introduction of stabilising mutations 
was, however, not attempted, since such mutations might result in a non-native conformation. 
Another reason why membrane protein crystals can result in poorly diffracting crystals, can 
be that the detergent micelle limits the number of possible crystal contacts between proteins 
[78]. One solution frequently used to overcome this problem is the use of shorter chain de-
tergents, which for 33SSP unfortunately did not improve the diffraction. Another option is to 
increase the accessible surface area by co-crystallising with a binding partner, a so-called crys-
tallisation chaperone. Commonly used crystallisation chaperones for membrane proteins in-
clude antibody fragments, which have been used successfully for many years [83] and in many 
cases [84], or other protein scaffolds, such as monobodies [85] or designed ankyrin repeat 
proteins (DARPins) [86]. While monobodies and DARPins are always selected from synthetic 
libraries, antibody fragments used for crystallography are often selected from synthetic librar-
ies or made from monoclonal antibodies. When selecting binders from a synthetic library, 
the screening can be fast and the proteins can subsequently be expressed recombinantly. In 
comparison, generation of monoclonal antibodies can be time consuming and costly, but does 
hold the advantage that the produced antibodies have been affinity matured by the immune 
system of the animal. 
Antibody fragments can, however, also be generated by a combined approach, where a library 
is made from the blood cells of an animal that has been immunised with a target protein. 
Making such a library would be complicated for normal antibodies, since they consist of two 
separate chains, termed heavy and light chains. However, camelids and sharks also produce 
antibodies consisting only of heavy chains [87,88], in addition to the normal antibody types. 
By immunising a camelid, typically a llama or alpaca, with a target protein, a library can be 
made to select the variable part of such a heavy chain antibody [89]. This variable part known 
as VHH or a nanobody, is small (approximately 15 kDa) and can generally be recombinantly 
expressed in E. coli. Furthermore, it can often bind to epitopes that are not usually targeted by 
classical antibodies, such as clefts or active sites [90]. Nanobodies have by now been success-
fully used for crystallisation of many different proteins, including membrane proteins [91].
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2.3.2. Selection of nanobodies
As nanobodies had previously proven to be critical to the crystallisation of several membrane 
proteins in our lab [76,77], I decided also to raise nanobodies against 33SSP, with the hope of 
producing better diffracting crystals. At the time, the nanobody technology had only recently 
been established at the University of Zurich, thanks to the work by Dr. Saša Štefanić (Vetsuisse 
Faculty, University of Zurich), Dr. Eric R. Geertsma (at the time a post-doc in our lab, current-
ly at Institute of Biochemistry, Goethe University, Frankfurt) and others. For immunisation, 
an alpaca was injected four times with 33SSP, at two week intervals. 200 µg of 33SSP was used 
for each injection. After the last injection, a blood sample was collected and cDNA was gener-
ated from isolated lymphocytes. The genes encoding the variable fragments of the heavy chain 
antibodies were amplified from the cDNA and used to construct a phage display nanobody 
library. These steps were carried out by Yvonne Neldner in our group. 
The library was based on a phagemid vector, i.e. a plasmid vector containing the f1 origin of 
replication from bacteriophage f1. The open reading frame consisted of the following ele-
ments: PelB-leader sequence, nanobody, 6×His-tag, EPEA-tag, HA-tag and finally the gene 
III from bacteriophage M13. An amber stop codon was placed between the EPEA-tag and the 
HA-tag, allowing an amber suppressor strain such as E. coli TG1 to occasionally fuse a nano-
body to the phage coat protein pIII, encoded by gene III. 
For the selection of nanobodies, 33SSP was immobilised on ELISA plates. Two different se-
lections were performed. For one selection, 33SSP was coated directly on the plastic surface 
of the ELISA plate. For the other selection, 33SSP had been expressed with a site-specific 
biotinylation sequence [92] and biotinylated using the E. coli biotin ligase BirA, during the pu-
rification, prior to the size-exclusion chromatography step. This biotinylated 33SSP was then 
bound to an ELISA plate that had been coated with neutravidin. These two selection methods, 
which were termed «direct coating» and «neutravidin coating», were carried out in parallel, 
but kept strictly separate. For each selection method, a well was also prepared without 33SSP 
to be used as a negative control. Phages were added to all wells. After elution, the phages were 
used to infect E. coli TG1 cells. In order to produce new phage particles, the infected E. coli 
cells had to be superinfected with a helper phage, in this case M13KO7. Phage particles could 
then be recovered and used for a new round of selection. 
Three rounds of selection were carried out. After each round, the number of phages was quan-
tified in a dilution series of the eluted phages used to infect small amounts of TG1 cells. From 
the number of colonies and the dilution factor, the phage concentration could be calculated. 
The calculated concentrations are shown in table 10. The concentrations are not directly com-
parable between the different selection rounds and coating methods, since different amounts 
of input phages were used and since the amount of coated protein probably varied between the 
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two coating methods. However, by compar-
ing the number of phages eluted from a well 
containing 33SSP with the number of phag-
es eluted from the negative control, the de-
gree of enrichment could be estimated. For 
the direct coating selection, a small amount 
of enrichment was observed already after 
the first round and after the second round 
this had increased to a 20-fold enrichment. 
A third round of selection did not lead to 
a higher enrichment. By comparison, the 
neutravidin coating selection reached a 
more modest enrichment of 5-fold after the 
second round, but was close to a 20-fold 
enrichment after the third round. Based on 
these results it was decided to analyse single 
clones from the second and third rounds of 
selection. 
Neutravidin
coating
Direct
coating
33SSP Negative control 33SSP
Negative 
control
Round 1 5 × 103 5 × 103 2 × 104 5 × 103
Round 2 1 × 108 2 × 107 2 × 107 1 × 106
Round 3 7 × 107 4 × 106 9 × 106 5 × 105
Table 10 – Concentrations of phages eluted after the dif-
ferent rounds of phage display. The numbers, which show 
the number of phages per ml, were calculated from the 
number of colonies observed after infecting E. coli TG1 
cells with a dilution series of the eluted phages. Columns 
labelled 33SSP show the output from wells coated with 
33SSP. Columns labelled negative control, show the out-
put from wells without 33SSP. Concentrations are shown 
for each of the two different selection strategies labelled 
"neutravidin coating" and "direct coating". In the first 
round, only one negative control was used, since this 
round used the same phage input for both selections.  
Figure 26 – Single-clone ELISA signals from the selection of nanobodies against 33SSP. Each coloured bar repre-
sents the signal from a single clone. Heights of the bars show how many times the signal was above the background 
signal, which was measured in wells without 33SSP but with nanobody. Some signals were more than forty times 
above the background, but have been reduced to the height of the plot in order to simplify the visualisation. Left 
and right halves show signals from ELISA performed after the second round and third round of phage display, 
respectively. Blue bars represent clones selected using the neutravidin coating procedure, whereas green bars rep-
resent those selected using the direct coating. A black line at 2.5× background represents the cut-off that was used 
to distinguish positive from negative signals. Heights are not directly comparable between different rounds and 
different coating techniques.
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The single-clone analysis was performed using ELISA. From small-scale cultures, periplasmic 
extracts were prepared by subjecting the cells to an osmotic shock. The periplasmic extracts 
were then added to ELISA wells that had been coated with 33SSP, using the same coating 
methods as during the selection. For each clone, a negative control well without any 33SSP 
was prepared. This was used to exclude that the observed signal was due to unspecific binding. 
Figure 26 shows the result of the ELISA analysis. 96 clones were tested for each round and 
selection strategy. Each bar represents an ELISA signal divided by the background signal mea-
sured in the negative control well. The exact heights of the bars, cannot be compared between 
the results from round 2 and 3, since these were tested on different days. Similarly, the results 
from the two different selection strategies should not be directly compared, since the amount 
of coated protein would be expected to vary, given that the coating methods were different. It 
is, however, clear that far fewer clones from round 2 resulted in signals that were significant-
ly above the background, when compared 
to round 3. In fact, all tested clones from 
round 3 gave positive signals, so it was de-
cided not to perform more rounds of phage 
display. 
Instead, plasmid was prepared from sin-
gle clones and sequenced. Initially, only 
clones from round 3 were sequenced, with 
an equal number of clones from the two se-
lections strategies. The clones from the di-
rect coating strategy were found to almost 
exclusively contain the same nanobody se-
quence, whereas the clones from the neu-
travidin coating strategy showed signifi-
cantly higher diversity. More clones were 
therefore sequenced from the neutravidin 
coating strategy. Additionally, clones were 
also sequenced from the second round of 
selection. In the end, it was counted how 
many times each nanobody sequence was 
observed. The result of this count is sum-
marised in table 11. The nanobody se-
quence, NB33_1, that dominated the out-
put from the 3rd round of the direct coating 
selection, was the only sequence observed 
Round 2 Round 3
Direct 
coating
Neutravi-
din coating
Direct 
coating
Neutravi-
din coating
NB33_1 16 11 45 32
NB33_2 1 5
NB33_3 1 4
NB33_4 3
NB33_5 5 6
NB33_6 1 3
NB33_7 1
NB33_8 7 8
NB33_9 1
NB33_10 1
NB33_11 3 9
NB33_12 1
NB33_13 5
NB33_14 1
NB33_15 1
NB33_16 1
NB33_17 3
NB33_18 1 2
NB33_19 2
NB33_20 2 2
NB33_21 1
NB33_22 1
NB33_23 1
Total 16 33 47 91
Table 11 – Count of identical nanobody sequences. The 
table shows the number of times that each nanobody was 
observed during sequencing of single clones from round 
2 and 3, using the two different selection strategies "di-
rect coating" and "neutravidin coating". For the purpose 
of counting, nanobodies were considered identical, if 
they had identical complementarity-determining regions 
(CDRs) with the surrounding regions only showing mi-
nor differences. 
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in the output of the 2nd round of the same selection. Additionally, this nanobody accounted 
for approximately a third of the sequences from the neutravidin coating selection, from the 
2nd as well as the 3rd round. No other nanobody was observed as frequently, although some 
were observed several times. 10 of the nanobodies were only observed once out of a total of 
187 sequences. It seemed likely that more unique sequences could potentially be discovered 
if more clones were to be analysed, but it was decided to test the expression of the identified 
nanobodies, before analysing additional clones. 
Of the 23 selected sequences, 22 were successfully cloned to an expression vector. One na-
nobody, NB33_21, could not be cloned despite several attempts and was therefore not used 
for further analysis. A multiple sequence alignment was made in order to characterise the se-
quence diversity of the selected nanobodies (Figure 27). As expected, the most sequence vari-
ation was observed in the three complementarity determining regions (CDRs), which were 
identified by comparing the sequences of the surrounding regions to those of llama nano-
bodies [93]. Also, as expected from llama nanobodies, the greatest length variation was seen 
Figure 27 – Multiple sequence alignment of identified nanobodies. One nanobody (NB33_21) is not included, 
since it could not be successfully cloned. The three complementarity-determining regions (CDRs) are labelled as 
CDR1–3. Residues encoded by the plasmid vector are not included. 
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in CDR3, where the length varied between 13 and 23 amino acid residues. By comparison, 
CDR1 had a length of 8 amino acid residues in all identified nanobodies, whereas CDR2 varied 
between 7 and 8 amino acid residues. 8 nanobodies contained a cysteine residue in CDR3 in 
addition to a cysteine residue before CDR2, indicating that an extra disulphide bridge could be 
present, like it has been suggested for some llama nanobodies [94]. 
From the 22 selected nanobodies, few were eliminated from further investigation. Nanobody 
NB33_2 was not persued, since its sequence was very similar to that of NB33_1. The two 
nanobodies had the exact same sequence in CDR1, two amino acid residue substitutions in 
CDR2 and one in CDR3. Since NB33_1 was found in many more clones, it was chosen instead 
of NB33_2. The CDRs of NB33_9 were found to be virtually identical to those of NB33_8, with 
the only difference being a phenylalanine to tyrosine substitution in CDR1. Since NB33_8 was 
observed in more clones than NB33_9, NB33_8 was kept for further analysis. More nano-
bodies could have been excluded in this way, since for example NB33_20 and NB33_11 also 
showed very high similarity. However, they were both included since, unlike NB33_9, they 
had been identified in several clones during the sequencing. Other similar pairs of nanobod-
ies, such as NB33_3 and NB33_4 or NB33_6 and NB33_7, were also included in the following 
studies. 
2.3.3. Expression, purification and complex formation
All selected nanobodies were cloned into an E. coli expression vector resulting in the fusion 
of maltose binding protein (MBP) to the N-terminus of the protein, since this had previously 
been shown by others to result in consistently high expression levels [95]. The vector addi-
tionally included the PelB leader sequence for periplasmic targeting, a 10×His-tag to aid in 
purification and a HRV 3C cleavage site to remove the 10×His-MBP fusion by proteolytical 
cleavage. As for the expression of the bacterial bestrophins, the expression was under the con-
trol of the L-arabinose inducible ParaBAD promoter. 
Each nanobody was initially expressed in 1.2 l of E. coli culture and purified using IMAC 
and SEC. The peak fractions and some additional fractions were further analysed by SDS-
PAGE. The results are shown in figure 28. Most nanobodies resulted in a single monodisperse 
peak, with only smaller amounts of protein eluting at the void volume. An example of such 
a nanobody is NB33_1, which also resulted in a relatively high peak, indicating a good yield. 
However, when judging the yields based on UV-absorption, the extinction coefficients had to 
be considered, since they varied significantly between different nanobodies. For NB33_1 the 
calculated absorbance of a 1 mg/ml solution equalled 1.15, whereas for NB33_13 the value 
was 2.7. Some nanobodies, such as NB33_10 had a very high void peak compared to the main 
protein peak. As shown on the gels, these peaks generally contained very little protein migrat-
ing at the size expected for a nanobody (around 15 kDa). Most of the analysed void fractions 
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Figure 28 – Expression and purification test of selected nanobodies. 20 different nanobodies were purified from 
1.2 l E. coli culture. (A) Size-exclusion chromatograms from the purification of different nanobodies on a Super-
dex 75 column. Blue lines on the bases of the chromatograms indicate the peak fractions, which were analysed by 
SDS-PAGE. Fractions are numbered for the cases where more than one fraction from a purification were analysed. 
Elution volumes for the peaks are shown as numbers next to the peaks. (B) SDS-PAGE analysis of peak fractions 
and a few other selected fractions. Samples were not boiled before loading on the gel.
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instead contained a quite dominant band between 37 and 50 kDa, which would be consistent 
with the molecular weight of the cleaved off 10×His-MBP-tag. The presence of these void 
peaks was not problematic, since they were well separated from the main nanobody peaks. 
Two nanobodies, NB33_3 and NB33_17, showed strong bands at high molecular weight on 
SDS-PAGE gels in addition to faint bands at the expected molecular weights. Before, the sam-
ples had not been boiled, to make it easier to compare these gel samples to complexes that 
also contain membrane protein, which generally cannot be boiled for SDS-PAGE. Since both 
nanobodies eluted from the size-exclusion column as well defined, monodisperse peaks, they 
were both included in the further analysis.
Four nanobodies, NB33_7, NB33_15, NB33_16, and NB33_22, were poorly expressed and thus 
not included in further analysis. For other nanobodies the yields varied between 0.5 mg per 
litre of culture for the worst expressing nanobody (NB33_17) to 2.8 mg per litre for the best 
expressing one (NB33_13). By comparison, NB33_1 which was the nanobody most frequently 
found in the selection had a yield of 1.9 mg per litre. 
Next, it was tested if the 16 remaining nanobodies could form stable complexes with 33SSP. 
This would be expected if they were binding with high affinity. For this purpose, each nano-
body was mixed with purified 33SSP in a 1:1 molar ratio. Each sample was then analysed by 
SEC. As controls, samples containing either nanobody or 33SSP alone were injected on the 
column. The control samples used the same amount of nanobody or 33SSP as the analysed 
samples. Figure 29a shows as an example the results obtained for the nanobodies NB33_10, 
NB33_14 and NB33_20. The complex between 33SSP and NB33_10 resulted in a peak that 
was visibly shifted to a smaller elution volume. The peak remained symmetrical and mono-
disperse, and almost all the added nanobody appeared to be bound to 33SSP as evidenced by a 
very small peak of free nanobody. The mixture of 33SSP and NB33_14 also resulted in a large 
peak shift, but in this case, the peak was broader and asymmetric, with a shoulder on the trail-
ing edge. The peak shift for this complex was much bigger than that for the 33SSP-NB33_10 
complex. The complex between 33SSP and NB33_20 gave only a very small peak shift and 
in this case a large fraction of the nanobody remained unbound. Figure 29b lists the elution 
volumes for all investigated complexes. All resulted in a peak shift, but the size of the shift var-
ied from nanobody to nanobody. Based on a calibration curve for the size-exclusion column, 
the expected shifts in elution volumes were calculated for different binding stoichiometries 
(Figure 29c). All nanobodies, except NB33_1 and NB33_14, eluted within the expected range. 
When comparing the actual elution volumes with the expected values, it seemed clear that the 
binding stoichiometry varied between the different nanobodies. However, since the expected 
differences were relatively small, the exact binding stoichiometries could not be determined.  
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Figure 29 – Test of complex formation between purified nanobodies and 33SSP. 16 successfully purified nano-
bodies were mixed with purified 33SSP in a 1:1 molar ratio. (A) Examples of chromatograms obtained from SEC 
analysis of nanobody complexes. Blue lines show the chromatogram obtained when 33SSP and the respective na-
nobodies were injected together. Red lines show the same amount of nanobody injected alone. As a reference, the 
grey lines show 33SSP injected alone (the same chromatogram is shown in all three plots). (B) Elution volumes of 
all tested complexes. (C) Expected elution volumes. *Average of three SEC runs. **Calculated based on an average 
NB molecular weight of 13.8 kDa, using a calibration curve made for the size-exclusion column. (D) SDS-PAGE 
analysis of peak fractions. Samples were not boiled before loading on the gel.
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Injected sample Elution volume (ml)
33SSP + NB33_1 9.191
33SSP + NB33_3 9.280
33SSP + NB33_4 9.344
33SSP + NB33_5 9.282
33SSP + NB33_6 9.325
33SSP + NB33_8 9.464
33SSP + NB33_10 9.258
33SSP + NB33_11 9.427
33SSP + NB33_12 9.473
33SSP + NB33_13 9.309
33SSP + NB33_14 9.049
33SSP + NB33_17 9.356
33SSP + NB33_18 9.429
33SSP + NB33_19 9.350
33SSP + NB33_20 9.477
33SSP + NB33_23 9.334
Nanobodies per 
pentamer
Expected 
elution volume (ml)
0 9.57 *
1 9.50 **
2 9.43 **
3 9.36 **
4 9.29 **
5 9.23 **
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For all 16 tested nanobodies, SDS-PAGE was used to confirm that the peak fractions con-
tained both nanobody and 33SSP. As shown in figure 29d, all 16 nanobodies formed com-
plexes with 33SSP. As observed previously (Figure 28b), two of the nanobodies (NB33_3 and 
NB33_17) migrated abnormally on the gel, despite behaving well in the SEC analyses. The 
intensities of the different nanobody bands varied markedly, but it was unclear if this was due 
to some nanobodies staining better or due to different binding stoichiometries. Interestingly, 
the nanobodies NB33_8, NB33_11, NB33_12, NB33_18 and NB33_20 resulted in relatively 
faint bands on the gels and only caused small shifts in the elution volumes during the SEC 
analyses (Figure 29b). Furthermore, during the SEC analyses a large amount of each of these 
nanobodies remained unbound (data only shown for NB33_20, figure 29a). It thus seemed 
likely that these nanobodies were binding to 33SSP at a low stoichiometric ratio, compared to 
the other tested nanobodies.
2.3.4. Crystallisation of 33SSP–nanobody complexes
For crystallisation screening, complexes of 33SSP and nanobodies were purified by SEC. Only 
the nanobodies NB33_1, NB33_5, NB33_6, NB33_8, NB33_11, NB33_12, NB33_13, NB33_14 
and NB33_23 were tested, due to time restrictions. All complexes were purified using a Super-
dex 200 column. Most complexes eluted between 10.6 ml and 10.9 ml, except for complexes 
with NB33_1 or NB33_14, which eluted at approximately 9.6 ml (data not shown). Given such 
a large shift in elution volume, it seemed likely that these nanobodies were causing dimers 
of 33SSP-multimers to form. Interestingly, when NB33_1 or NB33_14 were purified without 
33SSP, they eluted at similar volumes to the other nanobodies, suggesting that the nanobodies 
alone were not forming dimers (data not shown). 
Crystallisation plates were set up both with and without the addition of lipids (using the pre-
viously described HiLiDe method). Since 33SSP alone had been found to crystallise predomi-
nantly in PEG400, the crystallisation screen, previously used for crystallising different bestro-
phin homologues, was modified slightly. Where the previous version of the screen contained 
both PEG400 and PEG4000, the new version of the screen contained only PEG400, in 8 dif-
ferent concentrations. The lowest concentration of PEG400 was 10% in the new version com-
pared to 15% in the old versions, and the concentration was increased in 5% steps compared 
to the previous 10% steps. 
For the 33SSP–NB33_6 complex, no crystals were observed. For 33SSP–NB33_8, 33SSP–
NB33_12 and 33SSP–NB33_23 some crystals were observed, but their diffraction properties 
were not investigated further, because the crystals were small. For these complexes, crystals 
mainly appeared at PEG400 concentrations between 15% and 25%, both in the presence and 
absence of lipids. 
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For 33SSP–NB33_11 and 33SSP–NB33_13, the diffraction of crystals from several different 
conditions were tested, most of which were grown in the presence of lipids. Unfortunately, 
all tested crystals diffracted to very low resolution (typically less than 10 Å). 33SSP–NB33_5 
crystals were only observed in the absence of lipid but none of them showed promising dif-
fraction and in the best cases, diffraction spots were visible to a resolution of approximately 
7 Å.
Unlike the previously tested complexes, 33SSP–NB33_14 almost exclusively crystallised in 
drops containing 10% PEG400. A few crystals did appear in some conditions with 15% PEG400, 
but the majority of the crystals would probably not have been observed in a screen contain-
ing 15% PEG400 as the lowest concentration. 33SSP–NB33_14 crystallised in a wide range of 
different conditions, both in the presence and absence of lipids. However, only crystals grown 
in the presence of lipids were tested, since they were generally bigger and had more regular 
shapes. Most of these crystals diffracted significantly better than what was observed for the 
previously tested complexes. The highest resolution where diffraction spots could be observed 
was generally between 7 Å and 4 Å, depending on the crystal. Further attempts to optimise the 
diffraction of this complex were not made, as the efforts were focused on another complex. 
Complexes of 33SSP and NB33_1 also crystallised in many different conditions, both with 
and without lipids. Like for 33SSP–NB33_14, many crystals were found in drops containing 
10% PEG400. Although crystals grown without lipids diffracted only to low resolutions, a big 
improvement was observed for crystals grown in the presence of lipids. For several crystals, 
diffraction spots could be observed up to a resolution of approximately 4 Å. A particularly 
promising condition consisted of 10% PEG400 at pH 6.5. The condition contained no salt, so 
the final drop only contained the salt that was included together with the protein in the SEC 
buffer. This crystal also showed diffraction spots up to a resolution of 4 Å, but the diffraction 
pattern looked less anisotropic than some of the other tested crystals and the diffraction pat-
tern consisted of well-defined spots. 
The crystallisation condition was optimised by varying the concentration of PEG and the pH 
value. Different salt concentrations were tested by reducing the salt concentration of the pro-
tein solution after the SEC. Additionally, some drops were set up with either CaCl2 or EGTA. 
Crystals were also prepared using either PEG300 and PEG200 as precipitant and different 
cryoprotection strategies were tested. Eventually, one crystal grown at pH 6.5 in 13% PEG300 
with the addition of 2 mM EGTA, was found to diffract far better than what had previously 
been observed. Figure 30 shows the observed diffraction pattern, extending to approximately 
3 Å. Also shown in the figure is a picture of the crystal, which was grown in 1 µl sitting drops 
(final drop volume) and was estimated to measure approximately 150–200 µm in the longest 
direction. 
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Figure 30 – Diffraction of 33SSP–NB33_1 in DDM with the addition of high concentrations of lipid and detergent 
and 2 mM EGTA. (A) Observed diffraction pattern. The blue ring indicates the 3 Å resolution ring. The dashed line 
indicates the region which is enlarged in following panel. (B) Enlargement of the highlighted part of the diffraction 
image. (C) Picture of the crystal in the loop, mounted at the beamline. 
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2.4. Structure determination of 33SSP in complex with a 
nanobody
2.4.1. Data collection and data processing
For the data collection of a 33SSP–nanobody complex, several parameters had to be taken into 
account in order to collect a complete dataset. Previous indexing of another crystal from the 
same condition had indicated that the crystal system could be triclinic. Since the only symme-
try related reflections from a triclinic crystal are the Friedel pairs, a minimum of 180° rotation 
is required to get a complete dataset. However, since the detector used for the data collection 
(Pilatus 6M) contains gaps between the detector tiles, some reflections generally are not mea-
sured since they fall in a gap region. Using a larger rotation range can ensure that at least one 
half of the Friedel pair is measured in such cases. Also, a larger rotation range increases the 
redundancy, which can lead to a higher accuracy of the reduced structure factors [96]. On the 
other hand, a too large rotation range can lead to excessive radiation damage. Therefore, a full 
rotation of 360° was chosen. 
With single-photon-counting detectors such as the Pilatus 6M, data quality can sometimes be 
improved when the rotation range captured for each image, is approximately half of the crystal 
mosaicity [97]. Based on previous indexing of another crystal from the same condition, the 
mosaicity had been estimated to be approximately 0.35°. A rotation range of 0.2° per image 
was chosen for the data collection. The detector was placed at a distance of 550 mm, since 
this distance would allow complete data to be collected up to a resolution extending slightly 
beyond 3 Å. 
The collected data was indexed, scaled and 
merged with the XDS software package 
[98]. The data collection statistics are sum-
marised in table 12. The space group was de-
termined automatically using the program 
POINTLESS [99]. As expected from analy-
sis of previous crystals, the space group was 
found to be P1. Manual inspection of the 
output files from XDS gave the same result. 
Data was included up to a resolution of 3.1 
Å. This included relatively weak reflections, 
since doing so has been shown to generally 
improve the model quality [100]. The mo-
saicity reported by XDS was only 0.23° and 
Crystal
Protein:  33SSP–NB33_1 in DDM
Additive: 0.15% E. coli polar lipids, 0.75% DDM 
 2 mM EGTA
Condition: no additional salt
 50 mM ADA pH 6.5
 13% PEG300
Data collection
Beamline: X10SA, SLS
Wavelength: 1.00002 Å
Space group: P 1
Cell dimensions  
   a, b, c (Å): 99.08, 183.97, 211.88
   α, β, γ (°): 107.70, 92.18, 103.15
Resolution (Å): 48.86 – 3.10 (3.15 – 3.10)
Rmerge (%): 9.6 (106.7)
Rmeas (%): 11.3 (125.8)
CC1/2: 0.997 (0.632)
|I|/σ(I): 8.7 (1.2)
Completeness (%): 98.43 (98.33)
Redundancy:  3.5
Table 12 – Details of crystallisation and data collec-
tion statistics for the best diffracting crystal of 33SSP–
NB33_1 in DDM. Numbers in parentheses indicate the 
highest resolution shell and its statistics. 
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thus lower than expected. An ideal data collection strategy would therefore have involved an 
even smaller oscillation range. However, the difference between an oscillation range of half 
the mosaicity and an one equalling the mosaicity were reported to be very small [97], so most 
likely a slightly smaller oscillation range would not have made much of a difference. 
For the space group P1, one unit cell is known to contain one asymmetric unit. In order to 
estimate the number of biological units for each asymmetric unit, the Matthews coefficient 
(asymmetric unit volume per unit of protein molecular weight) was calculated for different 
numbers of biological units. For the calculation, it was assumed that 33SSP forms a pentamer 
and that five nanobodies would be bound to each pentamer, resulting in a molecular weight of 
237 kDa for the 33SSP–NB33_1 complex. The Matthews coefficients can be compared to the 
values expected from the known protein structures present in the Protein Data Bank [101]. 
Since membrane protein crystals, as previously discussed, typically have a high solvent con-
tent because of the detergent micelles, the most likely numbers of biological units were con-
sidered to be 5, 4 or 3, corresponding to Matthews coefficients of 3.00 Å3/Da, 3.75 Å3/Da or 
5 Å3/Da, respectively. Based on a typical protein density of 1.35 g/cm3 [102], these Matthews 
coefficients were expected to correspond to solvent contents of 59%, 67% or 75%, respectively. 
As previously discussed, the SEC elution profiles of 33SSP–NB33_1 suggested that the nano-
body NB33_1 caused the formation of dimers of 33SSP oligomers. Although it was not known 
if such dimers would also be present in the crystal, it was still considered likely. Therefore, the 
number of biological units per asymmetric unit was assumed to most likely be 4, since this 
would correspond to two of these dimers.
2.4.2. Molecular replacement
In macromolecular crystallography, the next challenge after collecting a dataset is usually to 
obtain a set of phases, since only the structure factor amplitudes can be determined directly 
from the recorded diffraction images. Several methods exist, but when a structure of a closely 
related homologue is available, the most straightforward method is usually molecular replace-
ment. With this method, initial phases are obtained by finding the best rotation and transla-
tion of the molecular model of the known structure in the unit cell of the unknown structure 
[103]. The method works best when the structure used as a search model is very similar to 
the unknown structure. While the best way to quantify the similarity between two structures 
would be root-mean-square deviation (RMSD) of the atomic positions, the only information 
that is available before the molecular replacement is the sequence identity. Typically, 30% se-
quence identity is considered the minimum for a good search model, although search models 
with a higher similarity might fail if the structures are too different and search models with 
lower similarity might succeed if the structures are similar [104]. 
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For solving the structure of 33SSP–NB33_1, several potential search models were available. 
Structures had previously been published of two bestrophin homologues, namely chicken 
BEST1 (cBEST1) [37] and a prokaryotic bestrophin homologue from Klebsiella pneumoniae 
(kpBEST) [67]. Additionally, many nanobody structures were readily available in the Protein 
Data Bank. However, as the molecular mass of a nanobody is small (12.6 kDa), one nanobody 
was only expected to make up 1.3% of the total protein mass (948 kDa) in the asymmetric unit. 
Therefore the scattering contributed by a single nanobody would be similarly low, meaning 
that it would be very difficult to correctly place a nanobody using molecular replacement 
[105]. By comparison a 33SSP pentamer (174 kDa without bound nanobodies) was expected 
to contribute 18.3% of the total protein mass, meaning that it should ideally be easier to place 
correctly during the molecular replacement search. kpBEST was considered the best available 
search model, since it showed a higher similarity to 33SSP (approximately 25% sequence iden-
tity) than cBEST1 (sequence identity <20%). 
In order to improve the search model, an alignment was produced between 33SSP and kp-
BEST. Based on this alignment, the side chains of non-conserved amino acid residues were 
truncated to the Cβ or Cγ position using the program SCULPTOR [106]. An initial molecular 
replacement search with PHASER [105] running on a single processor core did not return a 
solution within a few days and was therefore aborted. After testing various parameters, the 
Figure 31 – Molecular replacement solution obtained with Phaser. The four pentamers present in the asymmetric 
unit are shown as yellow ribbons. For two of the pentamers, the cytoplasmic and transmembrane regions are la-
belled. A 90° rotation illustrates how one pentamer is placed directly above another, with the cytoplasmic regions 
facing each other. 
90°
Transmembrane 
region
Cytoplasmic 
region
Transmembrane 
region
Cytoplasmic 
region
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expected RMSD between the search model and the unknown structure was lowered to 1 Å. 
Additionally, it was specified that placed components did not have to pack into a compact 
assembly, since the presence of detergent micelles and nanobodies could mean that very few 
crystal contacts would be present between the individual pentamers. After a lengthy search of 
41 hours total processing time (the actual time was decreased by running on multiple proces-
sor cores), a solution was found. 
In this solution, four pentamers were successfully placed in the asymmetric unit (Figure 31). 
Two pairs of pentamers were observed. In each pair, the cytoplasmic regions of two pentam-
ers were facing each other, separated by approximately 30 Å. Within each pair, the axes of the 
pores were found to line up, so that one straight line could be drawn running down the middle 
of the pore in both pentamers. If such lines were drawn through both pairs, a slight tilt was 
observed, meaning that the two pairs were not completely parallel. 
Figure 32 – Crystal packing of the molecular replacement solution obtained with Phaser. One asymmetric unit 
(the content of one unit cell) is shown in yellow. Seven additional asymmetric units are shown in grey. No potential 
crystal contacts could be observed. 
90°
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Further analysing the crystal packing (Figure 32) did not reveal any potential crystal contacts 
between any of the pentamers. Enough space was observed around the transmembrane re-
Figure 33 – Electron density maps and structures after molecular replacement and additional refinement or mor-
phing. All maps (2mFo−DFc) are contoured at 2σ and shown as meshes with a light blue colour. The same region 
of the map, surrounding the bestrophin pentamers, is shown in each subpanel. Coloured ribbons represent the 
structures.  (A) Solution obtained with Phaser. (B) Refinement of solution obtained with Phaser. (C) Morphing of 
solution obtained with Phaser. 
A
B
C
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gions to accommodate detergent micelles, as is typical for the so-called Type II membrane 
protein crystals [78]. For other proteins, the high concentration of lipid and detergent used 
during the crystallisation have sometimes been found to result in the formation of Type I 
crystals [82], where the packing resembles stacked 2D crystals, with the transmembrane re-
gions packed much closer together. This did, however, not seem to be the case for the 33SSP–
NB33_1 complex. 
Since it was not known if the molecular replacement solution was correct, i.e. if the placement 
of the search model corresponded to the actual structure, the electron density map was ex-
amined closely. Density was seen around the helices (Figure 33a), but this was not surprising 
since the phases were expected to be biased towards the search model [107]. Surrounding the 
pentamers, the map was found to be rather noisy and no indication of nanobody binding could 
be observed. 
As the next step, refinement of the solution was attempted. 5 cycles of restrained refinement 
in PHENIX [108,109] using NCS and secondary structure restraints, lowered the R-factors 
from 53%/53% (R-work/R-free) to 49%/52%. The electron density map did appear a little bit 
less noisy, but did still not reveal any new features (Figure 33b). Thus, it was still not clear if 
the solution was correct. 
Finally an attempt was made to improve the 
model using iterated local density-guided 
model deformation and refinement, also 
known as morphing [110]. The actual mor-
phing was performed automatically in the 
PHENIX software suite. In each cycle, a 
prime-and-switch map was calculated, since 
that type of map has been reported to be 
less affected by model bias than commonly 
used map types [111]. The model was then 
deformed to better fit the density and finally 
refined. This process was repeated 6 times. 
This procedure significantly improved the 
R-factors from 53%/53% (R-work/R-free) 
to 42%/46%. When inspecting the electron 
density map, a large improvement was ob-
served (Figure 33c). In addition to the maps 
being less noisy, clear density for a total of 
20 nanobodies could now be observed. 5 
Figure 34 – Placement of NB33_1. The figure shows the 
output from the phased molecular replacement proce-
dure used to place twenty nanobodies. The four 33SSP 
pentamers are shown as purple ribbons, while the twenty 
NB33_1 nanobodies are shown as white ribbons.
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nanobodies appeared to be bound to the cytoplasmic region of each pentamer, and two pen-
tamers appeared to be held together in a dimer of pentamers, due to nanobody–nanobody 
interactions. 
To further improve the structure, a nanobody model was added in twenty copies. While it 
might have been possible to manually dock nanobodies into the density, an easier solution was 
chosen. Phased molecular replacement done using the program MOLREP [112], easily placed 
twenty nanobodies in the expected positions (Figure 34). The placed nanobodies all appeared 
to bind identically to 33SSP and the nanobody–nanobody interactions also appeared identical 
for each of the nanobody dimers.  
2.4.3. Refinement
After placing all nanobodies correctly, the model was improved by iterative model building 
and refinement. Initial building efforts focussed on eliminating large errors. A loop on the 
extracellular side, between the first and the second transmembrane helix, was removed from 
each of the monomers in the structure as it was not supported by the density. This was not 
entirely surprising since this loop is four amino acid residues longer in 33SSP compared to 
kpBEST. Another surface loop between the third and the fourth transmembrane helices was 
also removed, in addition to a surface loop on the cytoplasmic side of the protein. Some of the 
side chains that had been removed in preparation for molecular replacement, were added back 
if supported by the density. For the nanobodies, the CDRs were found to be in poor agreement 
with the density and they were therefore also removed. Whenever possible, large segments of 
structure were copied using NCS operators, to avoid building the same parts twenty times. 
Refinement was carried out in PHENIX us-
ing torsion-angle NCS restraints [113]. Ini-
tially, only coordinates and isotropic B-fac-
tors were refined. Refinement with grouped 
B-factors did not improve the refinement 
results, as judged by the R-factors. In lat-
er refinements, TLS parameters were also 
added. One TLS group was used for each 
chain, since adding more were not expected 
to lead to significant improvements, based 
on analysis of a refined model with the TLS-
MD server [114]. 
At the time of writing, model building and 
refinement has still not been completed. 
Resolution (Å): 47.92  - 3.1 (3.211  - 3.1)
Total reflections: 870561 (84178)
Unique reflections: 246398 (24632)
   Used in refinement:  246218 (24622)
   Used for Rfree: 12314 (1232)
Wilson B-factor (Å2): 86.97
Rwork: 19.79 (35.37)
Rfree: 23.06 (39.90)
No. of atoms: 62854
Protein residues: 8006
RMS deviations
   Bonds (°): 0.004
   Angles (Å): 0.71
Ramachandran 
   Favored (%): 97.80
   Allowed (%): 1.97
   Outliers (%): 0.23
Rotamer outliers (%): 3.75
Clashscore: 7.10
Average B-factor (Å2): 104.81
Table 13 – Refinement statistics. Numbers in parenthe-
ses indicate the highest resolution shell and its statistics. 
5% of the unique reflections were used for the Rfree cal-
culation. 
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The current refinement statistics are shown in table 13. R-factors are already quite low (Rwork 
19.79%, Rfree 23.06%), possibly partially due to the extensive NCS restraints. The model still 
contains a higher than expected number of rotamer outliers, and certain surface loops are still 
missing from some of the pentamers. The number of amino acids placed in each subunit var-
ies between the four pentamers present in 
the asymmetric unit. In the most complete 
pentamer all loops have been built, except 
for the surface loop connecting the first and 
second transmembrane helices. An initial 
trace of this loop, which is on the extracel-
lular side of the protein, has been made for 
one of the subunits in this pentamer. The 
electron density for this loop is still weak, 
so the exact conformation of the loop and 
the conformations of the individual amino 
acid side chains are still not certain. Some 
electron density is, however, seen for some 
of the missing loops, so it is possible that 
these can eventually be built (Figure 35).
All nanobodies have been fully modelled, except for 5 unstructured amino acid residues on the 
N-terminus. Figures in the following sections have been prepared using the structure of the 
best modelled pentamer and its associated nanobodies.
Figure 35 – Electron density of missing loops on the ex-
tracellular side of 33SSP. Electron density map (2mFo−
DFc) contoured at 1σ and shown as a blue mesh. The 
structure of 33SSP is shown as a backbone trace, coloured 
in dark grey. 
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2.5. Structure analysis
2.5.1. Overview of the 33SSP structure
As expected from the structures of other bestrophins, 33SSP is a pentameric, α-helical pro-
tein. The five monomers are arranged symmetrically around a central pore axis (Figure 36). 
This can be observed as a hole in the middle of the protein when viewed from the top or bot-
tom. Based on the understanding of animal bestrophin topology [115], the N-terminus and 
C-terminus are both expected to be located on the intracellular side. As certain helices are 
more hydrophobic than others, the membrane spanning part of the structure was estimated 
to correspond to the top of the protein, when viewed from the side as in figure 36. A more 
precise estimate of the position and orientation in the membrane was produced with the PPM 
web server [116], using a theoretical, complete model of 33SSP where the surface loop missing 
from four of the monomers had been copied from the complete monomer. The boundaries of 
the hydrocarbon core of the bilayer are shown in figure 37a. The thickness of the bilayer was 
estimated to be 27.2 ± 1.0 Å. By comparison the size of a complete pentamer is approximately 
95 Å when measured along the pore axis and 75 Å across the cytoplasmic part of the protein. 
As illustrated in figure 37b, the protein consists of 8 longer α-helices. 4 of these helices are 
crossing the membrane and are labelled TM1–4. The first two and the last two of the trans-
membrane helices are separated by longer sequence regions constituting a folded intracellular 
component (Figure 37c). At the primary sequence level, the protein can thus not be divided 
into clearly separate domains. When looking at the structure, there are also no clear domain 
90° 90°
Top view
(extracellular side)
Bottom view
(intracellular side)
Figure 36 – Ribbon model of 33SSP. The figure shows the pentameric structure of 33SSP, with each monomer 
coloured in different colours. The middle part of the figure shows the protein viewed from the side, with the 
extracellular side on top and the intracellular side on the bottom. The left part of the figure shows the view from 
the extracellular side of the protein (top view), while right part shows the view from the intracellular side (bottom 
view). In the top and bottom views the pore is visible as a hole in the middle of the protein.  
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boundaries since the second helix, which is lining the part of the pore located in the mem-
brane, is connecting the transmembrane and cytoplasmic regions of the protein. 
The N-terminus of each monomer is positioned close to the membrane interface and is wrap-
ping around the protein (clockwise when viewed from the extracellular side) to the adjacent 
monomer, where a salt bridge is formed between Asp20 of one monomer and Lys222 of the 
Figure 37 – Protein topology and sequence. (A) Based on the most complete monomer (highlighted in blue), a 
theoretical, complete model was generated and its position in the membrane was estimated. Sheets of red and 
blue balls indicate the boundaries of the hydrocarbon core of the bilayer. The extracellular side is labelled "outside" 
and the intracellular side "inside". The approximate thickness of the bilayer is indicated as well as the approximate 
dimensions of the pentamer. (B) Structure of 33SSP with helices shown as cylinders. One monomer is highlighted 
in blue and helices longer than five amino acid residues are labelled. Positions of the N-terminus and C-terminus 
are indicated. (C) Sequence of the 33SSP construct used for crystallisation. Helices are annotated and labelled in 
accordance with the model in the previous panel. The second amino acid residue on the N-terminus and the last six 
amino acid residues on the C-terminus were introduced by cloning. The numbering was started at zero to account 
for the N-terminal addition. The first three amino acid residues on the N-terminus and the last amino acid residue 
on the C-terminus are not modelled in the structure. The loop between the first and the second transmembrane 
helices is only fully modelled in one of the monomers (highlighted in blue).
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adjacent monomer. Additional intermolecular salt bridges are observed from Glu111 to 
Lys171 and from Arg99 to Glu205, all in the intracellular region of the protein. Furthermore, 
the pentameric complex is stabilised by an average of 22 intermolecular hydrogen bonds. The 
interface area between two monomers measures approximately 3000 Å2, as calculated by the 
PDBePISA webserver [117]. 
Some parts of the structure appear to be 
more flexible than others. When analysing 
the crystallographic B-factors, these were 
found to be significantly higher in the trans-
membrane region compared to the core of 
the cytoplasmic region. This is illustrated 
in figure 38 where the average B-factors 
for each residue are mapped on a cartoon 
model of 33SSP. In the cytoplasmic region, 
the B-factors are generally low, except for 
loops on the surface. Getting closer to the 
membrane the B-factors appear to increase. 
The residues close to the outside and the 
extracellular loops, consistently appear to 
have B-factors much higher than average, 
indicating a higher degree of flexibility than 
the rest of the protein. Consistent with this 
observation, the structure has been more 
difficult to build closer to the extracellular 
side, where the electron density maps ap-
pear less well-defined, compared to the cy-
toplasmic region. 
Overall, the structure of 33SSP looks similar to the known cBEST1 and kpBEST structures. 
The topology is analogous and when positions on the surface of the proteins are excluded, 
the core helices are found to be conserved between all three homologues. In an attempt to 
compare the structures directly, the pentameric cBEST1 and kpBEST structures were each 
superimposed on the pentameric 33SSP structure using secondary structure matching [118] 
in Coot [119]. In this case the whole pentameric structures were rotated and translated as rigid 
bodies to provide the best fit to the 33SSP structure. The root-mean-square deviation of the 
Cα positions (core RMSD) was 3.76 Å for the superimposition of cBEST1 on 33SSP and 2.96 Å 
for kpBEST on 33SSP. These rather large deviations were also obvious upon visual inspection. 
Figure 38 – Distribution of B-factors in the 33SSP struc-
ture. B-factors were converted to isotropic B-factors, 
since refinement had been performed using TLS param-
eters. The average B-factor for each amino acid residue is 
displayed on the cartoon model of 33SSP, using colours 
ranging from blue (40 Å2) over white (105 Å2) to red (170 
Å2). The average B-factor for the entire 33SSP–NB33_1 
structure was calculated as 105 Å2.
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Figure 39 – Structures of cBEST1 and kpBEST superimposed on the structure of 33SSP. Structures were superim-
posed using secondary structure matching (SSM) in Coot. For the highlighted monomers, green is used for 33SSP, 
dark purple for cBEST1 and blue for kpBEST1. Furthermore, the positions of the N- and C-termini are indicated. 
(A) A cBEST1 pentamer superimposed on a 33SSP pentamer. One monomer of each structure is highlighted. (B) 
A monomer of cBEST1 superimposed on a 33SSP monomer.  The approximate rotation of the cBEST1 monomer 
compared to the previous panel is indicated. (C) A kpBEST pentamer superimposed on a 33SSP pentamer. One 
monomer of each structure is highlighted. (D) A monomer of kpBEST superimposed on a 33SSP monomer.  The 
approximate rotation of the kpBEST monomer compared to the previous panel is indicated.
33SSP and cBEST1
33SSP and kpBEST 33SSP and kpBEST
33SSP and cBEST1A B
C D
8°
5°
C-termini
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For both cBEST1 (Figure 39a) and kpBEST (Figure 39c) the structures were similar enough 
for a credible superimposition, but significant shifts were observed for most helices. However, 
when a monomer of either cBEST1 (Figure 39b) or kpBEST (Figure 39d) was superimposed 
on a monomer of 33SSP, the structures were found to align much better. In this case, the core 
RMSD values were 2.83 Å or 2.08 Å for the superimposition of cBEST1 or kpBEST, respective-
ly. When comparing the position of a cBEST1 monomer that had been superimposed as part 
of a pentamer, with a monomer that had been superimposed as a monomer, the difference was 
found to be a rotation of approximately 8°, around a point located between the cytoplasmic 
and transmembrane regions. For kpBEST a similar, but smaller, rotation of 5° was observed. It 
thus seems, that while the overall pentameric assemblies are similar, the exact orientation of 
the monomers with respect to each other, can vary between different homologues. 
When comparing the structure of 33SSP to the structure of kpBEST (Figure 39d), a striking 
difference was found in the N-terminus. Upon comparison of the amino acid sequences, the 
two homologues were found to have N-termini of similar lengths. However, in the structure 
of kpBEST, the N-terminal region preceding the first transmembrane helix does not appear to 
be structured. By comparison, 33SSP and cBEST1 seem to have N-termini of similar lengths, 
both located close to the membrane (Figure 39b). A discussed later, the N-terminus is involved 
in calcium binding in cBEST1. Additionally, cBEST1 has a significantly longer C-terminus, 
which wraps around the pentamer, covering two adjacent monomers. 
2.5.2. Ion conduction pathway
As previously discussed, the pore of 33SSP is straightforward to identify as a hole in the mid-
dle of the protein. Along the axis of this pore, narrow constrictions can be observed in two 
separate places. Towards the extracellular region of the protein, a constriction is formed by 
three residues in the second transmembrane helix. Looking along the pore axis from the out-
side of the protein, a constriction consisting of Phe67, Ile71 and Phe75 is clearly visible. Due 
to the fivefold symmetry of the protein, each of these residues are observed five times at the 
pore, where they are arranged symmetrically around the pore axis (Figure 40a). This region 
of the protein has previously been referred to as the “neck”, while another constriction has 
been referred to as the “aperture” [37]. Both terms will be used in the following when refer-
ring to these constrictions. The aperture can be observed when viewing the protein from the 
intracellular side. Here the residues Glu185 and Ile188 form a constriction, again with fivefold 
symmetry around the pore axis (Figure 40b). Whereas the neck is made up of hydrophobic 
residues in all three available bestrophin structures, the aperture of 33SSP is unique in having 
a ring of negatively charged residues at the position closest to the cytoplasm. At this position 
either a valine or isoleucine residue can be found in cBEST1 or kpBEST, respectively. Also un-
like the other bestrophin structures, the aperture in 33SSP is made up of two residues. At the 
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position of Ile188, cBEST1 and kpBEST feature either a glutamine residue that does not point 
toward the pore axis or a glycine residue, respectively. 
Figure 40 – View along the pore of 33SSP. Structure of 33SSP shown as grey ribbons. Highlighted residues are 
shown as yellow sticks. (A) Extracellular view of 33SSP (top view). Phe67, Leu71 and Phe75 are shown as yellow 
sticks.  (B) Intracellular view of 33SSP (bottom view). Glu185 and Ile188 are shown as yellow sticks. (C) View of 
33SSP from the side. Approximate membrane boundaries are shown. One monomer and the N-terminus of an ad-
jacent monomer are hidden, resulting in a free view to the pore. From the top to the bottom the following residues 
are shown as yellow sticks: Phe67, Leu71, Phe75, Asp82, Asp192, Ile188 and Glu185. The neck and aperture regions 
are rotated and enlarged for a clearer view. 
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Between the neck and the aperture, the structure contains a large inner cavity. Interestingly, 
in 33SSP two rings of negative charges can be found in this inner cavity. One ring is made 
up of Asp82 and located close to the neck. The other ring is made up of Asp192 and located 
close to the aperture (Figure 40c). These rings of negative charge together with the negative 
charges at the aperture contribute to a negative surface potential in the inner cavity of 33SSP, 
as described later. 
Most of the pore lining residues in the neck and aperture regions are well defined in the elec-
tron density as illustrated in figure 41. Only for the outermost residue (Phe67), the density is 
not clearly defining its exact conformation. Some density is, however, visible and other con-
formations consistent with that density would probably lead to clashes due to the narrow 
constriction at this position.  
To further analyse the constrictions at the neck and aperture, the pore dimensions of 33SSP 
as well as cBEST1 and kpBEST were calculated using the program HOLE [120]. The program 
measures the largest sphere that can fit at various positions sampled along the pore axis. The 
results presented in figure 42a show that the tightest constriction in 33SSP is found at the 
outermost position of the neck, where Phe67 is constricting the pore to a radius of 1.05 Å. 
Leu71 (middle position) and Phe75 (innermost position) lead to constrictions of 1.62 Å and 
1.25 Å, respectively. In the aperture region, 33SSP is found to be less constricted with the radii 
measuring 1.58 Å at Ile188 and 1.59 Å at Glu185. 
By comparison, the neck region of cBEST1 (Figure 42b) is constricted to a similar degree at 
the middle position (Phe80) as 33SSP at the outermost position (Phe67). At the innermost 
position of the neck, cBEST1, however, is less constricted with a pore radius of 2.02 Å. In the 
Phe67
Leu71
Phe75 Glu185
Ile188
Figure 41 – Electron density of pore constrictions in the structure of 33SSP. Electron density map (2mFo−DFc) 
contoured at 1σ and shown as a blue mesh. The structures of two 33SSP monomers are shown as backbone traces, 
coloured in dark grey. Selected side chains are shown and labelled. (A) Constriction in the membrane region (neck 
region). (B) Constriction on the intracellular exit from the pore (aperture region).
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aperture region, cBEST1 appears to be slightly more constricted than 33SSP, but only at one 
position, unlike the double constriction found in the aperture of 33SSP. 
The neck region of kpBEST is the least constricted of the three compared channels (Figure 
42c). Here the narrowest point is at the outermost position (Ile62) where the radius measures 
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Figure 42 – Pore dimensions of 33SSP compared to other bestrophin structures. Pore dimensions were calcu-
lated using the program HOLE and illustrated as solid surfaces coloured red where the pore is too narrow for a 
water molecule (< 1.15 Å), green where a single water molecule can fit (1.15 Å > radius < 2.30 Å) and blue where 
more than one water molecule can fit (> 2.30 Å). The protein structures are shown as grey ribbons. Approximate 
membrane boundaries are shown. To aid in visualisation, one of the monomers and part of the N-terminal and 
C-terminal sequences from an adjacent monomer are hidden from each structure, resulting in free views to the 
pores. Residues located at the pore constrictions are shown as sticks and coloured yellow. For each structure, a plot 
showing the pore radius is aligned along the length of the pore axis. (A) Pore dimensions of 33SSP. The neck and 
aperture regions are enlarged. (B) Pore dimensions of cBEST1. (C) Pore dimensions of kpBEST. 
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Figure 43 – Electrostatic surface plots of 33SSP compared to other bestrophin structures. For 33SSP, a theoretical, 
complete model, based on the most complete monomer, was generated and used for the calculation. Surface mod-
els of 33SSP as well as cBEST1 and kpBEST are coloured by electrostatic potential (red: −10 kT e−1, white: neutral, 
blue: 10 kT e−1). For the side views, the membrane positions are indicated. (A) 33SSP shown from the top (extracel-
lular side), from the bottom (intracellular side) and from the side. Additionally, a view of the pore is shown, where 
half of the structure has been cut away. (B) Pore view of cBEST1. (C) Pore view of kpBEST. 
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1.35 Å. Contrary to the neck, kpBEST is found to be more constricted than either 33SSP or 
cBEST1 at the aperture where it measures 0.99 Å. 
Comparing the pore lining residues in the necks of the three structures, it is evident that 
they all contain hydrophobic residues. The only position that appears to be fully conserved 
between the three channels is the innermost position, where a phenylalanine residue is found 
in each structure. This position also appears to be highly conserved when comparing to other 
bacterial bestrophins. Out of the 128 bacterial homologues that were selected for screening, 
121 (95%) had a phenylalanine at this position. In the remaining 7 sequences, either isoleucine, 
leucine or tyrosine was found. The middle position appears less conserved, but typically con-
tains a hydrophobic residue. 117 out of the 128 (92%) selected homologues contained either 
leucine, isoleucine, phenylalanine or valine at this position. The outermost position was also 
mostly hydrophobic with 86 of the 128 (67%) selected homologues containing phenylalanine, 
isoleucine, leucine or valine. However, 35 out of the 128 (27%) had either threonine or serine 
at this position. It thus appears to be the least conserved position. 
To further investigate the charge distribution, the electrostatic surface potential was calculat-
ed for 33SSP as well as cBEST1 and kpBEST. On the surface of 33SSP patches of positive and 
negative potential can be observed, but around the pore entry no charged binding pockets are 
found (Figure 43a), contrary to what has been reported for cBEST1 [37]. Looking inside the 
pore, a strong negative potential can be observed at both ends of the inner cavity, close to the 
neck and aperture, respectively. By comparison cBEST1 has a strong positive potential (Figure 
43b) and kpBEST a strong negative potential (Figure 43c) near the aperture. For 33SSP, the 
region inside the neck constriction also contains positive potential, but probably this is highly 
uncertain since this region is located close to the membrane interface and therefore could be 
expected to be strongly affected by the membrane electric field, which is not accounted for in 
these calculations. Therefore, to get a more detailed and accurate description of the electro-
statics, more advanced calculations of the electrostatic potential would be required, taking the 
presence of a membrane and the associated electric field into account. Also, if the structure of 
33SSP represents a closed channel, the electrostatics could change when the channel opens, if 
the opening involves large conformational changes. 
2.5.3. Ligand binding loop and N-terminus
cBEST1 is activated by calcium like the mammalian bestrophins [37]. As previously described, 
calcium ions are bound by the so-called calcium-clasp, which includes a stretch of five acidic 
residues (Glu-Asp-Asp-Asp-Asp), and a part of the N-terminus. In 33SSP this sequence is 
only partially conserved (Ile-Asp-Ser-Asp-Asp) and since kpBEST has been reported not to be 
activated by calcium, it is uncertain if 33SSP would be. 33SSP has a loop in the same location 
and of the same length as the calcium-clasp in cBEST1, but it is uncertain if an activating li-
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gand would bind in this location or somewhere else. It is nonetheless a possibility, so this loop 
will be referred to as the proposed ligand binding site. 
The proposed ligand binding site appears in two different conformations in the structure of 
33SSP. In one conformation, part of the loop is pushed in the direction of the last transmem-
brane helix. The possible binding pocket seems closed or collapsed in this conformation (Fig-
ure 44a). In the other conformation, the possible binding pocket appears more open (Figure 
44b). In order for the proposed ligand binding site to adopt the open conformation, another 
loop on the surface of the cytoplasmic region, must move away. This loop, starting around po-
sition 140 and therefore referred to as the 140-loop, would otherwise partially clash with the 
ligand binding site (Figure 44c–d). 
As the protein complex is crystallised with EGTA it is unlikely that calcium could be bound in 
the crystal. Since no other divalent ions or other potential ligands were added to the crystal-
lisation condition either, the two conformations of this loop are most likely both ligand-free 
Figure 44 – Structure of the proposed ligand binding site of 33SSP. (A) Collapsed conformation of the proposed 
ligand binding site (light green). Selected side chains and main-carbonyls are shown. (B) Open conformation of the 
proposed ligand binding site (dark grey). Selected side chains and main-carbonyls are shown. (C) The two different 
conformations of the proposed ligand binding loop are superimposed. The 140-loop is shown to illustrate how this 
loop moves to accommodate the open conformation of the proposed ligand binding site. (D) Overview showing the 
proposed ligand binding site of 33SSP and the 140-loop in the two different conformations. 
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conformations. The loop thus appears to move between these two conformations in the ab-
sence of a ligand. It is possible that binding of a ligand would lock the loop in one of these two 
conformations or in another conformation. 
The two different loop conformations appear well-defined by the electron density map, even 
though density is not clearly visible for all side chains (Figure 45). For the other monomers in 
the structure, the proposed ligand binding loop can be assigned to one of the two categories, 
although some small differences are observed. Also, in some monomers this particular loop 
appears less well defined in the electron density map, with density missing for most of the side 
chains. 
2.5.4. Nanobody structure and binding 
As previously described, 33SSP was crystallised in complex with a nanobody. The structure 
contains 20 nanobodies in the asymmetric unit. The structures of the individual nanobodies 
are largely identical, with only small variations observed. Typically, those variations are ob-
served in regions that are involved in crystal packing. As expected from other nanobody struc-
tures [121,122], the structure consists of a sandwich of two β-sheets (Figure 46) that are con-
nected by a disulphide bridge. The arrangement of the individual strands is consistent with a 
classical immunoglobulin fold [123], and the strands in figure 46 have thus been labelled using 
the immunoglobulin nomenclature. The only deviation from the described is found in strand 
A, which appears to be split in half (based on DSSP [124] secondary structure assignments) 
with each half of this strand being part of a different β-sheet. For this reason, the second 
half of strand A has been labelled A’ in figure 46. This split of the first strand can also be ob-
served when examining other nanobody structures (e.g. PDB accession numbers 1MEL [122] 
Figure 45 – Electron density of the proposed ligand binding site of 33SSP. Electron density map (2mFo−DFc) con-
toured at 1σ and shown as a blue mesh. The proposed binding sites of two different monomers showing different 
conformations are displayed. Additionally, the loops starting around residue number 140 are shown. (A) Proposed 
ligand binding site in the "collapsed" conformation. (B) Proposed ligand binding site in the "open" conformation.
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or 1HCV [121]) and is therefore not unusual. As expected the two β-sheets are anti-parallel, 
except for the second half of strand A which associates with strand G in a parallel orientation.
As expected the three CDR loops are located on one end of the nanobody, which binds to the 
target protein (33SSP). Each nanobody is binding on the cytoplasmic region of 33SSP (Figure 
47a–b), with five nanobodies per pentamer that are tilted with respect to the pore axis. The 
epitope is remote from the pore and the putative ligand binding sites, and it thus does not 
seem likely that binding of the nanobody would affect the function of the channel. The binding 
occurs at the interface between two adjacent 33SSP monomers, where one nanobody interacts 
with both monomers (Figure 47c–d). For each nanobody, the interface with one monomer 
buries 750 Å2 and with the other monomer 300 Å2 of its surface (both calculated by the PD-
BePISA webserver). 
As previously discussed, the nanobodies bring two pentamers in contact, thereby forming a 
complex, which can be described as a dimer of pentamers. This complex could be observed 
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Figure 46 – Structure and sequence of one nanobody from the 33SSP–NB33_1 complex. (A) The nanobody is 
shown as a ribbon model. CDR1 is coloured yellow, CDR2 red and CDR3 purple. β-strands are labelled with the 
strand names typically used for immunoglobulin folds. Additionally, the name A' is introduced for the strand be-
tween strand A and strand B. The strands form two β-sheets, which pack against each other in a sandwich struc-
ture. The lowermost β-sheet is formed by the strands A, B, E and D, while the uppermost is formed by the strands 
A', G, F, C, C' and C''. A conserved disulphide bridge, linking the two sheets, is shown between strand B and strand 
F. (B) 90° rotation of the nanobody. (C) Sequence of the nanobody construct used for crystallisation. 3 first amino 
acid residues on the N-terminus and the 1 last amino acid residue on the C-terminus were introduced by cloning. 
The numbering was started at −2 to account for the N-terminal addition. 5 amino acid residues on the N-terminus 
are not modelled in the structure. β-strands are annotated as blue arrows and the positions of the CDRs are indi-
cated with black lines. A dashed line shows the position of the disulphide bridge. 
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during purification as a peak that eluted at low volumes from the gel filtration column. How-
ever, when NB33_1 was purified alone it eluted at similar volumes as the other tested nano-
bodies, indicating that it was monomeric. Even when injecting the nanobody at high concen-
trations (approximately 20 mg/ml), there were no indications that it was forming dimers. An 
examinination of the the nanobody–nanobody interface that is observed in the crystal struc-
ture did also not reveal anything that resembled a high-affinity binding surface. The two na-
nobodies are interacting through hydrogen bonds between residues that are mainly located in 
the first two strands (Figure 48). No salt bridges were observed and the interface area is about 
400 Å2 in size (calculated by the PDBePISA webserver). The observed dimer of pentamers is 
therefore likely formed due to an avidity effect, where the sum of five weak nanobody–nano-
body interactions is enough to form a stable complex. The sequence of the interface region 
Figure 47 – Binding of NB33_1 to 33SSP. One pentamer shown in different representations with five nanobodies 
bound. The two 33SSP monomers closest to the front are coloured green and cyan; the remaining monomers are 
coloured grey. The nanobody closest to the front is coloured pink; the remaining nanobodies are coloured white. 
For the front nanobody, CDR1 is coloured yellow, CDR2 red and CDR3 purple. (A) Ribbon representation of the 
pentamer and the five nanobodies, seen from the side. (B) 90° rotation showing the pentamer from the cytoplas-
mic side. (C) Surface view of the pentamer with the nanobodies shown as ribbons, with the same orientation as in 
panel A. (D) Enlargement of the region indicated on the previous panel. The surface of the nanobody is shown as 
a transparent pink cloud. 
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appears to be identical to the other tested nanobodies, so the fact that the dimer of pentamers 
complex could form is probably largely due to the binding orientation of this particular nano-
body on the 33SSP pentamer. 
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Figure 48 – Structure of a nanobody dimer from the 33SSP–NB33_1 structure. (A) The two nanobodies are shown 
as ribbon models. One nanobody is coloured pink and the other nanobody aquamarine. CDR1 is coloured yellow, 
CDR2 red and CDR3 purple in both nanobodies. (B) 90° rotation of the nanobody dimer. (C) Closer look at the 
dimerisation interface indicated in panel A. The nanobodies are shown as backbone traces. Residues and backbone 
atoms involved in hydrogen bonding are shown and labelled. Possible hydrogen bonds are indicated with thin lines 
and the distances between donor and acceptor atoms are indicated. 
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3. Discussion
Since the start of the research project described in this thesis, two structures of other be-
strophin homologues have been published by other groups. From these structures, much has 
been learned about the function of bestrophins. With the structure presented in this thesis, 
this knowledge can be further expanded. However, important questions remain that cannot 
be clearly answered based on these structures alone. In this chapter I will attempt to discuss 
some of these questions and provide an outlook for further studies. 
3.1. Homologue screening and crystallisation
The homologue screening strategy used in this project was successful. Several homologues 
were identified that could not only be purified, but also crystallised. However, as the homo-
logue screening was done with many homologues in parallel, the focus was solely on identi-
fying well behaving homologues. Therefore, homologues that did not behave well were not 
tested further. This was also the case for the homologue 67KPN from Klebsiella pneumoniae. 
During the initial screening this homologue behaved promising, but during the later large-
scale purification the protein precipitated when the GFP-tag was cleaved off. Consequently, 
no more attempts were made to purify this homologue since the focus was instead shifted 
to other homologues. However, some time later a crystal structure of the same homologue 
(referred to as kpBEST) was published by another group [67]. It is not known why the purifi-
cation of 67KPN failed, but undoubtedly it would have been possible to purify this homologue 
if more time had been invested in optimising the expression and purification.
Fortunately, several other homologues behaved well, but they did not all provide well-diffract-
ing crystals. In case of 33SSP, it was generally difficult to reproduce well diffracting crystals. 
When crystallised either on its own or in complex with the selected nanobody, a large fraction 
of crystals diffracted poorly. This made it difficult to perform certain experiments, such as the 
location of potential ion binding sites using anomalous scattering. Although I have attempt-
ed to crystallise 33SSP in the presence of ions with anomalous scattering properties such as 
caesium and bromide, none of the tested crystals diffracted sufficiently well and thus were not 
used for data collection. Soaking such ions into the crystals did not yield any results either. 
It is possible that this problem would have eventually been overcome by testing a sufficient 
number of crystals. Due to limited time, however, other parts of the project were prioritised. 
It is still not known why it was difficult to reproduce well diffracting 33SSP crystals. One ex-
planation might be problems during cryoprotection. Since the crystals were grown at very low 
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concentrations of PEG, a substantial amount of cryoprotectant had to be added to avoid the 
formation of crystalline ice during the freezing. 
Another explanation could be that it was difficult for 33SSP to form crystal contacts due to 
protein flexibility. Based on analysis of the crystallographic B-factors, the transmembrane part 
of the structure towards the extracellular side appears to be more flexible than other parts of 
the structure. In the crystal structure of 33SSP–NB33_1, no crystal contacts involving the 
extracellular side of the protein could be observed (Figure 49). This is unlike the crystal struc-
tures of cBEST1 and kpBEST, where the extracellular regions are directly involved in crystal 
contacts (not shown). As previously mentioned, the interpretation of the density of 33SSP–
NB33_1 is not yet completed, since a certain loop on the extracellular side is not fully built for 
all 20 monomers. However, based on a preliminary analysis of the weak electron density in this 
region, in does not seem likely that this loop would extend far enough from the current model 
to provide any crystal contacts. 
If there are indeed no crystal contacts between the extracellular regions, then another expla-
nation could be that the crystal lattice is stabilised by polar interactions between neighbour-
ing detergent micelles [78]. If that is the case, the quality of the crystals could be expected to 
depend on the size of the detergent micelles, since smaller micelles might not be in contact, 
while too large micelles would not have sufficient space in the lattice [78]. This could possibly 
explain why 33SSP did not crystallise in DM, despite appearing to be stable in that detergent. 
Since lipid was added to the purified protein, it is also possible that the exact amount of lipid 
that became incorporated into the micelles could vary between different protein purifications. 
Figure 49 – Crystal packing of 33SSP–NB_1. Several unit cells are shown as grey ribbons. Gaps are observed be-
tween extracellular regions of neighbouring molecules. 
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That would probably also affect the micelle size to some extent. Therefore, part of the reason 
why the diffraction quality of the tested crystals was variable, could be due to variation in 
micelle size. If further attempts to crystallise 33SSP are made, it could be investigated if the 
addition of small amounts of slightly shorter or longer chain detergents, could improve the 
diffraction quality or reproducibility of the crystals. 
3.2. Structure
3.2.1. Ligand binding
While the motif of acidic residues involved in calcium binding appears to be highly conserved 
in animal bestrophins, this does not appear to be the case for bacterial homologues. In kp-
BEST only one of the five acidic residues is conserved, whereas in 33SSP three are conserved 
(Figure 50c). kpBEST has been reported to be active in the absence of calcium, consistent 
with the binding site not being conserved [67]. However, in the case of kpBEST the record-
ed currents were single-channel currents measured in a planar lipid bilayer. No macroscopic 
currents were recorded and it is debatable if the channel really is fully active in the absence of 
any ligands or if the recorded currents rather represent low basal activity that occurs in the 
absence of an unknown ligand.
It thus seems likely that both 33SSP and kpBEST could be activated by some ligand, although 
the identity of such a ligand is so-far unknown. The two channels could also very well be acti-
vated by different ligands since they evolutionally appear to be quite distantly related, with a 
shared sequence identity of approximately 25%. While this stretch of acidic residues found in 
animal bestrophins is not conserved in prokaryotic homologues, another feature is conserved. 
Directly preceding the acidic residues is a highly conserved Pro-Phe-Gly motif. Of the 128 
bacterial homologues that were selected for the initial screening, the motif is conserved in 84 
homologues (66%), while the remaining 44 homologues (34%) contain Pro-Phe-X. While it is 
highly speculative, it is possible that bacterial bestrophins are also activated by binding of a 
ligand in the loop following this conserved Pro-Phe-Gly motif. For that reason, this loop will 
be referred to as the proposed ligand binding site. 
When comparing the individual bestrophin subunits in the 33SSP structure, the proposed 
ligand binding site is found to exist in two different conformations (Figure 44). Figure 50a–b 
compares these two conformations to the conformation the calcium binding loop found in 
cBEST1. The first conformation appears to be collapsed compared to the cBEST1 structure, 
while the other conformation apparently is in an open conformation which is overall similar to 
that of cBEST1. Interestingly, the positions of the Asp271 and Asp274 sidechains are close to 
the positions of Asp301 and Asp304 in cBEST1, which are the two acidic residues that are di-
rectly interacting with the calcium-ion in the cBEST1 structure. Three main-chain carbonyls 
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are in similar positions in the 33SSP structure, compared to those involved in calcium binding 
in cBEST1. In the cBEST1 structure two N-terminal main-chain carbonyls additionally appear 
to contribute to the calcium binding, but in the 33SSP structure, the N-terminus is located 
further away. 
As previously mentioned, the five acidic residues found in animal bestrophins appear to be 
poorly conserved in bacterial bestrophins. In the case of 33SSP, the two acidic residues directly 
involved in binding calcium in cBEST1 appear to be conserved. It could thus be possible that 
33SSP binds calcium or a similar ion, although probably with lower affinity than the calcium 
binding in animal bestrophins. While kpBEST only has the last of these two acidic residues 
conserved, 77 out of 128 prokaryotic homologues (60%) selected for screening were found to 
have the sequence X-Asp/Glu-X-X-Asp. 35 of these homologues were found to have three or 
four acidic residues located in this loop. As discussed previously, 33SSP and other of the tested 
homologues, show a higher thermostability in the presence of calcium. This observation does 
not necessarily mean that calcium binds in this loop, and even if calcium would bind there that 
would not necessarily lead to activation of the channel. It does, however, remain an interesting 
observation that should be investigated further.
Another interesting observation comes from a fungal bestrophin homologue from Aspergillus 
nidulans, which has been reported to be calcium dependant, despite only having two acidic 
Figure 50 – The proposed ligand binding site of 33SSP compared to the Ca2+ binding site of cBEST1. The Ca2+ 
binding site of cBEST1 is shown as a yellow and cyan backbone trace, where yellow indicates the region containing 
the conserved acidic residues, while cyan indicates part of the N-terminus. The bound Ca2+ ion is shown as a large 
green sphere, while a water molecule is shown as a small red sphere. The side chains are shown for all the five highly 
conserved acidic residues and the main-chain carbonyls that are involved in Ca2+ binding are shown as well. Com-
parisons to 33SSP were made by locally superimposing the shown regions of 33SSP on the structure of cBEST1. 
For 33SSP, sidechains are only shown for the conserved acidic residues. (A) Comparison between the collapsed 
conformation of the proposed ligand binding site in 33SSP (light green) and cBEST1. (B) Comparison between the 
open conformation of the proposed ligand binding site in 33SSP (dark grey) and cBEST1. (C) Multiple sequence 
alignment of the Ca2+ binding sequence of cBEST1 and the same regions from kpBEST and 33SSP. The five, highly 
conserved acidic residues are highlighted on the cBEST1 sequence.
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residues in the proposed ligand binding region [66]. Unfortunately, no further studies have 
been performed with this fungal homologue, but if it is truly calcium activated that could also 
be the case for 33SSP and other prokaryotic homologues. 
3.2.2. Gating
As described previously, the observed conformations of 33SSP, kpBEST and cBEST1 all have a 
similar minimum pore radius, although this minimum is located at different points along the 
pore axis. In the case of cBEST1, it has been suggested that the solved structure represents an 
open or nearly open state [37], since the channel has been crystallised in the presence of calci-
um, which is known to activate it. As cBEST1 is anion selective, a typical permeant ion would 
under physiological conditions be chloride. Given an effective ionic radius of chloride of 1.81 
Å [125], it is questionable whether the cBEST1 structure really represents an open state. 
It has recently been suggested that the residues in the neck of cBEST1 form a gate that can 
open and close in response to calcium, since mutating the three pore lining hydrophobic resi-
dues in the neck to alanines, leads to a channel that is active in the absence of calcium [38]. Hy-
drophobic gates have also been observed in several other families of ion channels [126]. While 
the exact sequence of residues in the neck region varies between the available bestrophin 
structures, they are all hydrophobic and located at similar positions in the different structures. 
This suggest that at least part of the gating mechanism might be conserved across evolution-
ary distant homologues. 
Despite having several crystal structures available, it is still unknown what kind of structur-
al rearrangements occur during opening of the gate. For animal bestrophins, the opening is 
assumed to happen upon calcium binding. It is, however, not known how the binding causes 
opening of the channel and it is also not known what the open channel looks like. 
Since the structure of cBEST1 has not been solved without calcium, the conformation of the 
calcium binding site in absence of calcium is not known either. It is also not known where 
the cBEST1 N-terminus is located when calcium is not bound. In the cBEST1 structure the 
calcium ion appears to be buried in the protein, but it would become solvent exposed if the 
N-terminus would move away [37]. If the N-terminus would indeed change position upon the 
binding of calcium, this could also mean that the first transmembrane helix would change po-
sition, since this is located directly following the short N-terminal region. In this way binding 
of calcium could lead to a structural change, which could cause opening of a gate.
Another structural change that could possibly happen upon ligand binding can be observed 
in the structure of 33SSP. As mentioned, the so-called 140-loop appears to be flexible and can 
change between different conformations in order to accommodate the open conformation of 
the proposed ligand binding site. If the gate is placed in the transmembrane region, it would 
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be hard to explain how a slight movement of this seemingly flexible cytoplasmic surface loop 
would lead to structural rearrangements in the transmembrane region. It does, however, re-
main a possibility that should be kept in mind for further studies.  
3.2.3. Selectivity
While it seems likely that the gating of ion flow is performed in the hydrophobic neck region, 
it is so far unknown how selectivity for different ions arises. In the case of cBEST1, the aper-
ture has been suggested to form a size-selective filter, allowing easier passage to larger anions 
that are more easily dehydrated [38]. This is based on the observation that mutating the valine 
residue, which constricts the aperture of cBEST1, to alanine results in anions of different sizes 
permeating equally well. Since this mutation or the previously mentioned triple-alanine muta-
tion in the neck region do not change the anion over cation selectivity of cBEST1 [38], it is so 
far unknown what causes cBEST1 to be an anion channel and kpBEST a cation channel [67]. 
In cBEST1 it has been proposed that the anion selectivity could be due to anion binding sites 
located just outside the neck and in the inner cavity of cBEST1, where chloride ions were 
observed in the structure [37]. These binding sites appear similar to those found in the gluta-
mate-gated chloride channel α (GluCl) from Caenorhabditis elegans [127], although the bind-
ing sites in that protein are on the intracellular side of the pore. Interestingly, GluCl belongs 
to the family of Cys-loop receptors, a group of pentameric ligand gated ion channels, which 
also includes cation selective channels such as nicotinic acetylcholine receptors. In cation se-
lective Cys-loop receptors, a ring of negative charges is typically found at the cytoplasmic side 
of the pore [128,129]. This ring of negative charges seems to affect the charge selectivity both 
in eukaryotic [130] and prokaryotic family members [131], although other mutations are also 
required to fully convert a cation selective channel to an anion selective one [132]. 
As described earlier, rings of negative charges were also observed at different positions in the 
cytoplasmic region of 33SSP. At present the charge selectivity of 33SSP is unknown, but since 
the other crystallised bacterial bestrophin homologue, kpBEST, appears to be cation selective, 
this could potentially also be the case for 33SSP. 
Although the charge selectivity of 33SSP is not known, it does seem questionable if a negative-
ly charged ion would be able to pass through the negatively charged aperture. Since 33SSP also 
appears to lack positive binding pockets outside the pore, a plausible hypothesis could be that 
33SSP forms a cation selective channel like kpBEST. This is of course still speculative, since the 
mechanism for ion selectivity in cBEST1 and kpBEST is not fully understood. 
When comparing the 33SSP sequence to those of other bacterial homologues, the Asp82 posi-
tion was found to be conserved. While it is not present in kpBEST, out of the 128 homologues 
that were selected for screening, 100 of them (78%) had either an aspartate or glutamate resi-
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due at this position. By comparison, in a set of 487 chordate bestrophin sequences download-
ed from the UniProt database [133], none of the aligning sequences were found to have an 
acidic residues at this position. 
The picture is, however, complicated by the previously discussed fungal homologue from As-
pergillus nidulans. This homologue has been reported to form an anion selective channel [66]. 
When aligning the sequence of the fungal homologue to the sequence of 33SSP, it appears that 
the fungal homologue has a glutamate residue at the position of Asp82. However, since this 
fungal homologue appears to be only remotely related to bestrophins from both animals and 
prokaryotes, it is difficult to judge whether this residue would have a similar conformation in 
the structure. Since the relationship of the fungal homologue appears to be distant, most of its 
sequence cannot be aligned well to the sequences of cBEST1, kpBEST or 33SSP. The sequence 
around Asp82 seems to align reasonably well, but no conclusions can be made about the other 
two acidic residues found along the pore of 33SSP.
In prokaryotes, these other two acidic residues appear to be much less conserved than Asp82. 
40 out of 128 (31%) prokaryotic homologues have an acidic residue at the position of Glu185, 
while 28 out of 128 (22%) have an acidic residue at the position of Asp192. At the aperture, 
none of the examined chordate sequences appear to have an acidic residue at the position 
of the 33SSP Glu185. However, at the position equivalent to Asp192, some of the chordate 
sequences, including human BEST2 and human BEST4, do contain an acidic residue, so it is 
probably less likely that this residue is of critical importance for the charge selectivity, com-
pared to the two other discussed residues. 
Whereas a high degree of sequence conservation does not necessarily define its functional 
importance, there is still an important correlation. Given that an acidic residue at the position 
of Asp82 appears to be highly conserved in prokaryotic bestrophin sequences, but completely 
absent from chordate bestrophin sequences, this could suggest a functional role of this residue 
in bestrophin selectivity, given that the selectivity of prokaryotic homologues differs from ani-
mal bestrophins. So far, the assumption that prokaryotic bestrophins might be cation selective 
is only based on one study of kpBEST. That study was, however, not very thorough, so more 
work is required to better understand the selectivity of prokaryotic bestrophins. 
3.3. Summary and outlook
Several questions regarding the function of 33SSP and other prokaryotic bestrophins are still 
not answered, as it has been discussed above. It is not yet known how prokaryotic bestrophins, 
including 33SSP, are activated. Also, it is not known how the binding of a ligand can cause the 
opening of channel. Finally, the selectivity of prokaryotic bestrophins is not fully understood 
either. 
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As discussed in the appendix, some initial experiments have been performed with reconsti-
tuted 33SSP. Attempts were made to fuse liposomes containing the reconstituted protein to 
planar lipid bilayers. Although currents could be observed, it is at this stage, however, not 
conclusive that those currents were produced by 33SSP.
Further studies should therefore focus on understanding the function of 33SSP using other 
methods. The crystal structure presented in this work may serve as a valuable framework 
for such studies, since the choice of experiments can now be based on structural knowledge. 
Hopefully this will lead to a better understanding of the structure and function of the bestro-
phin protein family.  
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4. Materials and Methods
4.1. Bioinformatics
Sequences of various prokaryotic bestrophin homologues were downloaded from the NCBI 
database [68]. For the second round of screening, sequences were aligned in the program CLC 
Main Workbench [134], using the default algorithm, followed by construction of a Neighbour 
Joining (NJ) tree, also using CLC Main Workbench. For the third round of screening, homo-
logues were aligned using Clustal Omega [135]. Sequences that aligned poorly were manually 
removed. Columns in the alignment that mainly contained gaps were also removed. Based on 
the alignment, a maximum likelihood tree was constructed using PhyML [136].
For analysis, smaller sets of sequences were aligned using PROMALS3D [137] whenever 
structural information was available. The full set of 128 bacterial homologues selected for 
screening, were aligned using MAFFT [138] (using the E-INS-i method, with default settings), 
before constructing a maximum likelihood tree with PhyML. The MAFFT alignment was fur-
thermore used to quantify the number of conserved residues in the proposed ligand binding 
site. A set of 487 chordate bestrophin sequences was downloaded from UniProt [133] and 
aligned with MAFFT (using the FFT-NS-i method, with default settings). Alignments were 
visualised using Jalview [139].
4.2. Cloning of homologues
For the first round of screening, all prokaryotic bestrophin homologues were cloned from 
genomic DNA prepared for another project [77]. For the second and third round of screen-
ing, most homologues were cloned from genomic DNA that was either purchased directly 
from the German Collection of Microorganisms and Cell Cultures (DSMZ) or purified from 
bacterial pellets, which were also purchased from DSMZ. Purification of genomic DNA was 
performed with the GenElute Bacterial Genomic DNA kit (Sigma-Aldrich). When genomic 
DNA or bacterial pellets were not available at DSMZ (homologues 93–94 and 108–128), genes 
were synthesised in a codon optimised version by GenScript. 
All cloning was done using the FX-cloning system [140], using the recommended primer 
design and cloning procedures. PCR was performed essentially under standard conditions 
using Phusion polymerase (New England BioLabs). The main exception from the standard 
conditions was that the polymerase was added when the reaction mixture had reached a tem-
perature of 90°C, before the initial denaturation step. Homologues were initially cloned into 
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the FX-cloning compatible entry vector pINITIAL_cat (chloramphenicol resistant) and then 
sequenced. After sequence verification, the homologues were sub-cloned to an FX-cloning 
compatible, L-arabinose inducible expression vector, such as pBXC3GH (ampicillin resistant), 
which added a HRV 3C cleavage site, GFP and 10×His-tag to the C-terminus of the inserted 
protein. All cloning and expression was performed with the E. coli strain MC1061. Terminal 
truncations of different homologues were made with FX-cloning compatible primers that only 
amplified a limited part of the gene.
4.3. Small scale expression screening
One day before expression, overnight cultures were prepared in Terrific Broth medium (TB) 
containing ampicillin. On the next day, the overnight cultures were used to inoculate fresh TB 
(including ampicillin). Typically, cultures were either grown as 1 ml or 4 ml cultures in deep 
well plates (96 or 24 wells, respectively). Cultures were incubated in an orbital shaker for 1.5 
hours at a temperature of 37°C. The temperature was then reduced to 25°C over the course of 
1 hour. Expression was induced by addition of L-arabinose to a final concentration of either 
0.04%, 0.004% or 0.0004%. In the later rounds of screening, the concentration 0.004% was 
used exclusively. After addition of L-arabinose, growth was continued overnight at 25°C. In 
the initial screening round, the lactose transporter LacS (in a truncated form lacking the last 
160 amino acid residues [141]) from Streptococcus thermophilus was included as a positive 
control. In later screening rounds the prokaryotic bestrophin homologues 12CPI or 33SSP 
were used instead of LacS.
On the following day, cells were harvested by centrifugation. All following steps were done 
with cold buffers and either on ice or in a cold room (4°C) to the extent that it was possible. 
Cells were resuspended in PBS. The optical density at 600 nm (OD600) as well as the whole-cell 
GFP fluorescence (excitation at 485 nm; emission at 535 nm) was measured using an Infinite 
M1000 (Tecan) plate reader. Fluorescence readings were normalised to the number of cells as 
judged by the OD600 reading. 
In 2 ml screw cap tubes, cells were added in an amount equivalent to 175 µl with an OD600 
value of 1. After a brief centrifugation, the cells were resuspended in 400 µl of lysis buffer (50 
mM potassium phosphate (KPi), pH 7.5, 1 mM MgSO4, 10% glycerol, 1mM PMSF, and 3 µg/
ml DNase I; for the last round of screening additionally 150 mM NaCl). Approximately 300 
mg of glass beads (diameter of ≤106 µm; Sigma) were added to each tube. Cells were lysed by 
shaking intensely in a FastPrep-24 benchtop homogeniser (MP Biomedicals) for 2 × 20 s at a 
speed of 6 m/s. Glass beads were removed by gentle centrifugation and DDM was added to a 
concentration of 1%. After 1 hour incubation on ice, 120 µl of the detergent extract was cleared 
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by ultracentrifugation for 15 min at 75,000 RPM, using the rotor TLA-100 (Beckman Coulter) 
placed in the Optima MAX-XP ultracentrifuge (Beckman Coulter). 
Samples from before and after the ultracentrifugation step were analysed by SDS-PAGE. 8 µl 
sample was mixed with 2 µl 5× Sample Buffer [74] and loaded on a gel. After completion of 
the electrophoresis, the GFP fluorescence was visualised directly in the gel by using a LAS-
3000 Imaging System (Fuji), which illuminated the gel with 460 nm blue light and filtered the 
emitted light through a Y515 filter. 
After recording the GFP fluorescence, the gel was analysed by western blot. The proteins were 
transferred to an Immobilon-P PVDF membrane (Merck Millipore), using the semi-dry blot-
ting procedure. The membranes were blocked with 5% skimmed milk powder in PBS and then 
incubated with an anti-His6-peroxidase antibody (Roche). ECL substrate (Biorad) was added 
and signals detected with the LAS-3000 Imaging System (Fuji). 
In parallel with the SDS-PAGE analysis, 50 µl of the sample from after the ultracentrifugation 
was analysed by fluorescence-detection size-exclusion chromatography (FSEC). The sample 
was injected on a Zorbax GF-450 column (Agilent) connected to an Agilent 1100 HPLC sys-
tem with fluorescence detection (excitation at 480 nm, emission at 530 nm). The column was 
equilibrated in 50 mM potassium phosphate (KPi), pH 7.5, 150 mM NaCl, 0.03% DDM for the 
first two rounds of screening. For the last round, the buffer was 20 mM HEPES pH 7.5, 150 
mM NaCl, 0.03% DDM. Terminal truncations of different homologues were evaluated using 
the same FSEC procedure.
4.4. Large scale expression and preparation of mem-
brane vesicles
One day before expression, overnight cultures were prepared in TB containing ampicillin. On 
the next day, the overnight cultures were used to inoculate fresh TB (including ampicillin). 
Cells were either grown as multiple (typically 32) 0.6 L cultures in 2 L shaker flasks, or as 9–18 
L cultures in a fermenter (Bioengineering). The initial temperature of 37°C was after approx-
imately 1.5 hours lowered to 25°C. Once the OD600 had reached 1 (shaker cultures) or 3 (fer-
menter cultures), expression was induced by addition of L-arabinose to a final concentration 
of 0.004–0.01%. For shaker cultures, growth was continued overnight at 25°C, whereas the 
temperature of fermenter cultures was lowered to 20°C before being left to continue growth 
overnight. 
On the following day, cells were harvested by centrifugation and resuspended in cold PBS at 
an OD600 of roughly 200. 0.1 mg/ml lysozyme, 2 µg/ml DNase I and 1 mM MgSO4 were add-
ed. After one hour of incubation at 4°C, the cells were lysed using a pressure based cell lyser 
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(custom build by the in-house workshop). Directly after lysis, 1 mM PMSF, 1.5 µM Pepstatin 
A (Applichem) and 2 µM Leupeptin (Applichem) were added. The lysate was centrifuged for 
1 hour at 42,000 RPM in a 45 Ti ultracentrifuge rotor (Beckman Coulter) cooled to 4°C. The 
supernatant was discarded. The pellet, containing the crude membrane vesicles, was resus-
pended in PBS + 10% glycerol using a Potter-Elvehjem homogeniser. Finally, the resuspended 
membrane vesicles were flash frozen in liquid nitrogen, before storage at −80°C.
4.5. Membrane protein purification
All purification steps were done with cold buffers and either on ice or in a cold room (4°C). 
DDM was mostly used as detergent for the described experiments. In case DDM was replaced 
by either UDM or DM, the buffers contained 0.09% UDM or 0.2% DM instead of 0.03% DDM. 
For the detergent extraction and initial steps of the purifications, detergent of the purity Sol-
grade (<5% α anomer) from Anatrace was used. SEC and later steps were done with Anagrade 
detergent (<2% α anomer), also from Anatrace.
Membrane vesicles were thawed and diluted to 0.1 g/ml in PBS + 10% glycerol. DDM was add-
ed to a concentration of 1.25%. The solution was stirred for 1 hour. Insoluble material was re-
moved by ultracentrifugation. Ni-NTA resin was added to the supernatant, imidazole (pH 7.5) 
was added to 15 mM concentration and the 10×His-tagged GFP fusion protein was allowed to 
bind to the resin while mixing for 1 hour. Ni-NTA resin was collected in a column and washed 
with at least 25 column volumes of wash buffer (20 mM HEPES, 50 mM imidazole, pH 7.5, 150 
mM NaCl, 0.03% DDM) and eluted with elution buffer (20 mM HEPES, 400 mM imidazole, 
pH 7.5, 150 mM NaCl, 0.03% DDM).  The eluted protein was mixed with HRV 3C protease in 
a molar ratio of 1:5 (protease/protein). While cleaving, the sample was dialysed for two hours 
against a dialysis buffer consisting of 10 mM HEPES, pH 7.5, 150 mM NaCl and 0.03% DDM. 
After the dialysis, the 3C protease (His-tagged) and the cleaved-off GFP (His-tagged) were 
removed by binding to Ni-NTA resin. The flow-through from the column, containing the 
protein of interest, was concentrated using an Amicon Ultra centrifugal concentrator (Merck 
Millipore) with a 100 kDa molecular weight cut-off. The concentrated sample was injected 
on a Superdex 200 column (GE Healthcare), typically equilibrated in 10 mM HEPES, pH 7.5, 
150 mM NaCl and 0.03% DDM. If the protein was intended to be used for crystallisation 
experiments, 5 mM HEPES was used instead of 10 mM. The peak fraction was analysed by 
SDS-PAGE. The absorbance at 280 nm was measured and concentrations were calculated with 
extinction coefficients calculated by the ExPASy server [142]. Depending on the application, 
the purified protein was further concentrated using a centrifugal concentrator. 
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4.6. Lipid addition
Lipids were initially added to the concentrated protein from a stock of liposomes in buffer. 
Extra detergent was added as needed from a separate stock. Later the HiLiDe [82] protocol 
was adopted as follows. Lipid solutions in chloroform was pipetted into small glass tubes (75 
mm long, 8 mm inner diameter). For most experiments E. coli polar lipids or DOPC was used 
(both from Avanti Polar Lipids). Chloroform was evaporated under a nitrogen stream and 
the tubes were placed in a vacuum desiccator for at least 2 h to remove residual chloroform. 
Concentrated protein was added directly to the glass tube along with detergent from a 10% 
stock solution. The final lipid concentration was in the range 0.1–0.25%, but typically 0.15% 
was used. Detergent concentration was in the range 0.5–1.0%, with 0.75% being most typically 
used. Typically, the final volume of the sample was at least 100 µl. A small PTFE-coated stir-
rer bar (5 × 2 mm) was added and the mixture was stirred overnight (130 RPM) at 4°C. On 
the next morning, non-solubilised lipids were removed by ultracentrifugation (10 minutes at 
190,000 g), before the sample was used for crystallisation. 
4.7. Crystallisation, data collection and data processing
Initial crystallisation screening was carried out by an in-house core facility. Protein drops (typ-
ically 0.1 or 0.2 µl) were mixed with an equal volume of reservoir solution in a 96-well sitting 
drop plate. The screen used was a custom grid screen consisting of 6 × 96 different conditions. 
Various salts were combined with different buffers at 6 different pH values ranging from 4.5 
to 9.4. For each buffer/salt combination, 4 different concentrations of PEG400 (15%, 25%, 35% 
and 45%) and 4 different PEG4000 concentrations (5%, 10%, 20% and 30%) were tested. A later 
version of the screen used exclusively PEG400, which was tested at 8 different concentrations 
(starting from 10%, increased in 5% steps). Crystallisation plates were incubated at 4°C or 20°C 
and automatically imaged by a Crystal Farm (Bruker) or a Rock Imager 1000 (Formulatrix). 
Conditions where crystals were observed were typically refined with 1 µl drops that were set 
up by manual pipetting in 24 well Cryschem M plates (Hampton Research). Typically, PEG 
concentrations increasing in 1% increments were used. 
Crystals were cryoprotected by increasing the PEG400 concentration in 5% steps, until a con-
centration of 35% was reached. For crystals growing in PEG4000, ethylene glycol was used as 
a cryoprotectant. Crystals were frozen in liquid propane. Most data was collected at the Swiss 
Light Source (SLS), at beamline X06SA on a Pilatus 6M detector. For the initial screening, 
occasionally a Mar225 CCD detector was used.
Data was indexed, integrated, scaled and merged using the XDS package [98]. The space group 
was determined using the program POINTLESS [99], part of the CCP4 suite [143]. Data sta-
tistics were calculated using the phenix.merging_statistics, part of the PHENIX suite [109].
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4.8. Multi-angle light scattering
Protein for multi-angle light scattering experiments was purified as described previously, ex-
cept that only the central part of the size-exclusion peak was used for analysis. 50 µg of puri-
fied protein at a concentration of 1 mg/ml was injected on a Superdex 200 column, equilibrat-
ed in the same buffer as used for purification by size-exclusion chromatography. The column 
was connected to an Agilent 1100 HPLC system with a UV detector. After the UV detection, 
the sample was further analysed using miniDAWN TREOS MALS detector and an Optilab 
T-rEX refractometer (both from Wyatt Technology). Bovine serum albumin was used as a 
protein standard and data was analysed using the Astra software suite (Wyatt Technology). 
Measurements were done at 20°C. 
4.9. Alpaca immunisation and generation of nanobody 
library 
33SSP was purified as described previously. 4 injections of 200 µg protein were injected into 
to an alpaca over the course of 6 weeks. The animals were not harmed and less than 100 ml 
of blood was collected in the final blood draw. All alpaca related work was done by Dr. Saša 
Štefanić (Vetsuisse Faculty, University of Zurich), who had acquired permission for the exper-
iment from the Cantonal Veterinary Office (Zurich, Switzerland). 
The following steps were performed by Yvonne Neldner. Leucosep tubes (Greiner Bio-One) 
were filled with Ficoll Paque Plus (GE Healthcare). Anticoagulated alpaca blood was diluted 
1:1 with 154 mM NaCl. 15–30 ml diluted blood was added to each Leucosep tube, which was 
centrifuged for 10 minutes at 1000g in a swing-out rotor at room temperature. Peripheral 
mononuclear cells were removed with a Pasteur pipette and washed twice with PBS. Total 
RNA was isolated using the RNeasy Mini Kit (Qiagen). First-strand cDNA was synthesised 
using the AffinityScript qPCR cDNA synthesis kit (Agilent) in combination with the CALL002 
primer [144]. VHH (nanobody) sequences were amplified by PCR using the forward primer 
CTG ARC TKG GTG GTC CTG GCT GC and a 1:1 mix of the reverse primers CTG ARC 
TKG GTG GTC CTG GCT GC and TTC GGN GGG AAG AYR AAG AC. A fragment of ap-
proximately 600 bp was isolated by gel electrophoresis and purified from the gel. The isolated 
fragment was further amplified by PCR using the FX primers ATA TAT GCT CTT CGG CAC 
AGN KGC ARY TSG TRG AGT CTG GGG G and ATA TAT GCT CTT CCA CTG GAG 
ACG GTG ACC SGG GTC CCY TKG CYC. A fragment of approximately 400 bp was isolated 
by gel electrophoresis and purified from the gel. An FX cloning compatible version of the vec-
tor pMES4 [145] was linearised using the restriction enzyme PmlI and dephosphorylated with 
calf intestinal alkaline phosphatase. The isolated DNA fragment was cloned into the linearised 
vector, using the FX cloning procedure, to generate the VHH library. Electro-competent E. coli 
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TG1 cells were transformed with the VHH library by electroporation. A small amount of the 
cells was used for a dilution series, in order to calculate the library size. The remaining cells 
were plated and grown overnight. The next day the cells were harvested from the plates and 
used to prepare glycerol stocks. 
4.10. Selection of nanobodies using phage display
33SSP was expressed with a C-terminal Avi-tag [92] fused to the C-terminus, followed by a 
3C cleavage site, GFP and 10×His-tag. 33SSP was biotinylated in a reaction mixture consisting 
of 30 mM 33SSP, 3 mM biotin, 5 mM ATP, 10 mM MgOAc, 20 mM HEPES pH 7.4, 0.1 mg/
ml BirA (E. coli biotin ligase) and DDM. The reaction was incubated overnight at 4°C. On the 
next day, biotinylated 33SSP was purified using size-exclusion chromatography as previously 
described.
Two selections were performed in parallel. In one selection neutravidin was used to capture 
biotinylated 33SSP (neutravidin coating) and in another selection 33SSP was directly coated 
on the plastic (direct coating). 100 µl neutravidin (4 µg/ml) in 0.1M NaHCO3 pH 8.2 or 33SSP 
(2 µg/ml) in PBS + DDM was coated in a MaxiSorp 96-well ELISA plate (Nunc). The wells 
were blocked with 200 µl 2% milk powder in PBS + DDM. To the plate coated with neutravi-
din, 100 µl biotinylated 33SSP (2 µg/ml) in PBS + DDM + 0.2% milk powder was added after 
washing. For the first round, one negative control well was prepared by blocking with 2% milk 
powder in PBS. For the subsequent rounds, two negative controls were prepared. One con-
tained only milk powder (control for the direct coating selection). The other was first coated 
with neutravidin and then blocked with 2% milk powder (as a control for the neutravidin 
coating selection). 
For the first round of selection, 100 µl of phages at a concentration of 1.4 × 1011 phages/ml (in 
PBS + DDM + 1% milk) was added to each well. After 2 hours of incubation, each well was 
washed 15 times with PBS + DDM. The phages were eluted by incubating with 100 µl 0.25 mg/
ml trypsin for 30 min at room temperature. The reaction was stopped by addition of 4-ben-
zenesulfonyl fluoride hydrochloride (0.25 mg/ml). 50 µl of the eluted phages were used to 
infect 350 µl E. coli TG1 cells (freshly cultured from a minimal media plate, in the exponential 
phase). Infection was done for 30 min at 37°C without shaking. The infected cells were then 
grown overnight in 2×YT + ampicillin + 2% glucose. A small amount of the eluted phages was 
used to make a dilution series. 10 µl of diluted phages were similarly used to infect 90 µl E. coli 
TG1 cells, which were plated on LB agar plates (with ampicillin and 2% glucose) for overnight 
growing. 
On the next day, the phage output was calculated from the number of colonies observed from 
the dilution series. The liquid culture was used to prepare a glycerol stock and to start a fresh 
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culture in 2×YT + ampicillin + 2% glucose. The culture was grown to the exponential phase 
and then superinfected with M13KO7 helper phage (prepared in advance, using essentially the 
same method as described here) at a multiplicity of infection of 20. The phages were allowed 
to infect for 30 min at 37°C without shaking. The cells were then pelleted and resuspended 
in 50 ml 2×YT + ampicillin + kanamycin and grown overnight at 37°C with shaking. On the 
following day, the cells were removed by centrifugation and 40 ml of the supernatant was 
mixed with 10 ml 20% PEG6000, 2.5M NaCl. The sample was mixed by inverting the tube and 
stored on ice for 30 min. The phages were pelleted by centrifugation, resuspended in 1 ml PBS, 
transferred to a 1.5 ml tube and mixed with 250 µl 20% PEG6000, 2.5M NaCl. The sample was 
again mixed by inversion and stored on ice for 15 min. The phages were collected by centrif-
ugation and resuspended in 1 ml PBS. Aggregated particles were removed by centrifugation 
and the supernatant, containing the phages, was transferred to a new tube. A small amount 
of the phages was used for a dilution series, as described above, to determine the phage con-
centration. A part of the remaining phages was used for the next round of selection or frozen 
for later use. 
4.11. ELISA screening and sequencing of single nanobody 
clones
For ELISA analysis, glycerol stocks prepared from the output phages were streaked on LB-
agar (with ampicillin and 2% glucose) and grown overnight. On the next day, colonies were 
picked. Each colony was first transferred to a fresh patch plate and next to transferred to 
1 ml TB + ampicillin in 96-well deep well plate, where it was grown for 6 h at 37°C. The 
temperature was then reduced to 25°C and each culture was induced with 1 mM isopropyl-β-
-1-thiogalactopyranoside. Cells were grown overnight at 25°C.
On the next day, cells were pelleted at 4°C and re-suspended in 200 µl cold TES buffer (0.2 M 
Tris-HCl pH 8.0, 0.5 mM EDTA, 0.5 M sucrose) by vortexing. The cells were shaken for 30 min 
in the cold room, before 300 µl cold TES/4 buffer (TES buffer diluted 4× in water) was added. 
After mixing, the cells were shaken again for 30 minutes in the cold room. Cells were pelleted 
and 400 µl of the supernatant, containing the periplasmic extract, was transferred to a new 
plate, where it was mixed with 100 µl PBS + 0.25% DDM. 
ELISA plates were coated either directly with 33SSP (for analysis of clones selected using the 
direct coating procedure) or with neutravidin followed by biotinylated 33SSP (for analysis 
of clones selected using the neutravidin coating procedure), as described previously. Every 
second column in the ELISA plate was used for negative controls, meaning that no 33SSP 
was added. After blocking with 2% milk powder in PBS, the periplasmic extract was added. 
After 1 h incubation at room temperature, the plate was washed with PBS + 0.05% DDM. An 
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anti-His6-peroxidase antibody (Roche) was diluted 1:2500 and added. After washing, signals 
were detected by adding BM Blue POD substrate (Roche). After sufficient colour had devel-
oped, the reaction was stopped by addition of 1 M H2SO4 and the absorbance at 450 nm was 
measured using an Infinite M1000 (Tecan) plate reader. For the clones selected for sequenc-
ing, a culture was started from the patch plate, plasmid DNA was isolated and the insert was 
sequenced. For all sequences, vector encoded elements were removed and the sequences were 
aligned. 
4.12. Expression of nanobodies, complex formation and 
crystallisation
Selected nanobodies were cloned into the FX-cloning compatible, L-arabinose inducible ex-
pression vector pBXNPHM3 (ampicillin resistant), which added a PelB leader sequence, MBP, 
10×His and a HRV 3C cleavage site to the N-terminus of the nanobody. Expression with the E. 
coli strain MC1061 and cell lysis, were performed as described previously for the bacterial be-
strophin homologues. After ultracentrifugation, the supernatant was mixed with Ni-NTA and 
the purification proceeded as for the bacterial bestrophin homologues, except that a Superdex 
75 column was used for the gel filtration step and that no detergent was added in the various 
buffers. Purified nanobodies were used immediately or stored at -80°C for later use. 
For a test of complex formation, purified nanobodies were mixed with purified 33SSP. The 
final concentrations were 1 mg/ml of nanobody and 2.5 mg/ml of 33SSP, resulting in an ap-
proximately 1:1 molar ratio. Complexes were analysed by SEC, using a Zorbax GF-450 column 
(Agilent) connected to an Agilent 1100 HPLC.
When 33SSP–nanobody complexes were prepared for crystallisation, purified nanobodies 
were added in a slight molar excess to 33SSP before the SEC-step. Purification then proceeded 
as usual for 33SSP. Addition of lipids and crystallisation was performed as described previous-
ly for the bacterial bestrophin homologues.
For crystallisation of 33SSP–NB33_1, protein was incubated overnight at a concentration of 9 
mg/ml together with 0.15% E. coli polar lipids and 0.75% DDM. The buffer used was identical 
to the size-exclusion buffer (150 mM NaCl, 5 mM HEPES, pH 7.5) On the next day, after clear-
ing the sample by ultracentrifugation, EGTA was added to a concentration of 2 mM. Crystal-
lisation plates were set up with sitting drops consisting of 1 µl of protein and 1 µl of reservoir 
solution. The two solutions were mixed by pipetting up and down. The reservoir solution con-
sisted of 13% PEG300 (v/v), 50 mM ADA, pH 6.5 (pH adjusted with NaOH). Plates were sealed 
with tape and incubated at 4°C. Crystals appeared within a few days and were typically frozen 
within a few weeks. The crystals were cryoprotected by transfer into solutions containing 
increasing concentrations of PEG300 (18%, 24%, 30% and 35%). The cryoprotection solutions 
102
contained the same salts and buffer concentrations as the crystallisation drop, low concentra-
tions of detergent and no added lipids. Crystals were frozen by plunging into liquid propane. 
The best diffracting dataset of 33SSP–NB33_1 was collected using a Pilatus 6M detector at the 
beamline X10SA of the Swiss Light Source (SLS). The detector was placed at a distance of 550 
mm and a wavelength of 1.00002 Å was used. Data was processed as described earlier. 5% of 
the reflections were randomly selected and assigned to the test set, which was excluded from 
the refinement. 
4.13. Structure determination and analysis
A molecular replacement search model was generated from structure of the bestrophin ho-
mologue kpBEST [67] (PDB accession number: 4WD8). Based on a sequence alignment, the 
search model was adjusted with the program SCULPTOR [106] using default settings. Mo-
lecular replacement was performed with PHASER [105], accessed through the CCP4 soft-
ware suite [143]. 4 33SSP pentamers were searched for. Solvent content was calculated based 
on 4 33SSP pentamers and 20 nanobodies. RMSD between the search model and unknown 
structure was specified as 1 Å. The setting «pack compact» was set to «off». Data up to a 
resolution of 3.5 Å was used. The molecular replacement solution was improved by iterat-
ed local density-guided model deformation and refinement («morphing») using the program 
phenix.morph_model [110]. 
Based on a structure of a nanobody [77] (part of PDB accession number: 5M94), a molec-
ular replacement search model for the nanobody NB33_1 was prepared, again based on an 
alignment using the program SCULPTOR. 20 nanobodies were added into the density with 
the Spherically Averaged Phased Translation Function and Phased Rotation function of the 
program MOLREP [112]. The model was improved through iterative cycles of building in the 
program Coot [119] and refinement in the program phenix.refine [108]. Atomic coordinates 
and isotropic B-factors were refined using automatically determined torsion-angle NCS re-
straints. Later rounds of refinement also included TLS parameters (one TLS group per chain). 
Most figures were prepared with the program UCSF Chimera [146]. Structures were super-
imposed using secondary structure matching [118] in Coot. Protein interfaces were analysed 
with PISA [117]. Pore dimensions were calculated with the program HOLE [120], using the 
default atomic radii. Electrostatic surface plots were made in PyMol (www.pymol.org) using 
APBS [147], with charges being assigned by using the AMBER forcefield in PDB2PQR [148].
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5. Appendix
5.1. Planar lipid bilayer experiments
5.1.1. Introduction
The presented structure of 33SSP shows what appears to be an ion channel in a closed con-
formation. As previously discussed, not much is known about the function of prokaryotic 
bestrophins, since the only available functional data comes from an article describing the 
structure of kpBEST [67]. It was therefore my goal to investigate the function of 33SSP. Since 
this protein can be purified and is stable in detergent, I decided to reconstitute the protein 
into proteoliposomes and attempt to record currents in a planar lipid bilayer (in the following 
referred to simply as ‘bilayer’). Bilayer recordings have been used to study both kpBEST and 
cBEST1 [38,67]. Unlike typical patch clamp experiments on living cells, endogenous currents 
from other channels can effectively be eliminated in a bilayer system since purified protein 
is used. Depending on the amount of proteoliposomes that are fused to the bilayer and the 
protein density of the proteoliposomes, single-channel currents or macroscopic currents can 
be measured. 
As described below, it was possible to measure currents when adding proteoliposomes con-
taining 33SSP to a bilayer. These currents unfortunately appear to be (at least partially) caused 
by artefacts and not by incorporated 33SSP.
5.1.2. Results
After adding proteoliposomes to the bilayer, macroscopic currents could be recorded. The 
current amplitude ranged from a few hundred pA to a few nA. To determine if the currents 
were cation or anion selective, different salt concentrations were used on the two sides of the 
bilayer and the currents were measured at different voltage steps (Figure 51). 
Based on the recordings, current-voltage curves (I-V curves) could be drawn and a reversal 
potential of −53.4 mV could be determined in a 10-fold gradient of NaCl (Figure 52). Using 
the Goldman-Hodgkin-Katz voltage equation, a permeability ratio between chloride and sodi-
um ions (P(Cl)/P(Na)) of 0.022 could be calculated, meaning that the observed currents were 
highly cation selective. 
The measurements were performed with proteoliposomes reconstituted at a lipid to protein 
ratio (LPR) of 50. Similar macroscopic currents were also observed with proteoliposomes pre-
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Figure 51 – Example of macroscopic currents recorded at different voltages. The upper part of the figure shows 
the recorded currents, while the lower part shows the applied voltage steps. The experiment was performed using 
ten times higher concentration of NaCl on one side compared to the other side of the bilayer. 
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Figure 52 – I-V curves used to determine the reversal potential. The results of six independent experiments are 
shown, all performed using ten times higher concentration of NaCl on one side compared to the other side of the 
bilayer. The average reversal potential was determined as −53.4 mV (SD = 1.7 mV).
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Figure 53 – Example of observed single channel currents. The measurement was performed at −100 mV. The 
buffers on both sides of the bilayer contained 200 mM NaCl. The observed current transitions correspond to 21 
pA or 210 pS. 
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pared at LPRs of 100 and 200, but not with those prepared at LPRs of 400 and 800. This indi-
cated that the observed currents were due to the incorporated protein. 
While the observed currents were typically macroscopic, sometimes smaller currents could 
be observed that contained transitions characteristic of single channels (Figure 53). However, 
those transitions corresponded to a conductance of 210 pS, which is large compared to other 
ion channels which typically have conductances below 100 pS [1]. 
Similar single channel currents were also observed when different salt concentrations were 
used on the two sides of the bilayer. Those currents also appeared to have a negative reversal 
potential, indicating that they were cation selective, which was in agreement with the ob-
served macroscopic currents. For one experiment the reversal potential was determined as 
−49.5 mV (Figure 54), corresponding to P(Cl)/P(Na) = 0.04. 
Since the recorded currents were found to be cation selective, the relative permeability of dif-
ferent cations was also investigated. Currents were observed for different sizes of monovalent 
and divalent cations but the permeabilities were generally found to increase with the ionic ra-
dii (Figure 55). This was consistent with findings from cBEST1 and kpBEST, which were both 
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Figure 54 – Cation selectivity of single channel currents. The current amplitudes of the observed single channel 
transitions were measured at different voltages and an I-V curve was plotted. The reversal potential was deter-
mined as −49.5 mV. The experiment was performed with 15 mM NaCl on the trans side and 150 mM on the cis side.
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Figure 55 – Selectivity for cations of different sizes. The permeabilities of different ions, compared to that of sodi-
um, are shown as bars. For reference, a bar is also shown for sodium.  
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more permeable to larger ions [38,67]. kpBEST was, however, not reported to be permeable to 
divalent cations, unlike the currents described here. 
5.1.3. Discussion
The described currents were initially thought to be produced by 33SSP for the following 
reasons: 1) The protein reconstituted into the liposomes had been carefully purified, thus 
minimising the risk of contaminations from other proteins. 2) Macroscopic currents were 
observed, but not from liposomes reconstituted with very small amounts of protein. 3) The 
currents were cation selective, in agreement with results for kpBEST. 4) Larger permeabilities 
were observed for larger cations, consistent with studies of kpBEST and bestrophins from 
animals. 
Several observations were, however, made that made me believe that the observed currents 
might instead be the result of some artefact. These observations are discussed below. 
First, cation selective macroscopic currents could also be produced by adding empty lipo-
somes. Initially, this observation was not made, most likely because I had difficulties to repro-
duce the observed currents in the beginning. Later, as I gained more experience with bilayers, 
it became easier to reproduce currents from 33SSP-containing proteoliposomes, but eventu-
ally I discovered that similar currents could also be produced with empty liposomes added to-
gether with 1−2 M KCl. Cation selective currents from empty liposomes have previously been 
observed by others when the liposomes were added close to the bilayer [149]. It is possible that 
those currents arise as an artefact from simultaneous fusion of a large number of vesicles, a 
phenomenon described by others as ‘massive vesicle fusion’ [150]. 
Second, no tested mutations changed the selectivity of the observed currents. Based on the 
crystal structure of 33SSP, I mutated the residues Asp82 and Glu185, believed to be involved 
in ion selectivity. As 33SSP is a pentamer, each mutation to a non-charged residue was expect-
ed to effectively remove five negative charges. Despite this, the currents observed from those 
mutants remained equally cation selective. 
Third, the channel appeared to be permeable to tetraethylammonium. Such quaternary am-
monium compounds are known blockers of different potassium channels [1] as well as cation 
selective pentameric ligand-gated ion channels [151,152]. It thus seemed surprising that this 
bulky ion would be able to permeate through 33SSP. 
Finally, the currents appeared to be originating from a permanently open channel and they 
were not affected by the addition of calcium or EGTA. This meant that the channel would 
either be constitutively open or it would be activated by some unknown ligand that was either 
co-purified with the protein or present in all the buffers. While these options could not be 
ruled out, they did not seem very likely. 
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In summary, the possibility remains that a part of the observed currents might be originating 
from 33SSP. However, it seems likely that a large part, if not all, of the observed currents in-
stead was caused by some artefact. Further experiments, using other techniques, are therefore 
required in order to study the function of 33SSP. Those experiments will be complicated by the 
fact that it is not known how bacterial bestrophins are activated. If 33SSP behaves similar to 
cBEST1, mutations in the neck region could potentially create a channel that would be active 
in the absence of a ligand. The triple alanine mutation of the neck residues that caused cBEST1 
to be active in the absence of calcium [38] could so far not be produced in 33SSP, but other 
combinations of mutations remain to be investigated.  
5.1.4. Methods
For bilayer recordings, small contaminations by bacterial outer membrane porins can be prob-
lematic since porins have very high conductances compared to typical ion channels [153]. To 
avoid this, 33SSP was expressed with a C-terminal streptavidin binding peptide tag [154] and 
bound to a streptavidin column. The bound protein was extensively washed with a 0.5M NaCl 
solution (>50 column volumes) followed by a shorter wash with 1M NaCl (~20 column vol-
umes) and elution with biotin. After cleavage of the tag (using SEC purified HRV 3C protease), 
the protein was purified by SEC on a Superdex 200 column, followed by anion exchange as a 
polishing step. 
The reconstitution into proteoliposomes was performed essentially as described elsewhere 
[155]. Liposomes were formed from a 3:1 mixture of E. coli polar lipids (Avanti Polar Lipids) 
and L-α-Phosphatidylcholine from egg yolk (Sigma). Large multilamellar vesicles were formed 
by sonication followed by three freeze/thaw cycles. These were used to form large unilamellar 
vesicles by extrusion through a 400 nm polycarbonate filter (Avanti Polar Lipids). The pro-
duced liposomes were destabilised by the addition of Triton X-100 (Sigma), while monitoring 
the optical density at 540 nm. The purified protein was mixed with the liposomes at different 
lipid to protein ratios (LPR). Typically, ratios ranging from 50 to 200 were used. The detergent 
was removed by incubation with Bio-Beads SM-2 (Bio-Rad). The produced proteoliposomes 
were flash-frozen in small aliquots that were stored at −80°C until later use. 
Protein incorporation in the liposomes was confirmed by extraction with DDM. Non-solu-
bilised lipids were removed by ultracentrifugation. The supernatant was first analysed by silver 
stained SDS-PAGE, which showed a band of the expected molecular weight. Next the sample 
was analysed by FSEC (using tryptophan fluorescence), which showed a monodisperse peak 
eluting at the volume expected for a pentamer. 
The bilayer was made in a horizontal setup, where a small piece of overhead foil served as 
the partition that separated the trans and cis chambers. A hole in the partition (diameter of 
108
roughly 100 µm) was made by poking the plastic with a needle and shaving off excess plas-
tic on the other side. For all measurements, a 3:1 mixture of 1-palmitoyl-2-oleoyl-sn-glyce-
ro-3-phosphoethanolamine (POPE) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-
glycerol) (POPG) (both from Avanti Polar Lipids) dissolved in decane was used to form the 
bilayer. To each chamber a silver chloride electrode was connected through a salt bridge. The 
trans chamber was held at ground, while the cis chamber was connected to the headstage of 
a Axopatch 200B patch clamp amplifier (Molecular Devices). The data was filtered through a 
1 kHz lowpass Bessel filter built into the patch clamp amplifier and digitised using a Digidata 
1322A data acquisition system (Molecular Devices). Recording was done using the pCLAMP 
9 software suite (Molecular Devices), with the sample rate set to 10 kHz. The headstage and 
the bilayer assembly was placed in a grounded metal box, which was standing on a vibration 
isolation table (Kinetic Systems Inc.).
For each day of measurements, a fresh aliquot of frozen proteoliposomes was thawed and 
briefly sonicated in a bath sonicator. Fusion was induced by mixing the proteoliposomes with 
1–2M KCl and adding the mixture on top of the bilayer. If necessary, additional KCl was add-
ed to promote fusion. Anion/cation selectivity was investigated using a 10-fold higher NaCl 
concentration in the trans chamber compared to the cis chamber (the amount of Na+ ions in 
the buffer was taken into account). Voltage clamp experiments were used to determine the 
reversal potential and the relative permeabilities for Na+ and Cl− ions were calculated using 
the Goldman-Hodgkin-Katz voltage equation [156]. Relative permeabilities of different cat-
ions were investigated by using buffers containing 200 mM NaCl in the cis chamber and 200 
mM of another salt in the trans chamber (100 mM was used for divalent cations). The Gold-
man-Hodgkin-Katz voltage equation was used to calculate relative permeabilities when only 
monovalent ions were present. When divalent ions were included, a modified form of that 
equation was used [157]. 
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